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ABSTRACT 
Cardiovascular disease is associated with multiple factors including the increased ability 
of platelets to aggregate. Natural compounds such as garlic are known to reduce the 
clinical onset of cardiovascular disease. Garlic is available in many forms 
commercially. One such form is aged garlic extract (AGE). It has been established 
through in vitro and in vivo testing that AGE can reduce the incidence of platelet 
aggregation stimulated by a variety of agonists; however, the mechanisms responsible 
for this observed inhibition have yet to be determined scientifically. Hence, the aim of 
this study was to examine and elucidate the inhibitory mechanisms of AGE on platelet 
aggregation both in vitro and in vivo. 
In vitro testing using platelet aggregometry showed that platelets when incubated with 
AGE (1.56-25 %, v/v) showed a significant concentration-dependent reduction in 
platelet aggregation when challenged with the following agonists: adenosine 
diphosphate, arachidonic acid, A23187, adrenaline, collagen and thrombin. Individual 
constituents found in AGE were tested individually and as part of a mixture to observe 
any potential inhibitory effects. It was found that the constituents were not as efficient 
as AGE in its natural form in inhibiting platelet aggregation. Thus, all the constituents 
that make up AGE are needed in order to bring about an inhibition in platelet 
aggregation. The effects of AGE were compared to several known classical inhibitors of 
platelet aggregation induced by ADP; in order to establish the areas within the 
biochemical signalling pathway(s) where AGE may exert its inhibitory effect. From 
these experiments the following biochemical signalling pathways were identified as 
possible targets for AGE: arachidonic acid metabolism, calcium mobilisation, 
fibrinogen binding and cAMP levels. 
Possible inhibitory mechanisms for AGE is via calcium mobilisation, in that the 
intracellular levels of calcium were significantly suppressed in the presence of AGE, 
when platelets were challenged with the agonists ADP and A23187. This was 
investigated using fluorescence spectrophotometry. Another area where AGE is exerting 
its inhibitory effect is via the final step in platelet aggregation (fibrinogen binding to its 
receptor GPIlb/Illa) and an increase in intraplatelet levels of cAMP. AGE was found to 
significantly reduce platelet aggregate formation via fibrinogen binding. This was 
monitored using a simple adhesion assay and flow cytometry. AGE was also found to 
increase intracellular levels of cAMP when compared to the known inhibitor PGEI. 
AGE had no effect upon arachidonic acid metabolism during platelet aggregation 
stimulated with the agonists ADP and thrombin. 
In vivo testing where participants consumed 5 mL AGE/day for 14 days, showed that 
AGE significantly inhibited agonist-induced platelet aggregation. Of the biochemical 
parameters that were analysed it was found that AGE significantly increased the 
intraplatelet levels of cAMP when compared to the baseline (Day 0) and washout (Day 
28) samples in both resting and platelets activated with ADP. 
Therefore, it can be concluded that the inhibitory mechanisms of AGE with regards to 
platelet aggregation is via calcium mobilisation, fibrinogen binding, and increased 
cAMP in vitro. Whereas in in vivo testing, increased cAMP levels are the only 
biochemical signalling parameter that AGE has any inhibitory effect upon. 
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CHAPTER1 
INTRODUCTION 
1. INTRODUCTION 
1.1. CARDIOVASCULAR DISEASE AND PLATELETS 
In the United Kingdom and Western World, cardiovascular disease (CVD) including 
atherosclerosis, heart attack, stroke and heart failure is the leading cause of morbidity 
and mortality, with the death rates increasing steadily each year (Chambers 2004; 
Harrison 2005; Scott 2004; Willoughby et al 2002). Statistics gathered by the American 
Heart Association (americanheart. org) revealed that twice the number of people 
diagnosed with CVD die, than those suffering from all types of cancers combined. 
There are many risk factors associated with CVD some of which are not modifiable 
such as age, ethnicity, male gender and genetics (Scott 2004). There are other risk 
factors which can be modified by changes to lifestyle; these include diet, obesity, 
smoking and lack of exercise. CVD is not restricted to diseases of the heart as, 
imbalances in food intake, energy metabolism, blood pressure, inflammation (Vlasuk 
and Scarborough 2005) and increases in the prevalence of disease states such as obesity 
and diabetes, have significantly contributed to the overall increase in the occurrence of 
CVD. The disease process is a complex one in that CVD, especially atherosclerosis 
does not occur spontaneously. McBane et al. (2003) reported that autopsy studies have 
shown that atherosclerosis (general term for the thickening and hardening of arteries) 
begins during adolescence and continues to develop slowly over many years reaching 
clinical onset with the presentation of symptoms usually in middle age. 
It has been suggested that platelets are involved in the development of atherosclerosis 
and the clinical onset of CVD, this is due to an increase in the number of aggregating 
platelets within the circulatory system (Banedee and Maulik 2002; Gawaz 2006; Huo 
and Ley 2004; Imano et al. 2002; Keating et al. 2004; McBane et al. 2003; Rauch et al. 
2001; Tan et al. 2004; VanWijk et al. 2003). In disease states such as atherosclerotic 
arteries, platelet aggregation plays a central role in coronary thrombosis and is related to 
a cascade of events including expression of adhesion molecules on the surface of the 
endothelium, the oxidation of lipoproteins, monocyte invasion of the vessel wall, foam 
cell formation, smooth muscle phenotypic change and proliferation and platelet 
deposition leading to myocardial infarction, stroke or sudden death (Andre et al. 2003; 
Dopheide et al. 2001; Huo and Ley 2004; Rahman 2001). 
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Historically, there have been 3 main theories of the development of atherosclerosis 
(Brydon et al. 2006; Gawaz 2006): 
1. Incrustation theory - one of the earliest theories of atherosclerosis proposed by 
Rokitansky in 1852. He suggested that disease development was due to fibrin 
deposition on the arterial wall. 
2. Lipid infiltration theory - involvement of plasma lipids and their cellular 
metabolism proposed by Virchow in 1858. 
3. Irritation theory - chronic inflammation reaction proposed by Ross and Glomset 
in 1973. 
In recent years atherosclerosis has been termed as a chronic inflammatory process in 
which leukocytes interact with the structurally intact but, dysfunctional endotheliurn of 
the arteries (Brydon et al. 2006). Platelets have been reported to be involved with the 
progression of this disease. However, their role in disease progression was always 
reported as occurring during the latter stages of atherosclerosis. Research conducted by 
Massberg et al. (2002) with Apo-E-deficient mice has shown that platelets play an 
important role in all stages of plaque development within arteries. Apo-E-deficient mice 
have elevated cholesterol levels, a common risk factor associated with atherosclerosis, 
and the mice also display widespread lesions that are similar in pathomorphology to 
humans with the disease. Fluorescence microscopy conducted in vivo showed that 
platelets were the first blood cell to arrive at the site of endothelial dysfunction, and that 
they adhered to the endothelium. Other studies have shown that platelet adhesion plays 
a critical role in the initiation and progression of atherosclerosis through leukocyte 
recruitment to the lesion site (Huo and Ley 2004; Massberg et al. 2002; Merten and 
Thiagarajan 2004). Adhesion of platelets to the endothelium. triggers platelet activation 
and the rapid expression of adhesion molecules such as Platelet-selectin (P-selectin). P- 
selectin binds to the leukocyte receptor and promotes leukocyte recruitment to the 
endothelium. Activated platelets release a wide array of adhesive and pro-inflammatory 
factors, which are deposited on the surface of leukocytes and endothelial cells through 
P-selectin-mediated reactions. These include cytokines and chemokines which are 
powerful chemoattractant agents that stimulate leukocyte migration to the endothelium. 
All these events are responsible to some degree for the development of atherosclerosis. 
Human studies involving the observation of activated platelets via flow cytometry 
3 
suggest that the same processes are likely to occur in patients with atherosclerosis as 
reported by Brydon et aL (2006). 
Platelets play an important role within the cardiovascular system (CVS), in that they are 
responsible for primary haemostatic functions through adhesion, aggregation and 
subsequent thrombus formation induced by agonists such as collagen, thrombin and 
many other factors exposed at sites of vascular injury (Andre et al. 2003; Payrastre et al. 
2000). Thus, the inhibition of platelet activation and aggregation is important in 
maintaining constant blood flow throughout the CVS. In normal vasculature, circulating 
platelets interact passively with the endothelial lining of the vessel wall, due in part to 
the secretion of platelet-inhibiting substances such as prostacyclin and nitric oxide 
(Dopheide et al. 2001). It is upon vascular injury and the exposure of the sub- 
endothelial matrix that platelets become activated, aggregate and form a thrombus 
(platelet plug) to arrest the flow of blood from the damaged vessel site (Gregg and 
Goldschmidt-Clermont 2003; Keating et al. 2004; Puri 1999; Rauch et al. 2001; 
Willoughby et al. 2002). During CVD blood vessels that have been injured and 
modified by smoking, cholesterol, or high blood pressure develop fatty plaques that line 
the vessel wall; these plaques can rupture and cause platelets to form thrombi. Although 
no bleeding has occurred within the vessel the platelets are fooled into thinking that an 
injury has taken place that will cause loss of blood. Thus, a thrombus is formed within 
the blood vessel that restricts blood flow, leading to heart muscle death, heart attack and 
eventually death. 
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1.2. PLATELETS 
Platelets were first described by Dorind in 1842 and classical descriptions of the cells 
were further elaborated by Bizzozero in 1881, which recognised the importance of 
platelet clumping in the blood clotting process (Freedman 2003; Dopheide et al. 2001). 
Platelets are non-nucleated cells that circulate freely in the blood as discoid shaped cells 
in a resting state. They are formed in the bone marrow via a process known as 
thrombocytopoesis from megakaryotic cells, which differentiate from pluripotent stem 
cells by a complex process that is orchestrated by a series of growth factors (Battinelli et 
al. 2001; Kaushansky 1996; Kaushansky 1997), and have a life span of approximately 
8-12 days (Harrison 2005; Jurk and Kehrel 2005; Solet et al. 2001; Willoughby et al. 
2002; ). Platelets are the smallest and second most numerous blood cells in the 
circulatory system with dimensions of approximately 1.0-2.0 by 0.5 pM. They are 
present in the circulation at a volume of 150450 x 109 platelets/L (Dopheide et al. 
2001; Harrison 2005). 
Platelets have a general cell physiology (Figure 1.1) in that they contain a plasma 
membrane, internal membrane (open canalicular and dense tubular systems), a 
cytoskeleton (microtubules and microfilaments), mitochondria, glycogen granules, 
storage granules (a-granules and dense granules), lysosomes (acid proteases, acid 
glycosidases, acid phosphatases, acid sulphates) and peroxisomes (catalase). The a- 
granules are important to platelet function in that they store and secrete proteins, such as 
fibrinogen, von Willebrand factor (vWf), platelet factor IV P-thromboglobulin and 
platelet-derived growth factor. Dense granules store smaller molecules (serotonin, ATP, 
ADP, Ca2+, pyrophosphate) and are responsible for sustaining platelet aggregation, 
which is necessary for the formation of a haemostatic plug. Platelet membranes contain 
a vast array of receptors and receptor-like proteins that are responsible for cell-to-cell 
adhesion and the biochemical signalling pathways responsible for platelet aggregation. 
These receptors also allow for the adherence of platelets to exposed sub-endothelial 
matrix at sites of vessel injury. 
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1.2.1 Platelet activation and aggregation 
Platelet activation occurs in two steps, activation and aggregation (Figure 1.2) and is a 
complex biochemical process that requires the co-activation of many signalling 
pathways within and outside the platelet. In order for platelets to become activated they 
first need to come into contact with proteins of the exposed endothelial matrix as a 
result of either blood vessel damage or rupture of an atherosclerotic plaque (Chambers 
2004; Solet et al. 2001). Collagen, vWf, and fibronectin are adhesive molecules found 
within the sub-endothelial matrix that when bound to their respective receptor on the 
platelet membrane results in rapid platelet activation (Jackson et al. 2003). Upon 
adhesion to the damaged blood vessel platelets change shape from an inactivated 
discoid to an activated 'spiny' shape through contractile rearrangement of the 
cytoskeleton leading to the formation of pseudopods (long dendritic extensions) 
facilitating adhesion (Dopheide et al. 2001; George 2000; Willoughby 2002). 
Organelles contained within the platelet such as mitochondria and storage granules are 
contracted towards the platelet centre and become enclosed in a tight-fitting ring of 
reassembled microtubules and microfilaments (Willoughby 2002; White 1999). The last 
stage in activation is the expulsion of secretory organelle contents. Activated platelets 
form stable adhesion contacts with the damaged vessel wall and spread out over the 
injured surface to form a pseudoendothelium. 
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Once this platelet layer is stable, it provides a highly reactive surface for the recruitment 
of other circulating platelets. These adherent platelets recruit other circulating platelets 
to the site of injury through the release of chemoattractant agents allowing for the 
formation of a thrombus thus, sealing the damaged vessel and arresting any further 
blood loss (Chambers 2004; George 2000). 
The platelet membrane contains a vast array of receptors, each specific for a particular 
agonist. The type of intracellular signal generated is dependent upon the potency of the 
agonist and its specificity for its corresponding receptor on the platelet cell surface 
membrane the binding of an agonist to its specific receptor sets in motion a series of 
biochemical signalling events that ultimately leads to platelet aggregation. The major 
agonists, receptors and adhesion molecules that are involved in platelet-platelet 
interaction are summarised in Table LL Platelet agonists (ADP, TXA2, adrenaline, 
serotonin, thrombin and collagen) interact with seven specific transmembrane receptors 
that are coupled by GTP-binding heterotrimeric G proteins or tyrosine kinase-linked 
receptors (Jurk and Kehrel 2005). The majority of platelet receptors are G proteins and 
these are regulatory proteins which mediate the interaction between cell surface 
receptors, and intracellular messengers such as phospholipases and ion channels. In 
platelets the receptor plays a major role in signal transduction by bridging the 
interaction between agonist receptor and the enzymes that produce second messengers 
for platelet aggregation to occur. These include receptors for adenosine 5'-diphosphate 
(ADP), arachidonic acid (AA), collagen, adrenaline, thrombin, vWf, serotonin and 
platelet-activating factor (PAF) amongst many others. 
Table 1.1. Agonists, ligands and receptors important for platelet function 
Platelet Function Agonists, ligands Receptors 
Initial and finn adhesion vwf GPIbN/IX 
TSPI GPIbN/IX, CD36 
Collagen a201, GPVI, CD36 
Fibrinogen alIbP3 
Fibronectin a5pi 
Vitronectin aVP3 
Leminin a6PI 
High shear stress GPIbN/IX 
Activation and 
amplification Thrombin PARI, PAR4, GPIbN/IX 
ADP P2Yj, P2y12 
TXA2 TPa, TPO 
Adrenaline a2A 
Serotonin 5-HT2A 
MMP-2, MMP-l ? 
Immune complexes FcyIIa 
Complement factors CIq, C3 a, C5 a receptors 
Plasmin ? unknown 
Streptokinase ? unknown 
Aggregation/ amplification 
and stabilisation Fibrin Activated allbP3 
vWf Activated alIbP3, 
GPIbN/IX 
TSP-1 Activated aIlbP3,, CD36, 
IAP 
Fibronectin Activated aIIbP3 
sCD40L Activated alIbP3 
Gas6 Axl 
SDF-1, TARC, MDC CXCR4, CCRA 
Taken from Jurk and Kehrel (2005). Key: TSP 1, thrombospondin- 1; MMP, matrix 
metal loproteinase; IAP, integrin associated protein; SDF, stromal, cell-derived factor, TARC, 
thymus and activation-regulated chemokine; MDC, macrophage-derived chemokine. 
in 
In general, following agonist interaction with its receptor an inhibitory signal is sent to 
adenylate cyclase (AC). This enzyme is involved in the formation of cyclic adenosine 
monophosphate (cAMP) - an inhibitor of calcium mobilisation within the cell thus 
inhibiting platelet aggregation. Tberefore, it is essential that the production of cAMP is 
discontinued allowing for aggregation to occur. The regulation of cAMP is an important 
mechanism for the suppression of platelet activation and aggregation. A rise in 
intraplatelet cAMP via AC or through the inhibition of phosphodiesterase leads to the 
sequestration of calcium within the cell. cAMP levels are increased through the 
stimulatory actions of the prostaglandins: prostacyclin (PGI2) and prostaglandin El 
(PGEI). Another signal is relayed to the plasma membrane where AA is metabolised 
from phospholipids by activated phospholipase A2 (PLA2). The AA can be converted 
into prostaglandin endoperoxides (PGG2/PGH2) by cyclooxgenase (COX) and 
subsequently to thromboxane A2 (TXA2) by thromboxane synthase (TS), leading to the 
mobilisation of calcium from intracellular stores within the platelet to aid in cytoskeletal 
reorganisation and the formation of pseudopodia. By-products of COX and TS reactions 
diffuse out of the platelet membrane and bind to surface receptors leading to the 
activation of phospholipase C (PLC). 
PLC catalyses the hydrolysis of phosphatidyl inositol bisphosphate (PIP2) into the 
second messengers: phosphoinositol triphosphate UP3) and diacylglycerol (DAG). IP3 
stimulates an influx of calcium from internal stores in the endoplasmic reticulum; the 
calcium along with DAG activates protein kinase C (PKC). Activation of PKC leads to 
rearrangement of the cytoskeleton and subsequent platelet shape change, during which 
the contents of the dense granules (a, 8 and %) are released into the surrounding 
extracellular environment. Substances such as; ADP and serotonin (5HT) aid in the 
amplification of the platelet response and recruitment of nearby platelets which join the 
platelet plug. The agonist also induces the exposure of the conformationally competent 
GP Ilb-Illa complex (fibrinogen receptor) via an inside-out signalling mechanism 
which, in the presence of released calcium ions (C2) binds to fibrinogen which allows 
for the cross-linking of platelets thus facilitating platelet aggregation and the formation 
of a thrombus (platelet aggregate) (Andre et al. 2003; Dopheide et al. 2001; Solet et al. 
2001). The cell signalling events involved in ADP platelet activation/ aggregation are 
summarised in Figure 1.3. 
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Figure 1.3. The biochemical events involved in ADP-induced platelet activation. ADP binds 
to its respective receptors P2Y, and P2YI2 on the platelet cell surface. Simultaneous binding 
of both receptors is required for platelet aggregation. ADP-receptor interaction triggers a 
series of events that ultimately leads to platelet aggregation. The P2Y, receptor stimulates the 
hydrolysis Of PIP2 into IP3 and DAG via the enzyme PLCP. IP3 binds to its receptor IP3R on 
the endoplasmic reticulum to release calcium ions into the intracellular environment. Ca 2' and 
DAG activate PKC to rearrange the cytoskeleton and the release of dense granule contents 
into the extracellular environment. These include substances such as ADP, fibrinogen, 5-HT 
etc. which aid in the recruitment and activation of nearby platelets. Ca 2' and other inside-out 
signalling mechanisms allow for the fibrinogen receptor allbP3 to undergo a conformational 
change allowing for the binding of fibrinogen to its receptor. The ADP receptor P2YI2 inhibits 
the actions of the enzyme adenylate cyclase and suppresses the levels of intracellular cAMP. 
Key: PIP2-phosphatidyl inositol bisphosphate; IP3-phosphoinositol triphosphate; DAG- 
diacylglycerol; PLCB-phospholipase C beta; IP3R-phosphoinositol triphosphate receptor; 
PKC-protein kinase C; 5-HT-serotonin. 
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1.3. INHIBITORS OF PLATELET AGGREGATION FOR THE TREATMENT 
AND PREVENTION OF CARDIOVASCULAR DISEASE 
Platelet aggregation plays a significant role in the development and progression of CVD 
(Banedee and Maulik 2002; Gawaz 2006; Huo and Ley 2004; Imano et al. 2002; 
Keating et al. 2004; McBane et al. 2003; Rauch et al. 2001; Tan et al. 2004; VanWijk et 
al. 2003). Over recent years a lot of research has been focused on both dietary 
supplements and conventional medicines that could be used in the treatment and 
prevention of CVD with the emphasis being on a reduction in the ability of platelets to 
form aggregates. 
1.3.1 Endogenous inhibitors of platelet function 
Platelets circulate freely within the body even though they are constantly in close 
contact with the endothelium. Therefore, there are natural mechanisms within the body 
that prevent spontaneous activation of platelets within the blood vessels thus preventing 
platelet aggregate formation. Also, once a platelet aggregate has been formed there has 
to be a mechanism that prevents the finiher recruitment of platelets to the injury site 
otherwise the effects could be detrimental. Platelets share mutually repellent negative 
charges with the endotheliurn via the release of substances such as Prostaglandin El 
(PGEI), Prostacyclin (PG12) (endotheliurn and platelets) and nitric oxide from 
endothelial cells. These substances interact with receptors on the platelet surface and/or 
diffuse across the plasma membrane where they lead to the secretion of substances such 
as cAMP and/or cyclic guanylyl monophosphate (cGMP). This interaction leads to the 
activation of protein kinases which decrease the Ca2+ concentration and prevents further 
platelet activation and aggregation from occurring. Another process by which the body 
controls platelet activation and aggregation is through the breakdown of extracellular 
ADP to AMP by the enzyme ecto-ATPdase (adenosine triphosphate disphosphorylase), 
which is expressed by endothelial cells (Tan et aL 2004). 
1.3.2 Pharmacological inhibition of platelet function 
In disease states the regulatory mechanisms that occur in healthy individuals cannot be 
relied upon to function normally to suppress the development of disease. Hence, 
pharmacological intervention is used in an attempt to redress the balance and hopefully 
halt further disease progression and return the body to normal physiological conditions. 
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The medicines currently available on the market can be divided into 3 groups: 
cyclooxygenase (COX) inhibitors, ADP receptor antagonists and GPlIb/Illa receptor 
antagonists. 
1.3.2.1. Cyclooxygenase inhibitors in the control ofplateletfunction 
The most established COX inhibitor to-date is aspirin. It is an effective anti-platelet 
drug which has multiple dose-dependent therapeutic effects (Clutton et al. 2001). 
Aspirin exerts its inhibitory effect upon platelet activation by irreversibly suppressing 
thromboxane A2 synthesis during arachidonate metabolism. This is achieved by 
rendering the enzyme COX inactive through acetylation, without this enzyme 
arachidonate metabolism cannot continue and the platelet aggregatory process is 
stopped. It has been found clinically that administration of aspirirl produces dose- 
dependent inhibition of platelet COX activity after a single oral dose. The inhibitory 
effect of aspirin can be observed as quickly as 5 min after oral administration, and the 
inhibitory effect is maintained for the entire life-span of the platelet. This is because 
platelets lack the synthetic machinery to generate significant amounts of new COX 
(Michelson 2004), whose activity only returns when new platelets are generated and 
released from the bone marrow into the circulatory system. 
1.3.2 2. ADP receptor antagonists and their effect on the control ofplateletfunction 
ADP plays an important role in platelet activation and subsequent aggregation. Upon its 
release from dense granules it binds to its receptors P2Y I and P2Y12 (Hardy et al. 
2005), to initiate calcium mobilisation, and inhibit adenylyl cyclase activity, 
respectively (Gachet 2001; Puri 1999). For platelet activation and aggregation to occur 
successfully, it is essential that both ADP receptors are occupied with ADP. Thus, if one 
of the receptors were to be antagonised platelet aggregation would not be allowed to 
continue. There are two ADP receptor antagonists available clinically these being 
clopidogrel and ticlopidine. 
1.3.2 3. GPIM-Ma receptor antagonists 
GPIIb-IIIa receptor antagonism has a strong anti-platelet effect; this inhibition is due to 
interference of the final common pathway of platelet aggregation and is not dependent 
on a single activation pathway. To-date there are 3 main GPllb-lIla antagonists 
clinically available for the treatment of cardiovascular disease these are: abciximab (a 
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chimeric monoclonal antibody), eptifibatide (a cyclic heptapeptide) and tirofiban (a 
nonpeptide tyrosine derivative), all of which are administered intravenously for 
maximum cffect. 
1.3.3. Natural (alternative) inhibition of platelet function 
Pharmacological intervention can produce promising results, however it is not without 
risk. As prolonged treatment with drugs such as aspirin can result in the treatment no 
longer being effective and the patients can often develop a resistance to the drug 
rendering it ineffective. Therefore, both researchers and clinicians are always looking 
for alternative preventative and treatment methods. Research over the past. 40 years has 
shown that the use of dietary supplements such as green tea extract, ginger, kinetin, 
glucosamine, have caused a significant reduction in platelet aggregation both in vivo 
and in vitro studies (Hua et al. 2004; Nurtjahja-Tjendraputra et al. 2003; Sheu et al. 
2003; Son et al. 2004). Not only dietary supplementation but, foods in general can also 
inhibit platelet aggregation such as tomatoes, onions, chives, kiwi fruit, dark chocolate, 
turmeric, red wine (polyphenols present in wine) (de Lange et al. 2003; Duttaroy et al. 
2002; Innes et al. 2003; Moon et al. 2000; Osmont et al. 2003; Shah et al. 1999). One 
such food that has been researched extensively for its cardioprotective properties 
including its inhibition of platelet aggregation is garlic (Table 1.2). 
There are many benefits into researching alternative therapies for CVD. The primary 
reason is that the herb of interest is already well-established as a treatment/preventative 
method through its use in folklore medicine. Studies indicate that these herbs have 
multifactorial effects within the body. It is often expensive and time-consuming to 
research conventional treatments, as there are a number of stages of development and 
testing that needs to be done before it can be given to humans in clinical trials. Herbs 
have a variety of components that target many different cellular processes 
simultaneously whereas pharmacological trials look at the effects of one particular 
active constituent. Many pharmacological studies do not reach completion in that the 
constituent under investigation proves effective during initial testing but, often fails 
during clinical trials due to in part to the side effects that are associated with its use. 
New regulations and legislations into the therapeutic use of herbal remedies have been 
introduced in Europe by the European Union. This has caused an increase in the number 
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of scientific studies researching the protective and preventive properties of herbs to 
ensure that they actually are beneficial in the treatment of diseases such as CVD (Kroes 
2006). 
Herbal use throughout the world has reached high prevalence over the past 20 years 
Further research is necessary to elucidate the pharmacological activities of many herbal 
therapies now being used to treat CVD. This is the primary reason why it is important to 
conduct studies such as this one. 
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Table 1.2. Garlic as an inhibitor of Platelet aggregation: in vitro and in vivo studies 
Ref Preparation Study Type Effect 
Bordia et al. Essential oil of In vitro inhibition 
(1978) garlic 
Makhej a et al. Garlic extract In vivo inhibition 
(1980) 
Vanderhoek et al. Garlic oil In vitro inhibition 
(1980) 
Makhej a et al. Garlic extract In vitro inhibition 
(1980) 
Ariga et al. Essential oil, In vitro Dose-dependent 
(1981) methyl- inhibition 
allyl-trisulphide 
(MATS) 
Boullin Fresh garlic In vivo, 4h inhibition 
(1981) 
Bordia et al. Garlic oil Double-blind inhibition 
(1982) 
Apitz-Castro et al. Methanol extract of In vitro inhibition 
(1983) garlic 
Barrie et al. Garlic oil, In vivo, 3 months Inhibition decreased 
(1987) diallylsulphide, with garlic 
diallyltrisulphide administration 
(DADS, DATS) 
Harenburg et al. 600 mg, dried garlic In vivo No inhibition 
(1988) 
Kiesewetter et al. Garlic powder In vivo, 4 weeks inhibition 
(1991) 
Legnanietal. Chinese garlic In vivo, 14 days inhibition 
(1993) powder 
Steiner et al. Aged Garlic in vivo, 6 months Inhibition 
(1994) Extract (AGE) 
Morris et al. Oil extract of garlic In vivol in vitro Inhibition in vitrol 
(1995) no inhibition in vivo 
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Ali and Thompson Fresh garlic In vitrol in vivo inhibition 
(1995) 
Agarwal et al. cycloalliin In vivo inhibition 
(1997) 
Steiner and Lin AGE In vivo, II months inhibition 
(1998) 
Qi et al. Diallyl trisulfide In vitro inhibition 
(2000) 
Rahman and AGE In vivo, 13 weeks inhibition 
Billington 
(2000) 
Steiner and Lin AGE In vivo, 6 weeks inhibition 
(2001) 
Chan et al. Diallylsulfide, In vitro inhibition 
(2003) diallyl disulphide, 
diallyltrisulphide 
Chang et al. Alk(en)yl In vitro inhibition 
(2004) thiosulfate 
Allison et al. AGE, In vitro Inhibition 
(2006) Individual AGE Dose-dependent 
constituents No inhibition with 
individual 
constituents of AGE 
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1.4. GARLIC 
Garlic (Allium sativum) derived from the Old English word garleac, meaning "spear 
leek" dates back over 6000 years from its origins in Central Asia. It is a member of the 
lily (Liliaceae) family which also includes: onions, leeks, chives and shallots. Garlic has 
become domesticated over the years to suit different climates with over 300 varieties of 
the herb grown world wide. One of the most common varieties of garlic is American 
garlic which has white papery skin and is strong in flavour, other types include Mexican 
garlic which is pink in colour and has a medium flavour. Throughout history there are 
many references made in folk medicine to the use of this plant as a treatment for a 
variety of ailments. These include in the UK as a cold remedy, in certain parts of Asia it 
has been used in the treatment of conditions such as 'whooping cough, ' fungal and 
bacteria infections to name a few. 
1.4.1 Garlic and cardiovascular disease - the benerits 
Research conducted on the benefits of garlic consumption with regards to CVD has 
been carried out over the past 40 years and has shown that garlic has a positive effect on 
lowering its incidence. Studies have shown that garlic intake is associated with a 
lowering of blood glucose levels, a reduction in blood pressure, cholesterol levels, and it 
also inhibits platelet aggregation (Banedee and Maulik 2002; Barrie et aL 1987; 
Berthold and Sudhop 1998; Bordia et aL 1998; Fugh-Berman 2000; Orekhov and 
Grunwald 1997; Rahman and Lowe 2006; Tattelman 2005) 
1.4.2. Commercially available garlic products 
As garlic is very prominent in history in the treatment of CVD, many scientists and 
dietary supplement manufacturers have looked at alternative ways of processing raw 
garlic for supplementation into the diet. These can be found today on the shelves of 
many health food stores, and include: garlic tablets, aged garlic extract, oil of steam- 
distilled garlic, oil of oil-macerated garlic, ether extracted oil of garlic, liquid garlic. 
Each is processed in different ways and contain markedly different sets of compounds 
thus, making studies of comparison extremely difficult for researchers (Table 1.3). The 
garlic dietary supplement of interest in this particular study is aged garlic extract 
(Kyolic). 
In 
Table 1.3. Commercially available garlic products, their main compounds and 
characteristics. 
Product Main compounds and characteristics 
Garlic essential oil I% oil-soluble sulphur compounds (e. g., 
DAS or DADS) in 99 % vegetable oil 
No water-soluble fraction 
No allicin 
Not well standardised 
No safety data 
Garlic oil macerate Oil-soluble sulphur compounds and alliin 
No allicin 
Not well standardised 
No safety data 
Garlicpowder Alliin and a small amount of oil-soluble 
sulphur compounds 
No allicin 
Not well standardised 
Results on cholesterol are not consistent 
No safety data 
, 4ged garlic extract Mainly water-soluble compounds (e. g. 
SAC, SAMC or saponins) 
Standardised with SAC 
Small amount of oil-soluble sulphur 
compounds 
Various beneficial effects 
Well-established safety 
Heavily researched (300+ papers) 
Taken from Amagase et al. (2001) 
Abbreviations: DAS, diallyl sulphide; DADS, diallyl disulphide; SAC, s-allyl cysteine; 
SAMC, s-allyl mercaptocysteine. 
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1.5. AGED GARLIC EXTRACT 
AGE is produced by Wakunaga of America, Co., Ltd, Mission Viejo, USA. AGE is 
produced from organically grown garlic and is aged for up to 20 months in stainless 
steel tanks. This cold aging process modifies the raw garlic into a unique complex 
chemical mixture via natural chemical and enzymatic reactions. It is standardised with 
S-allYI-L-cysteine (SAC), a safe and stable organosulphur compound derived from garlic 
as a means of quality control and lot-to-lot product uniformity. AGE contains no more 
than 0.05 % SAC by dry weight (1.47 g/1). Scientific testing has confirmed through 
toxicological analysis that AGE is safe for human consumption and has no adverse side 
effects associated with its prolonged use (Lawson and Gardner 2005; Hoshino et al. 
2001; Kyolic 2006). 
1.5.1. Chemical composition of AGE 
Chemical constituents contained within raw garlic include: sulphur-containing 
compounds such as ajoene, alliin, cysteine sulfoxides, trisulfides etc, at least 17 amino 
acids, and a variety of vitamins and minerals (Brace 2002). The general composition of 
fresh garlic is shown in Table 1.4. The major component of garlic is water, other 
components present include: carbohydrates, sulphur compounds, protein, fibre, amino 
acids, saponins, vitamins and minerals (Lawson 1996). The characteristic flavour and 
aroma associated with garlic is due to the organosulphur compounds (Table 1.5) and the 
biological activity of this herb is attributed to these particular constituents (Agarwal 
1996; Block 1985; Block 1992; Rose et al. 2005; Tapiero et al. 2004; Xiao and Parkin 
2002). AGE differs in chemical composition to fresh garlic in that most of the 
components responsible for characteristics such as odour (thiosulfinates) are removed 
during the aging process. The major components found in AGE are water-soluble 
organosulphur compounds, and also present are unique biochemical constituents not 
found in fresh garlic: S-allyl-L-cysteine, fructosylarganine and 1,2,3,4-tetrahydro-B- 
carboline-3-carboxylic acids (Ryu and Rosen 2003) but are formed and their content is 
increased during manufacture. During the aging process y-glutamyl-S-allylcysteine, the 
parent compound to alliin is converted to S-allylcysteine (SAC), S- 
ally1mercaptocysteine (SAMC) and others. Weinberg et al. (1992) developed a method 
which detected and identified nine oil-soluble organosulphur compounds in AGE, these 
include: diallyl sulphide; triallyl sulphide; diallyl disulphide and diallyl polysulphide. 
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Several organosulphur compounds have been identified and isolated from AGE. These 
will be discussed in more detail in chapter 3. 
Table 1.4. General composition of garlic 
Component Amount (fresh weight; %) 
Water 62-68 
Carbohydrates 26-30 
Protein 1.5-2.1 
Amino acids: common 1-1.5 
Amino acids: cysteine sulphoxides 0.6-1.9 
y-Glutamylcysteines 0.5-1.6 
Lipids 0.1-0.2 
Fibre 1.5 
Total sulphur compounds 1.1-3.5 
Sulphur 0.23-0.37 
Nitrogen 0.6-1.3 
Minerals 0.7 
Vitamins 0.0015 
Saponins 0.04-0.11 
Total oil-soluble compounds 0.15 
Total water-soluble compounds 97 
Taken from Lawson (1996) 
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Table 1.5. Principal organosulphur compounds found in garlic 
Compound mg/g fresh weight 
S-(+)-Alkyl-L-CYSteine sulphoxides 
Allylcysteine sulphoxide (alliin) 6-14 
Methylcysteine sulphoxide (methiin) 0.5-2 
Trans- I -Propenylcysteine sulphoxide 0.1-1.2 
(isoalliin) 
Cycloallfin 0.5-1.5 
7-L-Glutamyl-S-alkyl-L-propenylcysteine 
y-Glutamyl-S-trans-l-propenylcysteine 3-9 
y-Glutamyl-S-allylcysteine 2-6 
-1-Glutamyl-S-methylcysteine 0.1-0.4 
Taken from Lawson (1998) 
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1.5.2. Therapeutic actions of AGE 
Since its development in 1955, there have been more than 350 scientific research studies 
conducted on the therapeutic actions of AGE and its constituents (Wakunaga of 
America; www. kyolic. com). The following therapeutic properties have been identified: 
cardioprotective, liver-protective, immune enhancement, antioxidant and 
radioprotective effects, anti-stress and anti-fatigue, anti-cancer, neurotrophic, anti-aging, 
anti-depression, anti-fungal, and anti-bacterial (Wakunaga of America, 
www. kyolic. com). The studies are a combination of both in vitro and in vivo testing. 
Clinical studies have shown that AGE is proficient in its ability to reduce cardiovascular 
risk factors associated with disease progression and these include: a reduction of blood 
lipids (serum cholesterol and triglycerides); inhibition of platelet aggregation; and a 
reduction in blood pressure following AGE administration for a specified period of 
time. Since this study is concerned with the effects of AGE on platelet aggregation, the 
cardioprotective properties of AGE found in clinical studies are summarised in Table 
1.6 (a brief summary of the various clinical studies that looked at the cardioprotective 
actions of AGE). 
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Table 1.6. The cardioprotective effects of AGE - Clinical studies 
Risk factor Study 
Lipid reduction Lau et aL (1987) 
AGE was administered to subject's withT 
cholesterol for 6 months. Results: I serum 
cholesterol, I LDL cholesterol, T HDL 
cholesterol. No change in the placebo 
group. 
Yeh et al. (1995,1997) 
5 month double-blind, randomised, 
placebo controlled trial of men with T 
cholesterol. Results: I total plasma 
cholesterol, I LDL cholesterol. 
Inhibition ofplatelet aggregation 
Lowering ofbloodpressure 
Rahman and Billington (2000) 
13 week randomised, double-blind study. 
I platelet aggregation induced with ADP. 
Steiner and Lin (I 996a) 
6 month double-blind crossover study. 
$ systolic and $ diastolic blood pressure. 
Steiner and Lin (1996b) 
6 month double-blind, placebo controlled, 
crossover study of hyperlipidemic patients. 
I systolic blood pressure. 
Inhibits plaqueformation Budoff et aL (2004) 
Randomised double-blind placebo 
controlled pilot study in heart surgery 
patients. I inhibits plaque formation in the 
coronary artery. 
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1.6. AIMS AND OBJECTIVES OF STUDY 
The first aim of this study was to investigate the effects of AGE and its constituents on 
agonist-induced platelet aggregation in vitro. 
e The effect of AGE on platelet aggregation induced by a variety of agonists was 
investigated using platelet aggregornetry. 
9 Individual components isolated from AGE and mixtures of these components 
were added to platelets and their inhibitory effect was monitored on platelet 
aggregation induced with the agonist ADP. 
9 Known classical inhibitors of platelet aggregation were compared to the 
inhibitory actions of AGE in platelets aggregated with ADP in order to elucidate 
a possible mechanism behind the observed inhibition of platelet aggregation 
with AGE. 
The second aim of this study was to try and establish a possible inhibitory mechanism 
for AGE on ADP-induced platelet aggregation. This was achieved by breaking down 
the biochemical signalling pathways involved in platelet aggregation in vitro. The 
effects of AGE on the following pathways was monitored: 
e The effects of AGE on calcium mobilisation were monitored using platelet 
aggregometry, fluorescent microscopy and fluorescent spectrophotometry. 
9 To investigate the effects of AGE on arachidonic acid (AA) metabolism when 
platelets were stimulated with the agonist ADP, was assessed using thin-layer 
chromatography (TLC). 
e The effect of AGE on the ability of fibrinogen to bind to its receptor GPlIb-IIIa 
to produce a stable platelet aggregate in vitro was measured using four 
independent methods: disaggregation, a simple adhesion assay, flow cytometry 
and SEM imaging. 
9 cAMP levels and the potential effect AGE has upon this nucleotide was assessed 
using a competitive ELISA assay. 
e To determine if AGE has any proteolytic activity was monitored by an azocasein 
assay and SDS-PAGE analysis, respectively. 
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The final aim of this study was to investigate and identify an inhibitory mechanism for 
AGE on platelet aggregation in vivo. 
" The ex vivo effect of AGE on ADP-induced platelet aggregation was measured 
using platelet aggregometry. Whole blood was incubated with AGE, the 
platelets were removed and aggregation curves were analysed and compared to 
that of a control. 
" Human clinical trial. Volunteers were recruited from the university population, 
and blood samples were taken at Day 0 (baseline), Day 14 (following AGE 
administration, 5 ml/day) and Day 28 (washout). The platelets were removed 
from the whole blood and the following parameters were tested: platelet 
aggregation induced by the agonists: ADP, AA, adrenaline and collagen, 
intracellular cAMP levels were monitored using an EIA assay, the expression 
and binding capabilities of the fibrinogen receptor GPIlb/IlIa (fibrinogen 
receptor expression on platelets were measured using flow cytometry), and total 
cholesterol was also determined. 
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CHAPTER 2 
MATERIALS AND METHODS 
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2. MATERIALS AND METHODS 
2.1. MATERIALS 
2.1.1. Chemicals 
Adenosine diphosphate (ADP), aspirin (acetylsalicyclic acid), A23187, AG527, 
aluminium fluoride (AIFA azocasein, L-arginine, L-cysteine, L-methionine, 
bisindolymaleimide (BIS), Bovine Serum Albumin (BSA), Bradford reagent, 
bromophenol blue, coomassie brilliant blue G-250, chymotrypsin, dimethyl sulfoxide 
(DMSO), ethylenediamineetetaacetic acid (EDTA), ethylene glycol-bis(2-amino- 
ethylether)-N, N, N', N'-tetra-acetic acid (EGTA), ethyl acetate, fibrinogen fraction I 
Type IV: from Bovine plasma, fixer and replenisher, Fura-2 pentakis (acetoxymethyl) 
ester (Fura-2/AM), genistein, glycerol, glycine, HEPES, hexadimethyldisilazane, 3- 
isobutyl- I -methylxanthine (IBMX), immunoglobulin G (IgG), indomethacin, 2- 
mercaptoethanol, okadaic acid (OKA), phorbol 12-myristate acetate (PMA), phosphate 
buffered saline tablets (PBS), phenylmethylsulfonyl fluoride (PMSF), poly-L-lysine, 
prostacyclin (PG12), Rose Bengal, sepharose 2B, sodium cacodylate, sodium citrate, 
sodium arachidonate, sodium dodecyl sulphate (SDS), pre-stained low range molecular 
weight markers were obtained from Sigma-Aldrich, Dorset, UK. Collagen, adrenaline 
and arachidonic acid were obtained from Bio/Data, Horsham, USA. Acetic acid, 
acetone, acrylamide, ammonium persulfate (APS), bis-acrylamide, chloroform, colloidal 
coomassie brilliant blue stain, diethyl ether, formaldehyde, glutaraldehyde, hexane, 
hydrochloric acid, methanol, triton X- 100, NNN', N'-tetramethylethylendimin 
(TEMED), Tris(hydroxymethyl)methylamine (Tris), trichloroacetic acid (TCA), 
prostaglandins D2, E2,172c, protease inhibitor cocktail set III, sulphuric acid was obtained 
from VWR International, Dorset, UK. Ecoscint A was obtained from National 
Diagnostics Limited (Wigan, UK). Absolute alcohol 100 purchased from Hayman 
Industries, Essex, UK was supplied via the university chemical stores. [14C]_ 
Arachidonic acid, chromium-5 1, cyclic adenosine monophosphate (cAMP) enzyme 
immunosorbent assay was obtained from Amersham, UK. PAC- I FITC IgM antibody 
and CD42a PerCP, clone Bebl was obtained from Becton Dickinson Biosciences UK 
Limited, UK. Aged Garlic Extract (Kyolic), alliin, cycloalliin, P-chlorogenin (PC), 
frutosylarginine (FA), S-allylcysteine (SAC), S-allylmercaptocysteine (SAMC), S- 
ethylcysteine (SEC), S-methylcysteine (SMC), and S-propenylcysteine (SPQ were 
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kindly provided by Wakunaga of America Limited (Mission Viejo, CA). NB. All 
solvents used were HPLC grade. 
2.1.2. Aged Garlic Extract 
Aged garlic extract (AGE) is produced by soaking raw garlic in 15-20 % aqueous 
ethanol for approximately 20 months at room temperature. The extract is then filtered 
and concentrated under reduced pressure at low temperature. The presence of water- 
soluble compounds found in AGE is relatively high compared to that of oil-soluble 
compounds which is low. The AGE used in this study for both in vitro and in vivo 
investigations contained 305 g/L extracted solids, with S-allylcysteine, the most 
abundant water-soluble compound, was present at 1.47 g/L. The same batch of AGE 
was used in both the in vitro and in vivo studies. 
2.2. VOLUNTEER BLOOD COLLECTION 
This study has been approved by both the Research Degrees and Ethics Committee 
(Liverpool John Moores University), and informed consent was obtained from all 
volunteers (Appendix I). Blood samples (20 mL) were collected via venepuncture from 
healthy volunteers who had not taken any medication known to interfere with platelet 
function for two weeks prior to donation, and was mixed with 3.8 % (w/v) trisodium 
citrate as the anticoagulant in the ratio 9: 1 ýv/v). 
2.3. PREPARATION OF HUMAN PLATELET SUSPENSIONS 
2.3.1. Preparation of human platelet-rich plasma 
Platelet-rich plasma (PRP) was prepared as described previously by Rahman and 
Billington (2000). In brief, whole-citrated blood was centrifuged for 10 min at 150 x g. 
The PRP was removed and the remaining blood was centrifuged further for 20 min at 
1500 xg to obtain platelet-poor plasma (PPP). The platelet count for the PRP was 
determined using a Neubauer Haemocytometer and the platelet count was adjusted if 
necessary to 2.5 ± 0.5 x 105 cells/mL by dilution with PPP. All the samples were kept at 
room temperature prior to testing, and the experiments were completed within 3h of 
blood collection. 
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2.3.2 Preparation of gel-filtered platelet suspensions 
Gel-filtered platelets (GFP) were prepared as described by Walkowiak et aL (2000). 
Briefly, aII mL packed Sepharose 2B column was washed and equilibrated in HEPES- 
Tyrode's buffer, pH 7.4 (13 8 mM NaCl, 3.3 mM NaH2PO4,2.9 mM KCI, I MM M902, 
I mg/mL glucose, 20 mM HEPES). Prior to platelet separation from PRP, excess buffer 
was removed from the top of the column. Upon the addition of the total PRP volume (I 
mL) to the gel surface, HEPES-Tyrode's buffer was layered onto the column gradually 
in volumes required for proper column operation. Platelet suspensions, with the 
appearance of clouded drops (1.5 mL) were collected after an elution volume of 2.5 mL, 
and platelet concentration was determined using a Neubauer Haemocytometer and the 
platelet count was adjusted with buffer if necessary to 2.5 x 105 cells/mL. 
2.3.3. Preparation of washed platelet suspensions 
Washed platelet suspensions were prepared following the method developed by 
Radomski and Moncada (1983). In brief, PRP was supplemented with PG12, to the final 
concentration of 300 nniol/L to prevent spontaneous platelet aggregation from occurring 
by increasing the intraplatelet levels of cAMP. The PG12 treated PRP was centrifuged 
for 15 min at 1000 x g, the resultant platelet pellet was resuspended in PBS or HEPES- 
Tyrode's buffer and centrifuged again. After the washing procedure was completed the 
platelet pellet was resuspended in buffer and the platelet count adjusted to 2.5 x 105 
cells/mL. 
2.4. PLATELET AGGREGATION STUDIES 
2.4.1. Measurement of platelet aggregation using a light transmittance method 
Platelet aggregation was performed in a PAP-41) Platelet Aggregation Profiler 
(Bio/Data Corporation, Horsham, PA), which was calibrated first with PPP (100 % 
aggregation) followed by PRP (0 % aggregation). Aggregation was carried out in 200 
pL of PRP at 37*C and initiated via the addition of 20 PL of an aggregating agent 
(Refer to Table 2.1. ). The PAP-413 is a multi-channel aggregometer that uses a light 
transmission method to measure the following parameters: total percentage aggregation 
and the initial slope of aggregation. The parameter used throughout these studies was 
II 
total percentage aggregation. In this study ADP was used as the primary agonist unless 
otherwise stated. 
2.4.2. Inhibition of agonist-induced platelet aggregation by AGE and its 
constituents 
The following reagents were added to freshly prepared human PRP and incubated for 10 
min at 37'C. Platelet aggregation was initiated via the addition of an aggregating agent 
(Table 2.1). To the controls an equal volume of the appropriate vehicle was added to the 
PRP and treated as above. 
i. Concentrations of AGE were prepared from neat liquid AGE (100 %) by dilution in 
PBS and the following final percentage concentrations (v/v) in PRP were: 0.78,1.56, 
3.12,6.25,12.5 and 25 % (v/v), respectively. 
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Table 2.1. Concentrations of agonists used to initiate platelet aggregation in vitro, that 
produced maximal total percentage aggregation when measured in a 
Watelelet aiagregometer. 
Agonist Final Concentration when added to 
PRP (0.2 xnL) 
ADP 8 pmol/L 
AA 250 pg/mL 
Adrenaline 20 pmol/L 
A23187 5 jimol/L 
Collagen 190 pg/mL 
Thrombin 0.1 U/L 
PMA 10 pmol/L 
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ii. Ethanol diluted in PBS to the final concentrations: 0.1,0.25,0.5 and 1.0 %, was 
added to 0.2 mL PRP respectively. To the controls an equal volume of PBS was added 
to the PRP and platelet aggregation was initiated via the addition of either ADP (8 
pmol/L) or collagen (190 pg/mL). 
iii. Nine individual components isolated from AGE: alliin, cycloalliin, P-chlorogenin 
(PC), frutosylarginine (FA), S-allylcysteine (SAC), S-allylmercaptocysteine (SAMC), 
S-ethylcysteine (SEC), S-methylcysteine (SMC), and S-propenylcysteine (SPQ were 
added to PRP and incubated for 10 min at 37'C platelet aggregation was initiated with 
the agonist ADP. The concentrations of individual components used in the experiment 
are presented in Table 2.2. 
The individual components listed in Table 2.2 were also mixed together and their effect 
upon platelet aggregation was examined. Seven mixtures were prepared; mixture I (M I) 
contained all nine components at the final concentrations in PRP that produced the 
greatest degree of inhibition compared to the control when tested individually (Table 
2.3). This was done to try and establish if all the individual components work 
synergistically to inhibit platelet aggregation. The subsequent six mixtures contained all 
nine constituents at the following final concentrations in PRP: 0.0 195,0.78,6.25,100 
and 250 pmol/L and 1.0 mmol/L. These concentrations were used as it is not known 
what the exact concentration of each constituent is within AGE. 
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Table 2.2 Final concentration range of each individual component from AGE added to 
PRP 
Components Concentration range of each component 
when added to PRP (ýLmol/L) 
Alliin 
Cycloalliin 
PC 0.78 
FA 3.125 
SAC 6.25 
SAMC 25 
SEC 100 
SMC 
SPC 
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Table 2.3. Concentrations of individual AGE components contained within 
mixture I (MI). Concentration used in MI was capable of inhibiting 
t)latelet aaareization when each component was examined individually. 
Individual component from AGE Concentration that produced most 
inhibition when tested on its own 
(jamol/L) 
Allfin 100 
PC 6.25 
Cycloalflin 3.125 
FA 0.78 
SAC 0.78 
SAMC 3.125 
SEC 0.78 
SMC 6.25 
SPC 6.25 
36 
iv. The amino acids L-arginine, L-cysteine and L-methionine are found within AGE. 
These amino acids were tested both individually and as a mixture for their possible 
inhibitory effects upon ADP-induced platelet aggregation in vitro. The following final 
concentrations were added to PRP: 0.195,0.78,6.25,100 pmol/L and 1.0 and 9.0 
mmol/L. 
v. The amino acids: L-arginine, L-cysteine and L-methionine and the nine isolated 
components from AGE: allfin, cycloallfin, P-chlorogenin (PC), frutosylarginine (FA), s- 
allylcysteine (SAC), s-allylmercaptocysteine (SAMC), s-ethylcysteine (SEC), s- 
methylcysteine (SMC), and s-propenylcysteine (SPC) were mixed together and the 
effect of this mixture upon platelet aggregation was examined. The following final 
concentrations of each individual component were mixed together and added to PRP: 
0.195,0.78,6.25,100,250 pmol/L and 1.0 mmol/L, respectively. 
2.4.3. Classical inhibitors of platelet aggregation 
Table 2.4 shows the classical inhibitors of platelet aggregation and the concentrations 
used in platelet aggregation studies. The effects of the various inhibitors were compared 
to that of AGE (25 % v/v). The inhibitory actions of each classical inhibitor is 
surnmarised in Table 2.5. 
Aspirin was diluted in NaCl, 0.9 % (w/v) and was used to make up the concentrations 
listed in Table 2.4. bisindolymalemide (BIS), genistein (GEN), 3-isobutyl-l- 
methylxanthine (IBMX), Indomethacin, okadaic acid (OKA) and prostaglandin El 
(PGEI) were dissolved in DMSO, and diluted with PBS to the required concentration 
for the aggregation study (Table 2.4), the concentration of DMSO was kept below 0.05 
% (v/v). Both AIF3 and NaF were diluted with PBS. 
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Table 2.4 Classical inhibitors of platelet aggregation. The following concentrations of 
inhibitors were added to PRP and incubated for 10 min at 3 7'C, prior to 
activation with the aizonist ADP. 
Classical inhibitors of platelet 
aggregation 
Concentrations used in platelet 
aggregation studies (Itmol/L) 
0.195,0.78,6.25,80,100,250,500 
Aspirin (acetylsalicyclic acid) pmol/L, and 1.0 mmol/L 
A1173 100 
AG527 35 
BIS 100 
GEN 100 
IBMX 150 
Indomethacin 3.9,16,62.5,250 pmol/L and 1.0 mmol/L 
NaF 100 
OKA 4 
PGEI 7.5,15,31.25,62.5,125 and 250 pmol/L 
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Table 2.5. Classical inhibitors of platelet aggregation and their mechanism of 
inhibition. 
Classical Inhibitor Mechanism of Inhibition 
A1173 G-proteins 
AG527 - Tyrphostin Protein tyrosine kinases 
BIS Protein kinase C 
GEN Protein tyrosine kinases 
IBMX cAMP and cGMP phosphodiesterases 
Indornethacin Cyclooxygenase inhibitor 
OKA Protein phosphatases 
NaF Ca2' mobilisation 
PGEI Increases intracellular cAMP levels 
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2.4.4. AGE and its disaggregatory effect on agonist-induced platelet aggregation 
To examine the disaggregatory effects of AGE, it was added at various concentrations 
(% v/v) to PRP that had been preaggregated with the agonists: ADP, collagen and 
thrombin. 
The experiment was conducted only if total percentage aggregation (%) was observed to 
be ý: 60 % upon the addition of an agonist to PRP in the platelet aggregometer. AGE at 
the following final concentrations: 0.78,1.56,3.125,6.25,12.5 and 25 % (v/v), 
respectively, was added to platelets that had undergone aggregation following agonist 
stimulation with ADP (8 pmol/L), collagen (190 jig/mL) or thrombin (0.1 U). The 
disaggregatory effect (dispersal of aggregated platelets) was measured as the reduction 
in total percentage aggregation compared to a PBS control, using the formula reported 
by Naimushin and Mazurov (2003). 
[(C-A)/C)l x 100 = DA (disaggregation effect) 
C- PBS control 
A- AGE treated platelets 
2.5. THE EFFECT OF AGE ON PLATELET INTRACELLULAR SIGNALLING 
PATHWAYS INVOLVED IN PLATLET ACTIVATION AND 
AGGREGATION IN VITRO 
2.5.1. The effect of AGE on intracellular calcium signalling in platelets 
Intracellular Ca2+ measurement was carried out using the method of Park el aL, (2004). 
In brief, Fura-2/AM (a fluorescent marker that binds to the calcium ion) was added to 
PRP at a final concentration of I pmol/L and incubated for 45 min at 370C. Fura-2/AM 
loaded platelets were washed by centrifugation with HEPES-Tyrode's buffer and 
resuspended in HEPES-Tyrode's buffer (see section 2.2.2) at a concentration of 2.5 x 
106 cells/mL. Washed platelets containing Fura-2/AM were incubated with either AGE 
or a diethyl extract of AGE at a final concentration of 5% (v/v), respectively for 10 min 
at 370C. These experiments were performed in the presence of I MM CaC12, I MM 
CaC12 Plus I mM EGTA or in the presence of EGTA alone prior to the addition of the 
agonists A23187, a calcium ionphore (5 pmol/L) or ADP (8 pmol/L). Fluorescence was 
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measured using the ratio scan function on a VARIAN Cary Eclipse Fluorescence 
Spectrophotometer (Australia) and its software, version 1.1(132). The ratio scan was 
performed over a3 min time period using two excitation wavelengths alternating 
between 340 and 3 80 nin every 0.5 seconds, with the emission wavelength set to 5 10 
nin, respectively. The calcium concentration was calculated for the first 2 min of the 
scan using the following equation developed by Grynekiwicz el aL (1985): 
[Ca2+] = kd x Rt-Rmin x Sf (U) 
Rmax-Rt Sb Q2) 
kd - the effective dissociation constant (135.00) 
Rmin - the limiting value that R can have at zero [Ca2+] 
Rmax - the ratio that has saturating [C2+] 
Rt - fluorescence ratio - Fj/F2 
S- the product of the excitation intensity (f - free dye measured at wavelength X2; b- 
calcium bound dye measured at wavelength X2) 
2.5.2. The effect of AGE on the arachidonic acid metabolic pathway in platelets 
Arachidonic acid uptake was monitored using the method outlined by Jin et al., (2002). 
In brief, PRP containing approximately 2x 108 cells/mL was incubated at 3 7'C for 20 
min with I ýtCi 14C labelled arachidonic acid in PBS. The labelled platelets were 
washed and resuspended in modified HEPES-Tyrode's buffer containing: 137 mM 
NaCl, 2.7 mM KCI, 2 MM MgC12,0.42 mM NaH2P04,5 mM glucose, 10 mM HEPES, 
pH 7.4 and 0.2 % (w/v) BSA. Aliquots (500 [tL) of the radiolabelled platelet suspension 
were activated with the agonists ADP or collagen that had been pre-incubated for 10 
min at 370C in the presence or absence of 3.12 % (v/v) AGE. 100 [IL aliquots were 
taken at the following time points: 0,0.5,1.0 and 3 min after agonist stimulation. 
Platelet aggregation was terminated via the addition of one-quarter volume of stopping 
solution containing 2% formaldehyde and 40 mM EDTA resulting in the rupture of the 
platelet membranes. Samples were collected and centrifuged at 5000 xg for I min and 
the supernatant was collected into scintillant (Ecoscint A) (National Diagnostics, UK) 
and the radioactivity (8 emissions) measured using a Beckman LS 6500 multi-purpose 
liquid scintillation counter (USA). To the controls PRP labelled with cold AA was 
compared to an equal amount of 14 C-AA contained within scintillant. 
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2.5.3. AGE and its effect upon flbrinogen binding in ADP-induced platelet 
aggregation 
The effect of AGE upon fibrinogen binding was monitored using a simple adhesion 
assay (Figure 2.1). The final step in platelet aggregation in vivo common to all forms of 
agonist stimulation is the binding of the fibrinogen molecule to its receptor GPIlb/111a. 
This binding allows adjacent activated platelets to cross-link with each other to form a 
platelet aggregate. Tbus, it is important to observe the effects of AGE on this process in 
vitro. This simple assay allows this by observing the effects of AGE-treated platelets 
and their ability to bind to immobilised fibrinogen when stimulated with an agonist such 
as ADP. 
A 96-well microtitre plate was coated with fibrinogen (3 g/L) overnight at 4'C. Excess 
fibrinogen was removed from the wells and non-specific binding sites were blocked 
with I% BSA in PBS buffer. PRP was pre-treated with AGE (0.78-25 % v/v) for 10 
min at 37*C. The AGE treated platelets were added to the fibrinogen coated wells and 
aggregation was initiated via the addition of ADP and the reaction was allowed to run 
for 5 min. The reaction was stopped by placing the microtitre plate onto ice. The non- 
adherent platelets was removed from each well via aspiration and was followed by 3x 
200 pL PBS washes. 200 pL of 0.2 % (w/v) Rose Bengal was added to the wells for 30 
min at room temperature. The Rose Bengal was removed and the wells washed again 3 
x 200 VL with PBS. The adherent platelets were lysed with lysis buffer (150 mM NaCl, 
50 mM NaF, 13 mM Na4P207- I OH20,1.1 mM Na3S04,5 mM EDTA, 10 mM Tris, pH 
7.4,1 % Triton X- 100). To the primary controls AGE was replaced with an equivalent 
volume of PBS and treated as above. To the secondary controls the platelets were not 
stimulated with ADP and to the tertiary controls, no Rose Bengal was added to the 
platelets. The released Rose Bengal from the platelet cytosol was measured using a 
Titertek Multiskan MCC/340 MK 11 plate reader with a 540 nin filter. 
In order to validate the Rose Bengal data, the experiment was repeated with chromium- 
51 (5 pCi/mL platelets). Excess chromium was removed via gel filtration (Section 
2.2.2). The released chromium was measured via liquid scintillation (Ecoscint A) using 
a Beckman LS 6500 multi-purpose scintillation counter (USA). 
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2.5.4. Flow cytometric analysis of the effect of AGE on fibrinogen binding 
The following method was used to measure the effect of AGE on fibrinogen binding 
using flow cytometry: 
Whole human citrated blood was diluted with HEPES-Tyrode's buffer (1: 10 v/v) 
immediately after collection. 5 pL AGE (25 % v/v), 24.5 pL diluted human blood, 1.5 
pL mouse anti-human CD42a-PerCP conjugate, 2.5 pL PACI-FITC conjugate and 1.5 
pL HEPES was incubated for 10 min at room temperature prior to activation with the 
agonist ADP (8 [Lmol/L). Following agonist stimulation the reaction mixture was 
incubated for a further 15 min at room temperature. The platelets were then fixed for 30 
min with 40 pL of 1.5 % formaldehyde in HEPES at room temperature. The samples 
were then diluted with 2 mL of HEPES prior to analysis using a Beckman Coulter Epics 
XL. MCL Flow Cytometer (USA). Platelets were identified by their characteristic 
forward and side light scatter profile and staining with CD42a-PerCP; 50,000 events 
were recorded and analysed. 
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2.5.5. cAMP enzyme immunosorbent assay 
Intraplatelet cAMP levels were measured using a competitive enzyme immunosorbent 
assay (Figure 2.2). 
Briefly, citrated PRP was incubated with AGE (25 % v/v, final concentration), PGEI 
(10 pmol/L, final concentration) or an equivalent volume of PBS (negative control) for 
10 min at 3 7T, respectively. ADP at a final concentration of 8 Pmol/L was added to the 
platelets to initiate platelet aggregation. Aliquots were taken prior to ADP stimulation 
(basal) and at the following time points immediately after agonist activation: 0,30 and 
300 seconds and placed on ice. The samples were centrifuged at 1500 xg for 5 min at 
4T, and the resulting platelet pellet was resuspended in lysis buffer (0.5 mL) (provided 
with the kit) and left for 20 min. Intracellular cAMP levels were measured using a 
Biotrak enzyme immunoassay kit, following the manufacturer's instructions; 100 pL of 
sample or standards (range 0-3200 fmol/well) were incubated in 96 well microtitre 
plates coated with a Donkey anti-rabbit antibody specific for Rabbit anti-cAMP for 2 
hours at 4T. cAMP-peroxidase conjugate was added to the wells and incubated for a 
ftirther I hour at 4T. The wells were washed thoroughly and incubated with the 
enzyme substrate solution, TMB for approximately 20 min at room temperature with 
gently shaking. Sulphuric acid (1.0 M) was added to the wells as a stop solution and the 
optical density was measured immediately at 450 nni using a microtitre plate reader. A 
typical standard curve is displayed in Appendix IL 
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2.6. IMAGING STUDIES OF PLATLET AGGREGATION 
2.6.1 Scanning Electron Microscopy imaging of platelet aggregation 
PRP was washed and resuspended in HEPES-Tyrode's buffer, pH 7.4 (see section 
2.2.2). The platelet suspensions were prepared as follows platelets were incubated with 
either PBS or AGE for 10 min at 37C and platelet activation was induced via the 
addition of ADP (8 pmol/Q. The platelet suspensions were mixed in an equal volume 
of fixative solution containing 2.5 % glutaraldehyde in 0.1 mol/L sodium cacodylate 
buffer containing 2% sucrose, pH 7.3 which had been previously warmed to 37'C. 
Platelets were centrifuged at 700 xg for 20 seconds, the pellet was resuspended in 0.1 
mol/L sodium cacadylate buffer. The platelets were allowed to adhere to P01Y-L-lysine 
coated coverslips for 45 min at 37'C, which had been previously incubated overnight at 
40C. Coverslips were washed 3x with 0.9 % NaCl, and the platelets dehydrated in 
graded ethanol solutions. Ethanol was replaced with hexadimethyldisilazane and the 
samples were air dried and sputtered with gold (Polaron E 5000 Gold Sputter Coater) 
before examination on the SEM (JSM Jeol 840 Scanning Electron Microscope). Images 
were captured using the PGT Spirit Image Capture and X-ray analysis software. 
2.6.2. Fluorescent microscopy imaging of platelets loaded with Fura-2/AM 
PRP was incubated for 45 min at 370C with 2 pmol/L Fura-2/AM. After the incubation 
period the platelets were washed and resuspended in HEPES-Tyrode's buffer (2 x 106 
platelets/mL). 100 pL aliquot of the platelet suspension were placed onto glass 
coverslips that had been pre-coated with fibrinogen (3 g/L) overnight at 40C. The 
platelets were left for 10 min at room temperature before activation with ADP (8 
ýtmol/L). The coverslips were washed gently with in HEPES-Tyrode's buffer to remove 
any non-adherent platelets and, then mounted onto microscope slides. Using an 
Olympus BX5 I fluorescent microscope, the platelets were excited at the following 
wavelengths 340 and 3 80 mn, respectively, with the emission wavelength set at 5 10 run. 
The resulting images were recorded using the Openlab 4.0.2 software. The following 
parameters were measured: 
1. Platelets activated with ADP 
2. Platelets pre-treated with AGE and activated with ADP. 
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2.7. PROTEOLYTIC ACTIVITY OF AGED GARLIC EXTRACT 
2.7.1. Protease assay to measure the proteolytic activity of AGE 
The proteolytic activity of AGE was assessed using a modified version of the method 
outlined by Brock et al. (1982). In brief, samples were prepared as follows: 500 pL of 
3 00 mM Tris-HCL buffer, 50 jiL of AGE (3.12,6.25,12.5,25 and 100 % v/v, final 
concentrations) diluted in PBS and 500 pl, of azocasein solution (10 mg/mL in distilled 
water) as the enzyme substrate was mixed thoroughly, and incubated for 0- 18 hours at 
370C. The reaction was terminated at specific time points via the addition of 70 % (w/v) 
TCA (final concentration 6 %), vortexed and placed on ice for 30 min. This was 
followed by centrifugation for 5 min at 3000 x g. The resulting supernatant was 
removed and an aliquot (500 pQ was placed into a cuvette containing IM NaOH. The 
optical density was measured at 450 nin in a Uvicon 930 dual beam spectrophotometer 
(Kantron Instruments, USA), against a blank containing Tris-HCL buffer, azocasein 
solution and water as a replacement for the AGE. 
The optical density readings generated in this study were compared to a standard curve 
(Appendix III) of a range of chymotrypsin standards (1,2,4,6,8,10,20,40,60,80 and 100 
pg/mQ a known protease specific for the protein casein. Chymotrypsin standards were 
prepared with distilled water and treated as the above. The standard curve was used to 
determine if AGE displayed proteolytic activity similar to that of chymotrypsin. 
2.7.2. Protein concentration determination in AGE using the Bradford assay 
The concentration of protein present in AGE was determined using the method of 
Bradford (1976). In brief, 100 pL of AGE (3.12-100 %, v/v diluted in PBS) was added 
to 0.25 mL NaOH and 5.0 mL Bradford reagent, vortexed and left to incubate at room 
temperature for 5 min. The optical density of each AGE sample was determined at 595 
nm. The protein concentration for each AGE sample was determined by comparing it to 
a BSA standard curve (Appendix IV). The BSA samples used were: 0.0 1,0.02,0.04, 
0.06,0.08,0.1,0.2,0.25.0.5,1.0,1.5 and 2.0 mg/mL, diluted in PBS. 
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2.8. THE EX VIVO EFFECT OF AGE ON PLATELET AGGREGATION 
Whole human citrated blood was incubated with AGE at various concentrations (12.5- 
50 % v/v) for approximately 20 min at 37T. The platelets were removed from the 
whole blood via centrifugation at 15 0xg for 10 min at room temperature. The platelet 
count was adjusted if necessary with PBS/PPP to 2.5 ± 0.5 x 105 platelets/mL. 
Aggregation was initiated with ADP (8 pmol/L) and the aggregation curves were 
monitored using a platelet aggregometer. To the control sample an equivalent volume of 
PBS was added to the whole blood and treated in the same manner as above. 
2.9. CLINICAL TRIAL - DIETARY SUPPLEMENTATION WITH AGE 
Volunteers for the clinical trial were recruited from the university population (n--20, age 
range 22-62 yrs) who appeared to be apparently healthy and had not taken any 
medication known to interfere with platelet function 2 weeks prior to the start of the 
trial. Informed consent was obtained from all volunteers before the start of the trial 
(Appendix V). All volunteers answered a short questionnaire (Appendix VI) regarding 
their age, gender, weekly alcohol consumption, daily cigarette intake, health conditions, 
prescribed medication and other dietary supplement intake. Volunteers consumed 5 mL 
of AGE daily for 2 weeks at set times throughout the day, usually in the morning. The 
dose of AGE used in this trial is that recommended by the manufacturer's of AGE, and 
has been shown previously to be beneficial in the reduction of platelet aggregation 
following AGE ingestion (Rahman and Billington, 2000). The volunteers were asked to 
follow their usual diet and lifestyle throughout the study. Venous blood samples (20 
mL) were taken before the ingestion of AGE (baseline), after 2 weeks of AGE ingestion 
and following a2 week washout period were no AGE was consumed at all. 
The following parameters were measured during the trial: 
e Platelet aggregation initiated with the agonists: ADP, AA, adrenaline and 
collagen (see section 2.3.1. ). 
9 GPlIb/IIIa receptor binding using flow cytometry (see section 2.5.4. ). 
o cAMP levels (see section 2.4.4. ) 
im Total cholesterol analysis 
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2.10. STATISTICAL ANALYSIS 
Experimental results are expressed as the means ± SEM and are accompanied by the 
number of observations. Data was assessed using the student's paired t-test (Microsoft 
Excel ToolPak, Statistical Software Add-on). A P-value of less than 0.05 was 
considered statistically significant. 
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CHAPTER 3 
THE EFFECT OF AGED GARLIC EXTRACT AND ITS 
CONSTITUENTS ON AGONIST-INDUCED PLATELET 
AGGREGATION IN VITRO 
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3. THE EFFECT OF AGED GARLIC EXTRACT AND ITS CONSTITUENTS 
ON AGONIST-INDUCED PLATELET AGGREGATION IN VITRO 
3.1 INTRODUCTION 
Platelet aggregation is a complex process that requires the co-operation of many 
biochemical pathways. Before platelets can aggregate they need to be activated by 
agonists such as ADP (adenosine diphosphate), AA (arachidonic acid), collagen and 
adrenaline etc. The ma . or physiological agonists are collagen and thrombin, and these 
agents are referred to as strong agonists because they are the primary agonists in vivo. 
The aggregating agents ADP and adrenaline are known as weak agonists, as in normal 
platelet aggregation processes they do not normally induce platelet aggregation; instead 
they aid the stronger agonists by amplifying their initial responses (Wilde et aL 2000). 
ADP and adrenaline are stored within the dense granules of platelets, and upon 
activation the contents within these granules are released extracellularly and act in both 
an autocrine and paracrine manner, via specific receptors on the platelet surface or 
adjacent platelets, and this then leads to further activation and aggregation (Jackson 
200 1; Puri 1998; Solet et aL 200 1). ADP also assists platelet adhesion and the formation 
of a platelet aggregate. It is well established that AGE, when added to platelets both in 
vitro and in vivo reduces the ability of the platelets to aggregate when challenged with 
agonists, particularly ADP and collagen (Allison et al. 2006; Steiner and Li 1998; 
Rahman and Billington 2000; Steiner and Li 2001). 
In this study, the aim was to examine the effects of AGE and some of its constituents: 
(Table 3.1) on their ability to inhibit platelet aggregation initiated by the agonist ADP. 
The major difference between fresh garlic and AGE is caused by the aging and 
extraction processes. In AGE there is a high abundance of water-soluble organosulphur 
compounds which are result of the hydrolysis of y-glutamyl-S-allylcysteine compared to 
the content of raw garlic. There are also compounds unique only to AGE as a direct 
result of the aging and extraction process. 'Me primary focus of this investigation was to 
validate previous platelet aggregation work with AGE and, to identify a possible 
mechanism for the inhibitory actions of AGE. This was achieved by comparing the 
effects of AGE to known classical inhibitors of platelet aggregation e. g. indomethacin, 
PGEI etc. All these experiments were carried out in vitro using the platelet 
aggregometry method. 
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3.1.2. Overview of study 
Measurement of platelet aggregation in the laboratory can be achieved by a number of 
different methods. In this study the effects of AGE on agonist-induced platelet 
aggregation was monitored by utilising a light transmittance method, whereby, PRP was 
incubated with various concentrations of AGE or its constituents for 10 min at 37T. 
Aggregation was initiated via the addition of agonists such as ADP, collagen or the 
calcium ionophore A23187. The principle behind this method is that as light passes 
through the cuvette any platelet aggregates that are formed will increase the amount of 
light that can pass through the cuvette. The more light that passes through the cuvette, 
the higher the percentage aggregation value indicating that platelet aggregation has 
occurred and platelet aggregates have been formed. If more light passes through the 
cuvette via incubation with AGE or its constituents this is an indication that inhibition 
of platelet aggregation has occurred, for detailed methods used in this study see chapter 
2, section 2.4, page 3 1. 
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Table 3.1. Isolated compounds found in AGE; physical properties and chemical 
structures. 
Constituent Physical Structure 
property 
Alliin s-allylcysteine 0 1142 
sulphoxide, 
biosynthesied COOH 
from its parent 
compound, y- 
glutamyl-s- 
allylcysteine 
Cycloalliin A sulphur 
containing 
amino acid 
which is not 
transformed 
during the 
aging process 
COOH 
PC A saponin -a 
compound such 
as this 
distinguishes 
garlic from 
other alliurn. 
vegetables 
FA An antioxidant 
not present in 
either heat 
treated or raw 
garlic, a unique 
product due to 
the aging 
process 
NN 
COCA 
SAC Unique to AGE, 
used for COON 
standardisation 
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3.2. RESULTS 
3.2.1 The effect of AGE and its constituents on agonist-induced platelet 
aggregation in vitro 
3.2.1. L Effect ofA GE on agonist inducedplatelet aggregation 
PRP (platelet-rich plasma) (2.5 x 105 platelets/mL) was incubated with various 
concentrations of AGE 0.78-25 % (v/v) for 10 min at 370C. Aggregation was initiated 
by the addition of the following agonists (for concentrations used see table 2.1, Chapter 
2, page 33): ADP (82 %±9.1), AA (72 %±5.0), adrenaline (77 %± 12.0), A23187 (83 
%±7.3), collagen (77 %±5.8), thrombin (81 %±5.0) and PMA (81 %±6.0), 
respectively (Figures 3.1-3.7, respectively). AGE at all concentrations had a greater 
inhibitory effect upon platelet aggregation when aggregation was initiated with the 
agonists ADP (Figure 3.1), adrenaline (Figure 3.3) and thrombin (Figure 3.6). A 
reduction in platelet aggregation was evident for the majority of agonists when platelets 
were preincubated with AGE at a concentration of 1.56 % (v/v), however this was not 
the case for collagen (Figure 3.5) as a higher concentration of AGE (6.25 %, v/v) was 
required before inhibition of platelet aggregation was statistically significant (P<0.05) 
when compared to the control AGE dose-dependently inhibited platelet aggregation 
induced by the following agonists: ADP, adrenaline, collagen and thrombin. PMA 
(phorbol 12-myristate acetate) when added to platelets induces the stimulation of the 
enzyme PKC (protein kinase Q, an important cell signalling molecule common to many 
signalling pathways; BIS (bisindolymaleimide) inhibits the action of this enzyme. BIS 
was used in this experiment to ensure that the PMA was able to induce platelet 
aggregation via PKC. From these experiments the IC50 values for the effect of AGE on 
each agonist was determined (Table 3.2). It was noted from these experiments that the 
agonists AA, A23187 and collagen had higher IC50 values (>6.25 % v/v) when 
compared with the remaining agonists (IC50 = 3.12 % AGE). 
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Figure 3.1. AGE and its effect upon ADP-induced platelet aggregation in vilro. PRP 
was incubated with various AGE concentrations for 10 min at 37T. Aggregation was 
initiated with ADP (8 l. Lmol/L). Aggregation curves were analysed for total percentage 
aggregation. Values are means ± SEM, n=6. *Statistically significant, P<0.05, 
* *P<0.0 1, compared to the PBS control. 
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Figure 3.2. AGE and its effect upon AA-induced platelet aggregation in vitro. PRP was 
incubated with various AGE concentrations for 10 min at 37T. Aggregation was 
initiated with AA (250 pg/mL). Aggregation curves were analysed for total percentage 
aggregation. Values are means ± SEM, n=6. *Statistically significant, P<0.05, 
* *P<0.0 1, compared to the PBS control. 
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Figure 3.3. AGE and its effect upon Adrenal ine-induced platelet aggregation in vitro. 
PRP was incubated with various AGE concentrations for 10 min at 370C. Aggregation was 
initiated with Adrenaline (20 pmol/L). Aggregation curves were analysed for total 
percentage aggregation. Values are means ± SEM, n=6. *Statistically significant, P<0.05, 
* *P<0.0 I compared to the PBS control. 
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Figure 3.4. AGE and its effect upon A23187-induced platelet aggregation in vilro. PRP 
was incubated with various AGE concentrations for 10 min at 37T. Aggregation was 
initiated with A23 187 (5 junnol/L). Aggregation curves were analysed for total 
percentage aggregation. Values are means ± SEM, n=6. "Statistically significant, 
P<0.0 I compared to the PBS control. 
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Figure 3.5. AGE and its effect upon collagen-induced platelet aggregation in vilro. PRP 
was incubated with various AGE concentrations for 10 min at 370C. Aggregation was 
initiated with collagen (190 Vg/mL). Aggregation curves were analysed for total 
percentage aggregation. Values are means ± SEM, n=6. *Statistically significant, 
P<0.05, ** P<0.0 1, compared to the PBS control. 
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Figure 3.6. AGE and its effect upon thrornbin-induced platelet aggregation in vilro. 
PRP was incubated with various AGE concentrations for 10 min at 37T. Aggregation 
was initiated with thrombin (0.1 U/L). Aggregation curves were analysed for total 
percentage aggregation. Values are means ± SEM, n=6. "Statistically significant, 
P<0.0 I compared to the PBS control. 
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Figure 3.7. AGE and its effect upon PMA-induced platelet aggregation in vilro. PRP was 
incubated with various AGE concentrat ions for 10 min at 370C. Aggregation was initiated 
with PMA (10 pmol/L). Aggregation curves were analysed for total percentage 
aggregation. Values are rneans ± SEM, n=6. *Statistically significant, P<0.05, **P<0.0 I 
compared to the PBS control. 
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Table 3.2. The inhibitory effects of AGE on platelet aggregation induced by various 
-platelet agonists. IC5o values of AGE are means ± SEM of 6 experiments 
for each agonist treatment. The IC5o values represent the concentration of 
AGE needed to produce 50 % of the maximum possible inhibitory response. 
AGONIST IC5o VALUE OF AGE (% v/v) 
ADP 3.12 ± 4.0 
AA 12.5 d: 2.7 
Adrenaline 3.12± 7.0 
A23187 12.5 ± 4.7 
Collagen 6.25 ± 2.6 
Thrombin 3.12 ± 2.5 
PMA 3.12 d: 3.0 
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3.2.1. Z Effect ofethanol on ADP-, and collagen-inducedplatelet aggregation 
The purpose of this experiment was to determine whether the enzyme phospholipase D 
(PLD) plays a significant role in ADP-induced platelet activation and subsequent 
aggregation, as it is not certain of the exact role if any that this particular enzyme has on 
platelet aggregation. This was achieved by the indirect examination of the effects of 
ethanol at different percentage concentrations on both ADP- and collagen-induced 
platelet aggregation. Ethanol has been shown to inhibit the actions of the PLD and that 
this enzyme plays an important role within the PLC (phospholipase C) pathway (Houle 
and Bourgin 1999; Natajaran et al. 1996; Nozawa et al. 1991) for the generation of 
phospholipids mediators such as iniositol polyphosphates, diacyclglycerol, and 
arachidonic acid, all are important in sustaining platelet activation and subsequent 
platelet aggregate formation. During the manufacture of AGE ethanol is used in the 
ageing process, and the final product contains ethanol at a concentration of 10 % (v/v). 
Therefore it is essential to establish that the inhibitory actions of AGE are due to its 
garlic constituents and not by the non-specific effect of ethanol contained within the 
AGE product. The recommended daily dose for AGE consumption is 5 mL; the ethanol 
content contained within this specified dose is less than 0.05 % (v/v), this is the primary 
reason why concentrations of 0.1-1.0 % (v/v) were used in this study. 
Ethanol (0.1-1.0 % v/v) when added to PRP and aggregation initiated with ADP (8 
pmol/L), showed no significant inhibition (P>0.05) in platelet aggregation when 
compared to the PBS control (Figure 3.8). Collagen-induced platelet aggregation was 
dose-dependently inhibited by the addition of ethanol at all the concentrations tested. 
Significant (P<0.05) inhibition of collagen-induced platelet aggregation was noted at the 
following ethanol concentrations (0.25-1.0 % v/v), when compared to the PBS control 
(Figure 3.9). 
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Figure 3.8. The effect of various ethanol concentrations on ADP-induced platelet 
aggregation. Aggregation curves for ethanol treated platelets were analysed for total 
percentage aggregation and values are expressed as means ± SEM, n=6. No significant 
inhibition was detected for any of tile ethanol concentrations tested compared to tile PBS 
control. 
100 
T 
.LT 
80 
0 
cc 
r 
IZE, 11 R 4) 
M 
40 
cc 
20 
0 
c 0.1 0.25 0.5 1 
Control and EtOH Concentrations (% v/v) 
Figure 3.9. The effect of various ethanol concentrations on collagen-induced platelet 
aggregation. Aggregation curves for ethanol treated platelets were analysed for total 
percentage aggregation and values are expressed as means ± SEM, n=6. *Statistically 
significant (P<0.05) when compared to the PBS control. 
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3. Z 1.3. Effect of isolated componentsfrom A GE on platelet aggregation 
It has been established from section 3.2.1 in this study that AGE when pre-incubated 
with PRP has an inhibitory effect upon agonist-induced platelet aggregation in vitro. 
Ethanol was also tested and found not to inhibit platelet aggregation induced by the 
agonist ADP. AGE is a complex chemical mixture made up of over 400 plus products 
which is a result of an aging process that occurs in ethanol. The mixture contains a high 
concentration of organosulphur water soluble compounds in relation to raw garlic; some 
of these products are unique only to AGE. Nine initial compounds were selected: allfin, 
cycloalliin, PC, FA, SAC, SAMC, SEC, SMC and SPC and their potential inhibitory 
effects on ADP-induced platelet aggregation were examined in this investigation (0.78 - 
100 pmol/L). 
All the components when tested follow a similar biphasic pattern in the way they affect 
ADP-induced platelet aggregation. The results obtained showed that none of the 
individual components are very effective in inhibiting ADP-induced platelet 
aggregation in relation to AGE as a whole compound (data not shown, refer to 
Appendix V). Figure 3.10 shows the effects of alliin on ADP-induced platelet 
aggregation, no statistical significance was found for any of the concentrations tested. 
NB. A reduction in inhibition was noted at various concentrations used for each 
individual component, however, the results did not follow a set pattern, the profiles for 
each constituent of AGE are displayed in Appendix V. 
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This study has shown that the individual components of AGE are not effective 
individually as inhibitors of ADP-induced platelet aggregation. It has been found that 
AGE as a whole extract can significantly inhibit platelet aggregation induced by a 
variety of agonists. Hence, the assumption is for AGE to inhibit ADP-induced platelet 
aggregation all the components contained within the extract need to be present for 
inhibition of platelet aggregation. Thus, AGE exerts its inhibitory effect through 
synergism of its constituents. Therefore, it was decided to combine all nine components 
as a mixture to see if inhibition of platelet aggregation was greater when compared to 
the individual components. The assumption being that when these nine components are 
mixed together and added to PRP and platelet aggregation initiated with ADP, the 
amount of inhibition observed should be similar to that of whole AGE (Figure 3.1) 
Figure 3.11 shows the effect of a mixture of the isolated AGE components at different 
concentrations (0.000195-1.0 mmol/Q. Mixture I (MI) was incorporated into this study 
as it contains all the individual components at their optimal working concentrations 
(Table 2.3, Chapter 2, Section 2.3.2, page 36) when examined individually. The results 
depicted in Figure 3.12 show that the mixtures of the individual AGE components when 
added to PRP did not significantly inhibit ADP-induced platelet aggregation at any of 
the concentrations tested including MI. 
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A mixture of cysteine sulphoxides (SAC, SAMC, SEC, SMC and SPQ was compared 
to the inhibitory profile of AGE (Figure 3.1). All the members of this particular cysteine 
family have very similar chemical structures and physical properties i. e. all are water 
soluble, sulphur-containing amino acid compounds (Table 3.1), and should theoretically 
behave in a similar manner. i. e. collectively the individual cysteine sulphoxides should 
enhance the inhibitory actions of each other. 
The results in figure 3.12 show that the inhibitory actions for the mixture of all five 
cysteine sulphoxides at their optimum concentrations are very similar to that obtained 
for the mixture of all nine components from AGE. Mixture I did not result in any 
significant difference when compared to the PBS control. For the mixture 
concentrations 0.000195 and 1.0 mmol/L there was a significant (P<0.05) reduction in 
the amount of platelet aggregation observed compared to the PBS control.. 
In another set of experiments both alliin and cycloallin were mixed together at various 
concentrations and their combined effect upon ADP-induced platelet aggregation was 
examined. The inhibition that was observed followed a bi-phasic pattern in that the 
amount of inhibition noted was linked to the mixture concentration (Figure 3.13). The 
greatest degree of inhibition was prevalent at the concentration 1.0 mmol/L. With all the 
mixture concentrations being statistically significant (P<0.05) when compared to the 
PBS control. Although the inhibition of platelet aggregation was deemed significant, it 
is apparent from Figure 3.13 that the amount of platelet inhibition is not comparable to 
AGE in its natural form. 
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Figure 3.12. The effect of a cysteine sulphoxide mixture oil ADP-induced platelet 
aggregation SAC, SAMC, SEC, SMC and SPQ. MI- mixture I contains all five 
components at concentrations that produced optimal inhibition of platelet aggregation 
when tested individually (Refer to Table 2.3, page 36). Tile remaining concentrations 
contain all nine components at specific concentrations (0.00019-1.0 millol/L). 
Aggregation curves were analysed for mean total percentage aggregation. Values are 
expressed as means SEM, n=6. *Statistically significant when compared to the PBS 
control. 
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Figure 3.13. The effect of an alliin and cycloalhin mixture on ADP-induced platelet 
aggregation. MI- mixture I contains both components at concentrations that produced 
optimal inhibition of platelet aggregation when tested individually. The remaining 
mixtures contain both components at specific concentrations (0.00019-1.0 111mol/L). 
Aggregation curves were analysed for mean total percentage aggregation. Values are 
expressed as means ± SEM, n=6. All the mixture concentrations are statistically 
significant (P<0.05) when compared to the PBS control. 
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3.2.1.4. The effect ofamino acidsfOund in AGE on ADP-inducedplatelet aggregation 
The amino acids L-arginine, L-cysteine and L-methionine were not efficient at 
inhibiting ADP-induced platelet aggregation. Figure 3.14 shows that L-methionine was 
the only amino acid significantly effective in inhibiting ADP-induced platelet 
aggregation at the concentration range 0.001-1.0 mmol/L. The exception being at 0.006 
mmol/L, at this particular concentration the mean total percentage aggregation value 
was very similar to that of the PBS control sample. At the concentration 9.0 mmol/L, 
both L-arginine and L-cysteine significantly (P<0.05) inhibited platelet aggregation 
when compared to their respective controls, whereas L-methionine did not. 
A mixture of all three amino acids was added to PRP before the initiation of platelet 
aggregation with ADP. It was found that as a mixture the amino acids were not efficient 
at reducing the amount of platelet aggregation observed compared to the PBS control. 
Inhibition was observed at the mixture concentration 0.00078 mmol/L (Figure 3.15). 
The results were not statistically significant (P>0.05) when compared to the PBS 
control. 
It is known that AGE is a complex mixture of many different compounds, including 
organosulphur compounds, saponins, amino acids etc. Therefore the three amino acids 
plus the nine isolated AGE components were combined into a series of mixtures and the 
effects of these mixtures was examined on ADP-induced platelet aggregation. PRP that 
had been pre-incubated with these mixtures and aggregation initiated with ADP resulted 
in a normal distribution (bell-shaped curve) in the way each mixture concentration 
affected platelet aggregation. At both low (0.000195 mmol/L) and high (1.0 mmol/L) 
mixture concentrations there was evidence of inhibition of platelet aggregation (Figure 
3.16). The concentrations in between these showed no noticeable inhibition of platelet 
aggregation compared to the control sample. Significant inhibition (P<0.05) was 
observed at the mixture concentration 1.0 mmol/L. 
The major finding generated in this section is that for AGE to inhibit ADP-induced 
platelet aggregation, AGE in its natural form is required to bring about the desired 
effects. Hence, synergism of all AGE components must be taking place for inhibition to 
occur effectively. 
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Figure 3.14. The effect of individual amino acids on ADP-induced platelet 
aggregation (L-arginine, L-cysteine and L-methionine). Aggregation curves were 
analysed for mean total percentage aggregation and the values are expressed as 
means ± SEM, n=6. *Statistically significant (P<0.05) compared to the PBS control. 
80 
0 
60 
(a 
cb 
40 
ID 
B 
r 20 
0 
Figure 3.15. The effect of an amino acid mixture on ADP-induced platelet aggregation. 
Aggregation curves were analysed for mean total percentage aggregation and values are 
expressed as means ± SEM, n=6. There was no statistical significance (P>0.05) noted 
for any of the mixture concentrations when compared to the PBS control. 
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3.2.2. Classical inhibitors of platelet aggregation and their effect upon 
ADP-induced platelet aggregation 
Within activated platelets there is a variety of cellular inhibition that can be targeted 
through certain cell-signalling pathways. There are a number of pharmacological agents 
that inhibit platelet aggregation through well-established mechanisms (Table 3.3). In 
this study, the primary objective was to compare the actions of AGE, to that, of known 
inhibitors via their aggregation profiles in order, to establish a starting point for the 
breakdown of the biochemical signalling pathways involved in platelet aggregation 
which will be looked at in more detail in chapter 4. This will hopefully lead to an 
inhibitory mechanism for AGE with regards to ADP-induced platelet aggregation. 
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Table 3.3. Classical inhibitors of platelet aggregation and their mechanism of 
inhibition. 
Classical Inhibitor Mechanism of Inhibition 
A1173 G-proteins 
AG527 - Tyrphostin Protein tyrosine kinases 
BIS Protein kinase C 
GEN Protein tyrosine kinases 
IBMX cAMP and cGMP phosphodiesterases 
Indomethacin Cyclooxygenase inhibitor 
OKA Protein phosphatases 
NaF Ca2+ mobilisation 
PGEI Increases intracellular cAMP levels 
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The inhibitors of platelet aggregation listed in table 2.5 (Chapter 2, Section 2.4.3, page 
38) were incubated with PRP and platelet aggregation was initiated with ADP and 
aggregation traces results were compared to that of AGE (25 % v/v). The mechanistic 
actions of all these inhibitors are well documented in the literature (Dhar 1993; Feijge et 
al. 2004; Ferri et al. 1994; Gazit et al. 1989; Kikura, et al. 2000; Kondo et al. 1991; 
Kong 2004; Liu et al. 1998; Schwarz et al. 2001). 
The first classical inhibitor that was tested was aspirin which is used clinically in the 
treatment of CVD. Its mechanistic action is through the inhibition of platelet 
aggregation is by interfering with AA metabolism via the suppression of the enzyme 
cyclooxygenase. Thus, prostaglandins that aid the aggregation process are unable to be 
formed. Aspirin inhibited ADP-induced platelet aggregation at the following 
concentrations: 0.00078,0.1 and 0.5 mmol/L. The effect of aspirin was not dose- 
dependent, and statistically significant inhibition (P<0.05) was only observed at 0.00078 
mmol/L (Figure 3.17); the aspirin concentration 0.1 mmol/L reduced platelet 
aggregation compared with the other concentrations used but was not deemed 
significant following statistical analysis. 
PGEI was dissolved in DMSO (concentration did not exceed 0.05 %, v/v in PRP 
sample) and diluted to its final concentrations in PBS. The following final 
concentrations (7.5,15,31.25,62.5,125 and 250 pg/mL) were pre-incubated with PRP 
prior to the initiation of platelet aggregation with ADP. As expected, PGEI at all the 
concentrations tested significantly (P<0.01) inhibited ADP-induced platelet aggregation 
when compared to the control (Figure 3.18). 
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Figure 3.17. The effect of various aspirin concentrations on ADP-induced platelet 
aggregation. Aspirin (0.00078- 1.0 rnmol/L) was added to PRP for 10 min at 370C, 
aggregation was initiated via tile addition of ADP. Aggregation curves were analysed for 
inean total percentage aggregation. Values are expressed as means ± SEM, 11=6. 
*Statistically significant (P<0.05) cornpared to the control. 
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Figure 3.18. The effect of various PGEI concentrations on ADP-induced platelet 
aggregation. PGE, (7.5-250 pg/ml-) was added to PRP for 10 min at 37'C, 
aggregation was initiated via the addition of ADP. Aggregation curves were analysed 
for rnean total percentage aggregation. Values are expressed as means ± SEM, n=6- 
"Statistically significant (P<0.0 I) compared to the control. 
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Seven more classical inhibitors (AIF3, AG527, BIS, GEN, IBMX, NaF and OKA) of 
platelet aggregation were examined and their aggregation profiles were compared to 
that of AGE (Figure 3.19). The inhibitors GEN and IBMX were the only ones that 
significantly (P<0.0 1) inhibited platelet aggregation induced by the agonist ADP. 
In another set of experiments the inhibitory actions of AGE were compared to that of 
the classical inhibitor indomethacin (Figure 3.20). Indomethacin at the concentrations 
0.0 15-1 .0 mM significantly (P<0.0 1) reduced platelet aggregation initiated with the 
agonist ADP. These concentrations were compared to that of AGE (12.5-25 %, v/v) and 
it was observed that the inhibitory actions of AGE were more potent than that of 
indomethacin on ADP-induced platelet aggregation. Collagen was used to ensure that 
indomethacin was working correctly, as its mode of action is through the suppression of 
the cyclooxygenase pathway; and this pathway is involved in collagen-induced platelet 
aggregation. Indomethacin treated platelets when challenged with collagen resulted in 
significant inhibition of platelet aggregation. Indomethacin had a more profound 
inhibitory effect upon collagen-induced platelet aggregation than during platelet 
aggregation initiated with the agonist ADP. 
Following a comparison to AGE the classical inhibitors PGEI, GEN, IBMX and 
indomethacin had similar inhibitory aggregation profiles to that of AGE. The pathways 
that are affected by these four inhibitors were investigated further and the results are 
reported in the in the next chapter. 
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Figure 3.19. The effect of seven known platelet aggregation inhibitors compared to 
AGE upon ADP-induced platelet aggregation. AIF3 (100 [imol/L), AG527 (25 Pmol/L), 
BIS (100 pmol/L), GEN (100 pmol/L), IBMX (150 pmol/L), NaF (100 Pmol/L) and 
OKA (4 [Lmol/L) were incubated with PRP and aggregation was initiated with ADP (8 
pmol/L). The aggregation curves were analysed for mean total percentage aggregation 
and the results were compared to that of AGE (25 % v/v). Values are expressed as 
means ± SEM, n=6. "Statistically significant (P<0.01) when compared to the PBS 
control. 
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Figure 3.20. The effect of indomethacin on ADP- and collagen-induced platelet aggregation. PRP was 
incubated with either indomethacin (0-003-1.0 mM) or AGE (12.5-25 %, v/v) for 10 min at 370C. 
Platelet aggregation was initiated with ADP (8 pmol/L) or collagen (190 pg/mL). AGE treated 
samples were activated with ADP. Values are expressed as means ± SEM, n=6. All the concentrations 
(AGE and indomethacin) are statistically significant (P<0.01) when compared to the controls. 
Exception indomethacin concentration 0.003 mM when aggregation was stimulated with ADP- 
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3.3. DISCUSSION 
The primary objective in this study was to try and ascertain a possible inhibitory 
mechanism for AGE via the platelet aggregation technique. This was achieved by the 
following: 
1. The effect of AGE on platelet aggregation induced by a variety of agonists. 
2. Observed the effects of selected components found in AGE for their potential 
inhibitory effect - synergism. 
3. Aggregation profile of AGE was compared to that of 9 classical inhibitors of 
platelet aggregation with well established mechanistic actions. 
It has been found during studies using aged garlic extract (Rahman and Billington 2000 
Steiner and Lin 1996) that this dietary supplement prevents platelet aggregation both in 
vitro and in vivo. In this study it was found that the pre-treatment of human platelet-rich 
plasma with various AGE concentrations resulted in inhibition of platelet aggregation 
for all the agonists examined. The degree of inhibition observed was directly related to 
the aggregating agent used and the signalling pathway which it initiates to propagate the 
aggregation process. i. e. A23187 (calcium ionophore) induces platelet aggregation 
through an increase in calcium mobilisation within the platelet (Lapetina et al. 1978; 
Pickett et al. 1977). The ionophore has been shown to activate PKC, in addition both 
PKC and Ca2+ are able to synergise to bring about a full secretion response via the 
release of 5-HT from the platelet microenviro=ent thus, showing cooperation between 
C2' and PKC signalling pathways (Stafford et al. 2001). Apitz-Castro, (1983) and 
Srivastava (1986) also looked at the effects of garlic and pure isolated components on 
A23187-induced platelet aggregation. In their respective studies it was found that garlic 
inhibited platelet aggregation induced by A23187. This leads to the suggestion that 
AGE may suppress calcium mobilisation, this will be further investigated in the next 
chapter in more detail. 
Another interesting observation is that AGE inhibited platelet aggregation induced with 
the agonist PMA. It is known that PMA directly activates the enzyme PKC and, that this 
enzyme is involved in cytoskeleton rearrangement and the release of granule contents 
such as ADP and 5-HT into the platelet extracellular environment which further 
propagates platelet aggregation. This enzyme is common to all forms of agonist 
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stimulation of platelet aggregation. Therefore, it is possible that AGE directly inhibits 
PKC activity or inhibits a point downstream of PKC signalling during the platelet 
aggregation process. 
The major finding in this study was that AGE at concentrations >6.25 % (v/v) inhibited 
platelet aggregation. These results validate previous studies that examined the effects of 
AGE on platelet aggregation (Steiner and Lin 1998; Steiner and Li 2001; Rahman and 
Billington 2000). Thus, it can be concluded that AGE directly affects agonist-induced 
platelet aggregation in vitro. This study also suggests that AGE possibily exerts its 
inhibitory effect during the latter stages of platelet activation/aggregation and not at the 
receptor level for each agonist. 
It has been suggested in the literature that the weak agonists such as ADP activate 
platelets via the phospholipase A (PLA) pathway in the early stages of agonist-induced 
platelet aggregation (Kunapuli 1998; Puri 1999). During the secondary phase of 
activation with the release of the dense granule contents the phospholipase C (PLC) 
pathway is brought into play (Brass et al. 1993). This is not the scenario for strong 
agonists such as collagen, as they activate the PLC pathway directly upon collagen 
binding to its receptor on the platelet cell surface (Packham and Mustard 2005). 
This was not reflected in the results obtained during this study as ADP-induced platelet 
aggregation was inhibited by the inhibitors GEN, IBMX indomethacin and PGEI. All of 
which are common to all forms of agonist stimulation. Hence, AGE may not exert its 
effect during the primary stages of platelet activation but rather during the metabolism 
and release of second messengers and possibly the release of dense granule contents and 
the bioavailability of calcium within the platelet. 
The main purpose of this study was to determine the inhibitory mechanisms of AGE 
within the platelet. In order to achieve this goal, ADP was chosen as the agonist of 
choice, its biochemical pathway has been well established over recent years within the 
platelet. Before the pathway was dissected it was imperative to establish that the 
inhibitory responses observed by AGE was due to the natural constituents present 
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within AGE and not by the non-specific effects of products such as ethanol that are used 
during the aging process and are present within the final product. 
Ethanol is used during the manufacture of AGE; therefore it is essential that the 
inhibition of platelet aggregation observed with AGE is due to the garlic constituents 
and not the ethanol. This was done indirectly by examining the effects of ethanol at 
different concentrations on ADP-induced platelet aggregation. As the enzyme 
phospholipase D (PLD) activity is retarded by ethanol and this enzyme plays an 
important role within the PLC pathway (Houle and Bourgin 1999; Natajaran et al. 1996; 
Nozawa et al. 1991). It was found in this study that ethanol did not significantly inhibit 
ADP-induced platelet aggregation (Figure 3.8) compared to the PBS control. These 
results are similar to those obtained by de Lange et al., (2003) in that they too found that 
ethanol present in red wine did not inhibit platelet aggregation and the observed 
inhibition was a result of polyphenols present within the red wine. Figure 3.8 shows that 
there is the possibility that at a much higher concentration of ethanol ADP-induced 
aggregation may be inhibited. Although this may be the case and further investigation 
would be required, it is highly unlikely that the daily recommended dose of AGE (5 
mUday) will contain more than I% ethanol. Therefore, ethanol does not inhibit ADP- 
induced platelet aggregation and the inhibition that was observed following AGE 
incubation with platelets is due solely to other constituents and not any ethanol present 
within the liquid AGE extract. 
The literature states that phosphatidic acid (PA) production and secretion is inhibited by 
ethanol and that ethanol also inhibits arachidonate release (Houle and Bourgin., 1999; 
Huang et aL 1991). If this is the case, then why was there no inhibition of aggregation 
stimulated by ADP? The answer to this question is that not all agonists stimulate 
activation and subsequent aggregation to the same degree. This is due to the strength of 
the agonist used in the initiation of aggregation. ADP, a weak agonist on its own cannot 
stimulate PLD activity, but can reinforce the effects of low doses of stimulatory agents 
such as thrombin and collagen (Exton 1999; Frohman and Morris 1999). Thus, ADP 
initially activates the PLA2 signalling pathway upon platelet activation. Hence, this may 
be a reason why ethanol did not inhibit ADP-induced aggregation. 
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To test the theory that strong agonists activate PLC signalling mechanisms directly 
upon platelet activation collagen was used as a replacement for ADP. Ethanol 
significantly inhibited collagen-induced platelet aggregation (Figure 3.9). These results 
aid in the study of the mechanisms by which AGE inhibits platelet aggregation. It can 
be assumed that ADP induces a different biochemical pathway during activation to that 
of collagen. PLC is possibly still activated during ADP-induced aggregation but is not 
an essential component. 
AGE is a complex chemical mixture which is rich in water-soluble organosulphur 
compounds. Although some of these compounds are found in raw garlic, their content 
within AGE is increased considerably during the aging process and unique products 
such as SAC, and FA are formed during aging and extraction which are unique only to 
AGE (they are not found in either raw or heat-treated garlic). 
The following twelve components found within AGE were examined: allfin, beta- 
chlorogenin, cycloallfin, and fructosylarginine, L-arginine, L-cysteine, L-methionine, S- 
allylcysteine, S-allylmercaptocysteine, S-ethylcysteine, S-methylcysteine and S- 
propenylcysteine. It was found that each individual component was not effective at 
inhibiting platelet aggregation both on its own and as a mixture. The components were 
not as effective as AGE in its natural form in inhibiting platelet aggregation. This leads 
to the conclusion that the twelve components of AGE act synergistically along with 
many other compounds present in AGE to bring about this observed inhibitory effect, as 
these isolated components are not the only inhibitors of platelet aggregation found 
within AGE. There may be other compounds present within the AGE extract that are 
responsible for inhibiting agonist-induced platelet aggregation. One possible 
explanation for the results generated in this study is that the concentration range used is 
not a true representation of the concentrations actually found within AGE. Another 
possible reason is that it has not been taken into account the uptake of AGE components 
via the gastrointestinal tract as this process may have an effect upon the results. Also 
there is the variation between individuals as it has been found throughout this study that 
certain volunteers are more susceptible to the actions of both the individual components 
and their mixtures than others. 
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Agarwal et al. (1977) conducted a clinical trial involving the ingestion of cycloallfin 
(0.25 g/day). In their trial they found that cycloallfin had a profound effect upon platelet 
aggregation induced by ADP. In this study we found that cycloallfin inhibited platelet 
aggregation at all the concentrations used. However, these results were not deemed 
significant. Thus, this work does not support the findings of Agarwal et al. (1977). 
It was found that the cysteine sulphoxide mixture was very effective in inhibiting 
platelet aggregation at relatively low concentrations. It was also observed that the extent 
of aggregation had a tendency to return to the control level at high concentrations. This 
was as expected as it has been reported in previous studies (Eyre et al. 1983; Macdonald 
and Langer 2004; Macdonald et al. 2000; Morimitsu et al. 1992; Yanagita et al. 2003) 
using different garlic preparations that these individual compounds are thought of as 
some of the main bioactive constituents of garlic. It has also been reported in the 
literature that these compounds are responsible for garlic's characteristic odour 
(Morimitsu et al. 1992; Wang et al. 1999; Xiao and Parkin 2002). However, the results 
obtained in this study show that the inhibitory properties of AGE are not due to any one 
of the organosulphur compounds tested. In order for AGE to inhibit agonist-induced 
platelet aggregation effectively all the constituents must be present. 
The results obtained for the three individual amino acids were unexpected, as it was 
thought that the amino acids L-arginine and L-cysteine would have had a significant 
effect upon platelet aggregation. Anfossi et al. (2001) conducted a study examining the 
anti-aggregatory effects of L-cysteine in the form of N-acetyl-L-cysteine (NAC). They 
found that NAC a thiol compound exerts direct anti-aggregatory effects through an 
increased bioavailability of platelet nitric oxide (NO). It is known that both NO 
produced by the endothelial cells (Morihara et al. 2002) and also by the platelet acts as 
an inhibitor of platelet aggregation in vitro. NO synthesis within platelets is controlled 
by the amino acid L-arginine as it provides a guanidino nitrogen group for NO synthesis 
through NO synthase activity (Anfossi et al. 2001; Sago et al. 2000). This leads to the 
question does an increase in the availability of these amino acids modulate the response 
of human platelets in vitro? As AGE is known to contain these particular amino acids 
and is it possible that the inhibitory effect of AGE is due to the actions of these 
particular amino acids? 
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Neither L-arginine nor L-cysteine had a profound inhibitory effect upon platelet 
aggregation at any of the concentrations used apart from 9.0 mmol/L. The same cannot 
be said for L-methionine as it was found to be an effective inhibitor of platelet 
aggregation. However, it may be argued that L-cysteine is not a stable compound and 
studies that have looked at the effects of this particular amino acid have chosen to use it 
in the form of NAC, a much more stable compound. Also the amino acids may not have 
been transported readily across the platelet membrane and that the levels of endogenous 
L-arginine are more important than the exogenous ones. Even though both of these 
amino acids are used as supplements the concentrations that may be given orally are 
significantly higher than those used in this study. Another factor is that prolonged 
conditioning may result in a reduction of inhibition as 10 min incubation may not have 
been long enough for noticeable effects to be observed. 
Aspirin (acetylsalicyclic acid) is a known inhibitor of platelet aggregation and has been 
used clinically for a number of years both in vivo, in vitro and in the treatment of 
cardiovascular disease (Awtry and Loscalzo 2000; Chakraborty et al. 2003; Clutton et 
al. 2001; Nailin et al. 2003; Kong 2004). Aspirin prevents aggregation by irreversibly 
impeding cyclooxygenase (COX) and reducing thromboxane A2 (TXA2) and 
prostaglandin synthesis (Awtry and Loscalzo 2000; Clutton et al. 2001; Ferri et al. 
1994; Pollack 2003). The majority of in vitro studies have used agonists such as 
collagen and thrombin to stimulate platelet aggregation. There have not been many 
studies that have utilised ADP. In one such study Chakraborty et al. (2003) found that 
aspirin can inhibit ADP-induced platelet aggregation. As this study is involved with the 
mechanisms of inhibition by AGE the most logical approach would be to compare AGE 
and its inhibitory action to those of known inhibitors. The findings in this study oppose 
those by Chakraborty in that aspirin did not inhibit ADP-induced aggregation at the 
concentrations used in their study. It was found in this study that slight inhibition was 
noted at two of the concentrations used (0.00078 and 0.1 mmon respectively) but it 
was not significant. These results strengthen the argument that the biochemical 
pathways that result in platelet aggregation via stimulation with ADP are different to 
those initiated by other agonists. Thus, it can be assumed from this study that the 
enzyme COX does not play an important role in ADP-induced aggregation and that 
platelets can be activated by pathways that are not blocked by aspirin (Kong 2004). 
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Thus, a TXA2 independent pathway must contribute to platelet aggregation induced by 
ADP. 
However, there may be another explanation for the observed results as it has been found 
that between 8-45 % of the population are resistant to the effects of aspirin. As the 
optimal dose required to induce complete inhibition of platelet aggregation is subject to 
inter-individual variability - the mechanism(s) by which some people are resistant to 
aspirin in vivo remains to be determined (Kong 2004; Macchi et al., 2002). 
AGE aggregation was compared to other known classical inhibitors of platelet 
aggregation (AIF3, AG527, BIS, GEN, IBMX, NaF, OKA, indomethacin and PGEI), 
the inhibitory mechanisms of these classical inhibitors are well established (Table 3.3). 
The only inhibitors that had any significant inhibitory effect upon ADP-induced platelet 
aggregation were: GEN, IBMX, indomethacin and PGEI. Each inhibitor has its own 
mechanism for inhibiting platelet aggregation. Using this information these pathways 
will be explored in more detail in chapter 4, as the next logical step in this study would 
be to examine the biochemical pathways which are inhibited by these four classical 
inhibitors (protein tyrosine kinase activity, cAMP and cGMP phosphodiesterases and 
intracellular cAMP levels) to see if AGE exerts its inhibitory effect at these points 
during platelet activation and subsequent aggregation. 
ADP was chosen as the primary agonist for inducing platelet aggregation because the 
results obtained with the particular agonist were consistent and easily reproducible 
throughout the study. 
The major findings generated in this study are summarised, in Figure 3.2 1. 
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3.4. SUMMARY OF RESULTS 
AGE inhibits agonist-induced platelet aggregation in freshly prepared human 
PRP. 
9 AGE is more effective in inhibiting platelet aggregation induced by the agonists: 
ADP, adrenaline and thrombin at low percentage concentrations than in 
aggregation initiated by A23187, AA, collagen and PMA. 
e Ethanol does not inhibit ADP-induced platelet aggregation therefore the enzyme 
PLD has no significant role in platelet aggregation initiated with ADP. 
e Ethanol inhibits collagen-induced platelet aggregation in a dose-dependent 
manner. Therefore the enzyme PLD must play an important role in platelet 
activation and subsequent aggregation initiated with collagen. 
& Isolated components from AGE do not inhibit ADP-induced platelet 
aggregation. 
*A mixture of the nine individual components at their optimum concentrations 
did not inhibit platelet aggregation significantly compared to the control. 
e The amino acids are not very effective inhibitors of ADP-induced platelet 
aggregation both individually and as a mixture. It was found that L-methionine 
produced the greatest degree of inhibition. 
op A mixture of nine components found in AGE and the three amino acids did not 
significantly inhibit ADP-induced platelet aggregation. 
9 Aspirin did not inhibit ADP-induced platelet aggregation, when tested in a 
concentration-dependent manner. Inhibition was observed at certain 
concentrations, but tended to follow a biphasic pattern. Therefore, platelet 
aggregation must occur through pathways that are thromboxane-independent 
when initiated with ADP. 
* The only inhibitors that inhibited ADP-induced platelet aggregation were 
IBMX, indomethacin, GEN and PGEI. 
86 
er 
E 
0 
0 to cm L- 0) cm. - 6- 
Co 
ýa, 
'0 
9m -g 
1) 2- A "a E0 
(D cm 1- Co CL 
8.0 
m 
M 
Co Z 0 
CL- 
W- Lo ru 
0w 
1620 CL r m0 M< L, CL 
0 
e 0 
'Z 3-5* 53 «IC'u 
(2 
. 92 0 Z 
.r 
Z0 
, 2,0 
92 
0 
Cm ZZ LLi 
w 
< 
Z 
et 
:? 2Z 
0E 
4 -0 
ý 
--s 
g 
-CDL c 
CD 
0) 0 
Co 
2. C»O CM < Co 0 Ug 9 99 - r= *7n C 15 >, -0 -ir) - l'- u 
-g e cm 15. im «a wm or m J. >. 1 
.p t= -L«A 
ro CL o :2 
0 
u w > a6 ID M 
< 
0 
>, 
(U 
ci 
00 
r r- 
< «e 
to 
8-. 
-1 -0 M uc UP Aý 
Z c3) S c» m 
E 
0 
to . M 0 U 
m c3 
2. 
- 
M (0 m MZ m 72 E 
w (A 
0: e 9 c <d a) «3 12 A 0 
<8 
« ?, Co t 15 8 ;A;; - 12 - em 
'E EN (L) M .2 pw 
.2 c» a) < FL Z ri 0m (0 A2 'W c3) 4) -g CL 
0 15 
«a Zmm r- ro 12 ýT 3 0 Z u E- m «t3 m £2 k4 
87 
CHAPTER 4 
THE INHIBITORY MECHANISMS OF AGE AND ITS 
EFFECT ON THE BIOCHEMICAL EVENTS THAT 
INITIATE PLATELET AGGREGATION IN VITRO 
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4. THE EFFECT OF AGE ON SIGNALLING EVENTS DURING 
PLATELET AGGREGATION 
4.1. INTRODUCTION 
Platelet activation and subsequent aggregation is an agonist-dependent process i. e. the 
biochemical signalling pathways involved are dependent upon the stimulating agonist 
and the class of receptor to which it binds. As mentioned previously (refer to section 
1.2.1, Chapter 1) platelet activation and aggregation is a complex biochemical process 
that requires the cooperation of many signalling pathways in order to bring about the 
formation of a stable platelet aggregate both in vitro and in vivo. The main objective of 
the studies reported in Chapter 3 was to identify possible inhibitory mechanisms for 
AGE on agonist-induced platelet aggregation by comparing the actions of known 
platelet aggregation inhibitors to that of AGE using platelet aggregometry. 
To reiterate AGE inhibited platelet aggregation induced by a variety of agonists. The 
only classical inhibitors that significantly inhibited platelet aggregation induced by ADP 
were, IBMX, GEN and PGEI. IBMX exerts its inhibitory response through the 
degradation of both cAMP and cGMP phosphodiesterases leading to an increase in 
cAMP levels within the platelet. GEN down regulates PTK activity which reduces 
platelet aggregation, whereas, the prostaglandin PGEI exerts its inhibitory effect by 
increasing the intracellular levels of cAMP within the platelet. 
Therefore, it was decided from these results to examine the effects of AGE on the 
following four pathways involved in platelet aggregation: 
* Calcium mobilisation - common to all forms of agonist stimulation. Calcium 
mobilisation is essential for cytoskeletal rearrangement in platelets from a 
resting discoid to the formation of pseudopia to allow for aggregate formation. 
e AA metabolism - due to the strong indication in the literature of its importance 
during platelet aggregation. Also clinically available anti-platelet therapies are 
targeted against COX, an important mediator in AA metabolism. 
9 Intracellular cAMP levels - levels of cAMP regulate platelet aggregation in that 
increased levels prevent further aggregation from occurring. 
e Fibrinogen binding - the formation of a stable platelet aggregate 
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The primary reason for choosing the above events that occur during platelet activation/ 
aggregation is that all of them are associated with events that occur downstream of 
soluble agonist /receptor interaction (Figure 1.3, page 12). The other reason is that from 
results obtained in chapter 3 (platelet aggregation studies) AGE; when compared to the 
classical inhibitors had a similar inhibitory profile to that of PGEI, GEN, IBMX and 
indomethacin, when platelet aggregation was initiated with the agonist ADP (for an 
explanation of ADP-induced platelet aggregation and the signalling pathways activated 
by this agonist, refer to Figure 1.3, Chapter 1, page 12). 
4.1.1. Calcium signalling and platelet activation/aggregation 
Changes to the levels of cystolic calcium within aggregating platelets is a critical step in 
various aspects of platelet activation such as shape change, aggregation, and secretion 
(Ardlie 1982; Fisher et al. 1985; Heemskerk and Sage 1994; Park et al. 2004; Sage et 
al. 2000; Sargeant and Sage 1994; Sage 1997; Sage et al. 1997). As platelets are non- 
excitable cells (cells which cannot propagate action potential) the levels of intracellular 
calcium are increased by platelet agonists via two sources: (1) influx across the plasma 
membrane through calcium channels, and (2) the release of calcium from intracellular 
stores contained within the dense tubular system. Agonists bind to receptors coupled to 
G-proteins on the platelet membrane which stimulates the enzyme PLC, leading to the 
formation of intracellular second messengers such as IP3. These second messengers 
stimulate the release of calcium from intracellular stores (Figure 4.1 b) which then 
regulates the influx of external calcium through calcium-conducting channels within the 
plasma membrane. The levels of calcium are sustained via PLA2 activation and the 
generation of TXA2 which further propagates platelet aggregation via the binding of 
fibrinogen to its receptor GPIIb-Illa (Huang et al. 1991; Heemskerk and Sage. 1994; 
Nesbitt et al. 2003; Park et al. 2004; Sage el al. 2000; Sargeant and Sage 1994; Sage. 
1997; Sage et al. 1997). 
Calcium plays a very important role in platelet aggregation. One possible mechanism by 
which AGE may inhibit platelet aggregation is that it interferes with calcium 
mobilisation by either suppressing the influx of this ion into the platelet or by chelation 
of calcium within the platelet cytosol or extracellular environment. It has been reported 
previously by Dillon et al. (2003) that AGE may chelate calcium ions present within the 
platelets. In support of this AGE was found to inhibit platelet aggregation induced by 
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the calcium ionophore A23187 (Section 3.1, Chapter 3, page 5 8). Hence it can be 
suggested that the anti-aggregation effect maybe related to an intraplatelet suppression 
of calcium mobilisation, which in turns activates the PLA2 pathway to propagate 
aggregation. 
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4.1.2. Arachidonic acid metabolism during platelet activation 
The liberation and metabolism of AA into its metabolites is an important step in platelet 
activation and subsequent aggregation. AA is a membrane-derived fatty acid that is 
released by PLA2 upon agonist stimulation of platelet activation. It is further 
metabolised in platelets via two metabolic pathways: (1) the cyclooxygenase pathway 
that forms TXA2 (a potent stimulator of platelet aggregation) and other prostaglandins, 
and (2) the lipooxygenase pathway that releases hydroxyeicosatetraenoic acids and 
leukotrienes (powerful chemoattractant agents that recruit cells such as neutrophils and 
eosinophils, which are involved in inflammatory processes) (Figure 4.2). Completion of 
these pathways leads to the release of granule contents, mobilisation of calcium within 
the platelet and the continuation of the aggregation process (Rao and White 1985). 
Many researchers working with garlic and other natural compounds have found that 
certain types of products exert their inhibitory effect upon platelet aggregation via this 
pathway (Ali et al. 2000; Apitz-Castro et al. 1983; Bordia et al. 1978; Jin et al. 2005; 
Kleijnen et al. 1989; Makheja et al. 1980; Moon et al. 2000; Shah et al. 1999; Sheu et 
al. 2003; Son et al. 2004; Srivastava. 1984; Srivastava. 1986; Srivastava and Tiwari 
1980; Stampfer et al. 1987; Vanderhoek et al. 1980). Due to this, the effect of AGE on 
this particular process was examined further. 
The effect of AGE upon AA metabolism was monitored using the method developed by 
An et al. (2002). In brief, 14 C-AA was incubated with PRP, excess radiolabel was 
removed by washing and the platelet pellet was then resuspended in buffer. Aggregation 
was initiated with ADP in the presence/absence of AGE and the reaction was terminated 
through the addition of a stopping solution after which the cells were centrifuged. 
Radioactivity was monitored using liquid scintillation counting of the supernatant 
contained within Ecoscint A. 
Simultaneously to PLA2 activation; intracellular levels of cAMP are suppressed in order 
for platelet aggregation to continue unabated. 
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Figure 4.2. A schematic representation of the AA metabolic pathway. Agonist receptor 
interaction stimulates the release of AA by PLA2. AA is metabolised further by two separate 
pathways (1) the enzyme COX into the prostaglandins D2, E2 and F2,, and, (2) the lipooxygenase 
pathway which releases hydroxyeicosatetraenoic acids and leukotrienes which promotes further 
platelet aggregation and activation. 
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4.1.3. cAMP and platelet aggregation 
The cyclic nucleotides regulate platelet function by controlling the amount of platelet 
aggregation that occurs in vivo; and include cAMP and cGMP which are both potent 
inhibitors of platelet aggregation. The levels of cyclic nucleotides within platelets are 
regulated by synthesis through AC (adenylyl cyclase) and guanylyl cyclase (GC) and 
are down-regulated through the degradation of phosphodiesterases (PDEs) -a family of 
enzymes that hydrolyses the Y-phosphoester bond on cAMP and/or cGMP, converting 
them into biologically inactive metabolites. If PDEs are inhibited, cAMP decomposition 
is reduced which in turn causes an increase in cAMP levels (Aktas et al. 2002). cAMP 
is formed from ATP via the catalytic actions of AC (an integral membrane 
glycoprotein). The prostaglandins (e. g. PG12, and PGEI) that are released from either 
platelets and/or endothelial cells, bind to specific receptors coupled to Gs proteins 
which, in turn leads to an increase in intraplatelet levels of cAMP (Brass et al. 2004; 
Daniel et al. 1999; Freedman 2003; Geiger 200 1; Prevost et al. 2003; Puri 1999; Savage 
et al. 2001; Schwarz et al. 2001; White 1999; Wilde et al. 2000). Agents that raise 
cAMP levels aid in reducing the amount of available calcium within the platelet which 
ultimately leads to inhibition of platelet aggregation. Also a reduction in calcium 
brought about by raised cAMP levels can reduce the binding capabilities of the GPIlb- 
IlIa receptor to form platelet aggregates via fibrinogen cross-links with adjacent 
platelets. During platelet activation/aggregation cAMP levels are suppressed via the 
actions of G, proteins (Figure 4.3), and this suppression allows for the aggregation 
process to continue unabated. 
Platelet aggregation (fibrinogen-receptor interaction to form a stable platelet aggregate) 
is dependent upon the levels of cAMP within the platelet. 
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PDE2 
Figure 4.3. The events surrounding cAMP formation and suppression during platelet 
aggregation. ADP mediates platelet aggregation by receptors coupled to G-protein mediated 
pathways. The receptor P2Y 12 inhibits AC activity via G, allowing for platelet activation and 
aggregation to occur. PGEI binds to IP receptor which is coupled to a Gs protein. This 
stimulates AC activity to increase levels of cAMP, thus inhibiting platelet aggregation. cAMP is 
degraded into AMP via PDE2. 
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4.1.4. Fibrinogen binding and platelet aggregation 
In agonist induced platelet aggregation, the action of the agonist on the generation of the 
signal that stimulates granule secretion is not caused by the binding of the agonist to its 
receptor but through the subsequent interaction of fibrinogen and probably other ligands 
with the receptor glycoprotein GPIIb-IIIa complex (integrin - allbP3). Fibrinogen 
binding and the formation of a platelet aggregate is the final step in platelet aggregation 
and is common to all forms of agonist stimulation. 
Fibrinogen is the primary ligand for GPIlb-IIIa however the receptor also recognises 
other adhesive ligands such as: fibronectin, vWf, CD40L and ICAM-4. There are 
approximately 80,000 copies of GPIIb-IIIa expressed on the surface of normal resting 
platelets (Basani et al. 2001; Brass et al. 2004; Chiang 2005; Dorsam et al. 2002; 
Frelinger et al. 2001; Fullar 2004; Furman et al. 2004; Jackson et al. 2003; Lindahl et 
al. 1992; O'Neill et al. 2000; Padoin et al. 1996; Payrastre et al. 2000; Seyfarth and 
Koksch 2004; Vickers 1993). Additional receptors are contained within the membranes 
of the a-granules and open canalicular system and are expressed during platelet 
activation (Matzdorff and Voss 2005). In inactivated platelets, GPIIb-Illa has a low 
affinity for fibrinogen. Upon platelet activation, the GPIIb-Illa receptor undergoes a 
structural conformational change (inside-out signalling) and the receptors' affinity for 
fibrinogen and other adhesive ligands increases via the RGD (Arg-Gly-Asp) sequences 
contained within the receptor, this leads to the generation of biochemical signals into 
the platelet (outside-in signalling), that further drives the aggregation process. These 
include an increase in tyrosine phosphorylation of signalling proteins such as Syk (a 
cytosolic nonreceptor tyrosine kinase involved in signal transduction processes such as 
an increase in Ca2+ mobilisation) and FAK (Focal Adhesion Kinase; where actions are 
mediated through outside-in signalling via the conformational change in the GPIlb-IIIa 
receptor, its function is in cytoskeletal reorganisation) (Buensuceso et al. 2005; de 
Virgilio et al. 2004; Hers et al. 1997); increase in calcium mobilisation (Nesbitt 2003; 
Quinton et al. 2002; Rosado et al. 2001), calpain activation and increased cytoskeletal 
organisation (platelets change from resting discoid to the formation of pseudopodia on 
the platelet surface) (Eckly et al. 2002; Levy-Toledano et al. 1997) GPIlb-IlIa receptors 
on adjacent platelets link together via fibrinogen cross-bridges to form platelet 
aggregates (Figure 4.4). 
97 
To monitor the effects of AGE upon fibrinogen binding during ADP-induced platelet 
aggregation, four independent methods were used as outlined below: -- 
1. The first method investigated involved platelet disaggregation. The platelet 
inhibitor PGEI had comparable inhibition profiles to that of AGE (Chapter 3). 
Another physiological characteristic of this prostaglandin is that when it is added 
to aggregated platelets it can reverse this process and disperse the platelet 
aggregate into single platelets which can be observed using platelet 
aggregometry (Kikura et al. 2002). Thus, it was decided to see if AGE acted in a 
similar manner to that of PGEI with regards to platelet disaggregation. To 
monitor this occurrence platelet aggregation was initiated via the addition of 
ADP and the reaction was allowed to run for 5 min in a platelet aggregometer. 
AGE was then added to the aggregated platelets and disaggregation was 
monitored using light transmittance platelet aggregometry (For a detailed 
method see Chapter 2, page 40). 
2. A simple adhesion assay was developed to monitor platelet aggregate formation 
to immobilised fibrinogen. Platelets were loaded with either the biological stain 
Rose Bengal or the radiolabelled chromium-51 and were allowed to adhere to a 
fibrinogen-coated surface upon stimulation with ADP. Two assays were 
conducted: direct and indirect. The indirect assay monitored the effect of AGE 
treated platelets and their ability to bind to fibrinogen following agonist 
challenge. The direct assay examined the effect of AGE directly upon the 
immobilised fibrinogen molecule (For a detailed method refer to chapter 2, page 
42). 
3. The simple adhesion assay produced results which suggested that pre-treatment 
of platelets with AGE reduced platelet aggregate formation. However, the 
method was very basic one and the results are not very consistent. Hence, a well 
established method was utilised: Flow cytometric analysis. This particular 
method analyses the binding capabilities of the fibrinogen receptor GPlIb/IIIa to 
its ligand fibrinogen through the use of antibodies specific for both platelets and 
the receptor GPlIb/IIIa (See page 42 for a detailed method outline). 
4. SEM imaging was used to monitor platelet aggregation in the presence/absence 
of AGE (refer to page 47, chapter 2 for a detailed method of the procedure). 
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Figure 4.4. Traditional model of platelet aggregation. Soluble agonists bind to one or more 
receptor on the platelet cell surface, initiating signalling events that are linked with the integrin 
ctllbp3 receptor activation. The active form of the receptor binds to fibrinogen, linking adjacent 
cells to form a stable aggregate (Dopheide et al. 200 1 ). 
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4.2. RESULTS 
4.2.1. The effect of AGE on calcium mobilisation during agonist-induced platelet 
aggregation 
L Measurement of intracellular calcium in activated and inactivatedplatelets 
Platelet aggregation is triggered by a variety of extracellular signals and many agonists 
interact with the receptors coupled to PLC, leading to the formation of DAG and IP3 
which in turn releases calcium from intracellular stores. The emptying of these calcium 
stores regulates calcium-conducting channels within the plasma membrane of the 
platelets, thus initiating the influx of external calcium ions into the platelets. This 
sustained level of calcium activates PLA2 resulting in the synthesis Of TXA2 and the 
subsequent release of secretory granules to complete the aggregation process. 
Although it is has been demonstrated that AGE may inhibit agonist-induced platelet 
aggregation, the direct effect of AGE on calcium mobilisation within the platelets is 
unknown. The main purpose of this experiment was to design a procedure that will 
effectively measure the changes in intracellular calcium in both inactivated (as a 
negative control, to ensure that the experiment was working correctly) and activated 
platelets. 
Using the method outlined in chapter 2, page 40, calcium mobilisation was monitored in 
both aggregated and non-stimulated platelet suspensions. It was found during these 
preliminary experiments (data not shown) that a Fura-2/AM concentration of I pM was 
not sufficient to produce a strong fluorescence signal that could be measured by the 
fluorimeter. However a Fura-2/AM concentration of 2 pM proved to be more effective 
in generating a significant signal. It was also noted that the original concentration of the 
ionophore A23187 (2 pM) needed to induce activation was not effective and that a 
concentration of 5 pmol/L was required. Platelets were then loaded with Fura-2/AM at a 
final concentration of 2 pM, both CaC12 (an external source of Ca2') and EGTA (a Ca2+ 
chelator) were then added individually and together to the platelet suspensions prior to 
agonist-induced activation at a final concentration of I mM. The calcium ionophore 
A23187 was used to initiate platelet aggregation and calcium influx at a concentration 
of 5 pM. In these experiments it was noted that external calcium is important and 
essential for platelet aggregation. As platelets that had not been exposed to an external 
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calcium ion source displayed a reduction in fluorescence intensity and ultimately a 
reduction in the calcium concentration within the platelet. 
From the experiments reported above it lead to the question can AGE inhibit agonist- 
induced platelet aggregation by reducing the amount of calcium available to the 
aggregating platelets through chelation of calcium ions? The following experiment was 
performed to answer this question. 
Fura-2/AM loaded platelets at a concentration of 2 pM were incubated with CaC12 at a 
final concentration of I mM and 25 % (v/v) AGE for 10 min at room temperature. 
A23187 at a final concentration of 5 pM was then added to the AGE treated platelets 
and the fluorescence was measured. It was found that AGE significantly decreased the 
calcium concentration when compared to the control (inactivated platelets). The 
experiment was repeated again with CaC12 being substituted for EGTA (a chelator of 
metal ions was used to determine if external calcium ion influx is important in 
maintaining agonist-induced platelet aggregation) at a final concentration of I mM. 
However, the results obtained were not viable due to the large negative values that were 
recorded by the fluorimeter. The addition of CaC12 to platelets acts as an external source 
of calcium ions. The purpose of this experiment was to observe if AGE had the 
potential to reduce the availability of external calcium ions to the aggregating platelets, 
as both internal and external sources of calcium ions are important for maintaining 
platelet aggregation. These results indicate that platelet aggregation was reduced when 
AGE was added to platelets that had been pretreated with CaC12. 
It is known from the experiments conducted by Dillion et al. (2003) that AGE has metal 
chelating properties and it is likely that AGE interferes with calcium mobilisation and 
subsequent inhibition of platelet aggregation. To ascertain whether AGE is really 
having an effect upon calcium influx and mobilisation within the platelet; the following 
points were examined: 
o EDTA used instead of EGTA as it is more specific for calcium - the above 
experiment suggested that external calcium ion influx is an important factor in 
platelet aggregation. In that, the addition of EGTA to platelet suspensions 
resulted in a decrease in platelet aggregation. The actions of EDTA will be 
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compared to that AGE to see if AGE has potential calcium ion chelating 
properties. 
* The ability of Fura-2/AM loaded platelets to aggregate in the presence/absence 
of external calcium was investigated. Aggregation was monitored using platelet 
aggregometry and compared to the control for aggregation induced by ADP. 
Platelet aggregometry is a good indicator of platelet aggregation therefore, it is 
essential to determine that AGE is directly affecting calcium mobilisation in the 
presence/absence of calcium ions. 
The results generated in this study show that platelets from different individuals, when 
stimulated with the agonists ADP and A23187, display variable aggregation and 
calcium mobilisation when compared to the PBS controls therefore, typical individual 
data is presented in this study. Figure 4.5 shows that ADP when added to platelet 
suspensions caused approximately 70% aggregation compared to the control sample. In 
the presence of Fura-2/AM, platelet aggregation induced by ADP was lower than 
platelets that had not been exposed to the Fura-2/AM (Figure 4.5). The addition of 
calcium ions to the platelets resulted in a decrease in the aggregation response, 
compared to the Fura-2/AM loaded platelets in the absence of calcium ions. The 
addition of AGE and calcium to the platelets resulted in a reduction in aggregation that 
was similar to Fura-2/AM loaded platelets in the presence of both external calcium ions 
and EGTA (Figure 4.5). 
Experiments that monitored calcium mobilisation showed that addition of ADP resulted 
in an increase in calcium ions, such that a peak was observed at approximately 0.5 min 
(Figure 4.6). This result supports earlier studies which showed that an increase in 
intracellular calcium concentration is indicative of platelet aggregation (Heemskerk and 
Sage 1994; Sage el al. 2000; Sage et al. 1997; Sage et al. 1997; Sargeant and Sage 
1994). The inclusion of AGE resulted in the significant inhibition of platelet 
aggregation and suppression of calcium ions. The results indicate that the pre- 
incubation of platelets with AGE had significantly lower calcium ion concentrations 
implying that AGE may be acting as a possible calcium ion chelator (Figure 4.6). 
The calcium ionophore A23187 also induced platelet aggregation with a concomitant 
increase in the intracellular calcium ion concentration, again the rise in calcium ion 
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concentration was apparent at 0.5 min (Figure 4.7), this agonist was used as a positive 
control as it induces calcium ion influx to initiate platelet activation and subsequent 
aggregation. The effects of AGE upon A23187-induced platelet aggregation were very 
similar to those observed with ADP. Thus, platelet aggregation was significantly 
reduced as was the increase in intracellular calcium ion concentration (Allison et al. 
2006). A23187 is an ionophore that promotes the influx of calcium ions into platelets 
(Connor et al. 2001) and it is possible that AGE interferes with this particular step or 
steps precedent to the generation of second messengers during platelet activation and 
aggregation or it simply chelates the available Ca2+. 
The activities of EGTA (a known calcium chelator) were compared to that of AGE. It 
was observed that EGTA at very high concentrations suppressed calcium mobilisation 
(results not shown). In this experiment there was no evidence of either light or 
fluorescence quenching by AGE. 
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Figure 4.6. The effect of AGE, 25 % (v/v) on ADP-induced calcium mobilisation. Fura- 
loaded platelets were suspended in HEPES-Tyrode's buffer containing CaC12 0 mmol/L) and 
incubated with AGE for 10 min at 3 7'C before the addition of ADP (8 Pmol/L). Key: (A) 
donor 1; (B) donor 2 (Results reproduced from Allison et al. 2006) 
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Figure 4.7. The effect of AGE, 25 % (v/v) on A23187-induced calcium mobilisation. 
Fura-loaded platelets were suspended in HEPES-Tyrode's buffer containing CaC12 0 
mmol/L) and incubated with AGE for 10 min at 370C before the addition of A23187 (5 
pmol/L). Key: (A) donor 1; (B) donor 2 (Results reproduced from Allison el al. 2006). 
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The results depicted in Figures 4.6-4.7 show the effect of AGE on intraplatelet calcium 
mobilisation in two individuals, as there was wide variation between individuals. This 
made it almost impossible to collect data for statistical analysis. Therefore, it was 
decided to repeat the experiment again. 
In the second set of calcium experiments data was generated for statistical analysis and 
the results are shown in Figure 4.8. This shows that for this particular group of 
individuals (n--3) the incubation of Fura-2/AM treated platelets with AGE (25 %, v/v) 
followed by ADP-stimulation results in a significant decrease in intraplatelet levels of 
calcium when compared to platelets that had no AGE treatment. As in the other calcium 
experiments (page 103) ADP-induced platelet aggregation shows a sharp increase (peak 
is apparent in Figure 4.8) in calcium ions at approximately 0.5 min. This peak was not 
observed in both inactivated and AGE treated platelets. The levels of calcium in both 
the AGE treated and inactivated platelets remained constant throughout the experiment. 
These results indicate that incubation of platelets with AGE reduces the amount of 
calcium present in both resting and ADP-activated platelets which ultimately leads to a 
reduction in platelet aggregation in the presence of the aggregating agent ADP. 
107 
I- LLI 
< C) 
(1/10wu) SUOIlellueouoo eo 
u -0 (Z MZ r- 
-5 0=> '5 
r=ýý 
-CD, Z 
19 Q) = cu c" m 
ýlý 4 s- r- -a (Z cý ý: 5u0 vi ý s: ý: r= 2CU 
&6'. 
,=3 (A ('ý 
'CD 
< 
(ýI .Z" 
r= U r- 
Z8 
tz. >ý .-5 
-a .S 
(A rj VW 
7i 
.e iz 2 -0 U CZ -ý; -0 
<< 
r- rA U 
0 -Z 
. Co ;-0 1-" ý- 61b c2.. 2 .0m., tü umeu e&. = ý: Mu2 
k'b -0 15 ýE - LU ý- Z 0; ý r_ Z) r_ > 9 
0 .20Eu lp, 5Z- r- "E 9. CA Mý 
. 14 u Co -, Z uý -0 9. = ;=ý: -2=U Wlb 0 .- tu ie 
ÖAI -E (i 2' r= -2: 0 
1 
uZ0. r- ;= cz U« 
< 
06 M. CD :D5: . 
tg O= ao -2 *IM, --" 0 >ý 'CJ 4) -mZ >- 
1-1 
108 
C) (D 
CD C) 
en CN 
4.2.2. The effect of AGE on AA metabolism during ADP-induced platelet 
aggregation 
AA liberation was measured using the method outlined in Chapter 2, section 2.4.2., 
page 40 AGE is very dark in colour and preliminary in studies a concern was that AGE 
may have been 'quenching' the radiolabel 14 C-AA, in that, the readings obtained via 
liquid scintillation counting were very inconsistent and not easily reproducible 
(radioactive CPM in the AGE samples were very similar to those of the negative control 
- no radiolabel present within the sample). 
In order to confirm this, the procedure below was carried out: 
I pL (1.85 PCi) of 14 C-AA was added to I mL of buffer and mixed. 10 pL of this 
mixture was counted for radioactivity along with a sample of buffer, a sample of AGE 
plus the 14 C-AA buffer mixture. The results are presented in Table 4.1. and it is clear 
that AGE had a significant 'quenching' effect. There is approximately 80 % reduction in 
the radioactive count for 14 C-AA + AGE when compared to 14 C-AA on its own. Thus, 
with these findings the experimental procedure outlined in chapter 2 was discarded as it 
was not deemed suitable for the measurement of AA metabolism. 
The experimental procedure that was used to monitor AA metabolism and the effect 
AGE has upon this process was thin-laycr chromatography (TLC). Platelets were 
washed and resuspended in HEPES-Tyrode's buffer. The washed platelet suspensions 
were incubated with I tCi 14 C-AA for 20 min at 37C. The platelet suspension was then 
further washed and centrifuged to remove any excess radiolabel and the platelet pellet 
was re-suspended in buffer (1 mL). Platelet suspensions were incubated with or without 
AGE 3.12 % (v/v) for 10 min at 3 7'C, and aggregation was initiated via the addition of 
ADP (8 pmol/L), and aliquots (200 pL) were removed at the following time points: 0, 
10,20,25 and 30 seconds and added to I mL ice cold saline (4 mM) pH to 3 by use of 
HCI, and immediately placed on ice to stop the aggregation process: The platelet 
mixture was vortexed and any released metabolites were extracted using cold diethyl 
ether (I x2 mL) followed by ethyl acetate (I x2 mL) extraction. The top colourless 
layer of the extract was removed and evaporated under heat (550C) using nitrogen gas. 
The ethereal extracts were re-dissolved in diethyl ether and spotted onto glass-backed 
silica Gel G TLC plates along with sodium arachidonate and the prostaglandins D2, E29 
and F2. as standards. The TLC plates were developed using: hexane/diethyl ether/ acetic 
109 
acid (80: 20: 1, v/v/v). After development the plates were allowed to dry and stained with 
iodine. However there was insufficient separation following iodine staining of the 
prostaglandins (no spots were present on the TLC plate to measure Rf values). The 
entire lanes for each each standard was scraped and measured for radioactivity using 
liquid scintillation counting. 
It was found in this study that platelets pre-labelled with 14C_AA when incubated with 
AGE and challenged with the agonist ADP showed no significant inhibitory effect upon 
AA metabolism when compared to the control sample. This was determined using 
liquid scintillation counting - no significant increases in radiolabelled metabolites were 
identified. A possible explanation for the observed result is that AA on its own is an 
agonist and activation may have occurred. Thus, adding ADP would not stimulate 
aggregation if it has already been initiated. 
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Table 4.1. The 'quenching' effect of AGE on liquid scintillation counting. 
Matelet suspensions labelled with 14 C-AA and pretreated with AGE prior to agonist 
Stimulation resulted in 'quenching' during liquid scintillation counting. AGE in the 
presence of 14 C-AA reduced the CPM by 80 % compared to 
14 C-AA on its own. 
Sample 
14C 
_ Counts per minute (CPM) 
Buffer 22 
3.12 % AGE 22 
14c-AA 1756 
14C-AA + AGE 363 
III 
There were numerous problems encountered with this particular method and it resulted 
in significant variation in the data. Hence this method was also discarded. The major 
problem in this experiment was that significant amounts of the radiolabel was lost 
during the washing step(s) and solvent extraction process. 
The above method was modified in that platelet-rich plasma was pre-incubated in the 
presence/absence of AGE for 10 min at 370C. Aggregation was stimulated by the 
addition of ADP and the aggregatory process was allowed to run for approximately 30 
seconds. The reaction was terminated by placing the PRP on ice followed by 
centrifugation at 1500 g at 4C for 10 min. The supernatant was then removed and the 
platelet pellet resuspended in HEPES-Tyrode's buffer. Aliquots (I mL) of the platelet 
suspension were homogenised on ice using a Donce Homogeniser. The platelet 
homogenate was equilibrated to 37'C for 5 min, after which, 2 mM CaC12 was added to 
the platelet lysate, immediately followed by the addition of 14 C-AA and unlabelled AA 
(I pCi and I pM, respectively). Aliquots (100 pL) were removed at the following time 
intervals: 0,0.5,1,2,3,5,10 and 15 min and placed into I mL ice-cold buffer and I 
mL ethyl acetate. The mixture was vortexed and centrifuged at 2000 g for 10 min at 
4'C. The organic layer was removed and dried at a temperature of 55T under nitrogen 
gas. Finally the residues were re-dissolved in ethanol and spotted onto glass-backed 
silica gel G TLC plates. Prostaglandins D2, E2, F2. and sodium arachidonate standards 
were spotted separately (Table 4.2). The plates were developed in: hexane/diethyl ether/ 
acetic acid (80: 20: 1, v/v/v) to a distance of 15 cm and plates were stained with iodine, 
the spots identified, scraped and measured for radioactivity. 
The following changes were made to the experiment: the development system used 
above provided data, however, it was found from an intensive literature search that the 
following system is more widely used and was used in futher experiments. 
chlorofom-t/methanol/acetic acid/water (100/15/125/1, v/v/v/v)- (Bailey et aL 1977) 
Table 4.2 displays the Rf values obtained for the standards using the developing system: 
chlorofomVmethanol/acetic acid/water (100/ 15/125/ 1, v/v/v/v). The Rf value for 
standards are similar to those published by Bailey et al. (1977). 
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'Me results obtained in this study (Figure 4.9) show that arachidonic acid metabolism 
does not, play a major role in platelet aggregation induced by the agonist ADP in vitro. 
AGE did not inhibit the incorporation of 14C_AA into platelets, uptake of approximately 
85 % occurred. The levels of labelled AA present in AGE treated samples were very 
similar to that of the controls indicating, that no AA metabolism had taken place upon 
ADP-induced platelet aggregation. A possible reason for the observed result is that the 
addition of unlabelled AA plus labelled AA may have resulted in the unlabelled AA 
being taken up into the platelet rather than the labelled AA. A similar result was 
obtained for the agonist thrombin. Tbus, the type of cell-signalling pathway that 
initiates platelet aggregation is dependent upon the stimulatory agonist used to induce 
platelet aggregation. Hence, ADP-induced platelet aggregation does not rely solely upon 
AA metabolism for platelet aggregation to occur. 
This experiment was modified a number of times as shown by the 3 methods used in 
this study, and was conducted numerous times in the presence of another agonist 
thrombin, and each time it was found that AA metabolism does not play a significant 
role in ADP-induced platelet activation and aggregation. 
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Table 4.2. Rf values for the standards Prostaglandins D2, E2, F2. and unlabelled, sodium 
arachidonate using the following development system chloroform: methanol: acetic 
acid: water (100/ 15/12.5/ 1, vlv/v/v). The Rf values for the standards were calculated by 
measuring the distance of the compound moved to the centre of the smear/spot and 
dividing the value by the distance moved by the solvent front (15 cm). 
Standards Rf Values 
Prostaglandin D2 0.18 
Prostaglandin E2 0.16 
Prostaglandin F2.0.1 
Sodium arachidonate 0.61 
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4.2.3. The effect of AGE on intraplatelet levels of cAMP 
Platelet activation and aggregation is a complex process and all the biochemical 
signalling events are interlinked. Elevation of cAMP, either by stimulation of AC or by 
inhibition of PDEs, is a potent regulatory mechanism of platelet inhibition. PGE I, a 
known inhibitor of platelet aggregation exerts its inhibitory response by increasing the 
intraplatelet levels of cAMP. It has been established that PGEj when added to pre- 
aggregated platelets results in disaggregation. It has been shown that both AGE and 
PGEI causes disaggregation (Allison et al. 2006), therefore, it was decided to monitor 
the effects of AGE upon intracellular levels of cAMP, to see whether AGE acted in a 
similar manner to PGE I. 
In this study intracellular cAMP levels were monitored using a competitive enzyme 
immunoassay system for platelets that had been pretreated with both AGE or PGE I, as a 
positive control. The basal levels of cAMP in both the PGE I (10.7 ± 0.42 pmol) and 
AGE (8.4 ± 0.28 pmol) treated platelets were significantly (P<0.01) higher than those of 
the control group (3.9 ± 0.72 pmol) (Figure 4.1 OA), indicating that incubation had 
caused a rise in cAMP with both PGEI and AGE. Immediately upon agonist stimulation 
the levels of cAMP at time 0 seconds decreased slightly when compared to the basal 
levels. Both the AGE (8.03 ± 0.34 pmol) and PGE 1 (9.15 ± 0.3 7 pmol) treated samples 
remained high throughout the course of the experiment time period and were 
significantly different (P<0.01) when compared to the basal samples (Figure 4.1 OB). 
The control and baseline levels of cAMP remained constant throughout the experiment. 
These results indicate that the antiplatelet activity of AGE may act at least partly 
through an increase in cAMP levels in human platelets. 
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Figure 4.10. The effect of AGE on intraplatlet cAMP levels in both activated and 
inactivated platelets. AGE increases intraplatelet cAMP in ADP stimulated platelets (B) 
in vitro. PRP was pre-incubated in the absence or presence of either PGEJ (10 ýLM) or 
AGE (25 % v/v) for 10 min at 370C. Aggregation was initiated by the addition of ADP 
(8 pmol/L) and aliquots were taken before aggregation (A) and at the following time 
points 0,30 and 300 seconds, at which point the platelets were immediately processed 
for cAMP levels. The assay was carried out in duplicate, and the results shown are 
means ± SEM, n=6. All values, both PGEI and AGE treated platelets are statistically 
significant (P<0.0 I) when compared to their respective control samples for both Figures 
A and B. KEY: B- basal, inactivated platelets; C- control, platelets treated with PBS, 
Figure A-unstimulated platelets, Figure B-ADP activated platelets; PGEJ - platelets 
pretreated with PGEI and activated with ADP; AGE - AGE treated platelets activated 
with ADP. 
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In chapter 3, the effect of classical inhibitors on ADP-induced platelet aggregation was 
examined. It was found that the inhibitor IBMX when added to PRP resulted in a 
significant decrease in platelet aggregation stimulated with ADP. It is known that IBMX 
exerts its inhibitory effect through PDE inhibition. Thus, cAMP levels are allowed to 
remain high and inhibit agonist-induced platelet aggregation. In this present study it was 
found that AGE increased the levels of intraplatelet cAMP (Figure 4.10). To ensure that 
the inhibitory actions of AGE were due to the stimulation of AC and not through the 
inhibition of cAMP PDEs, the following experiment was performed. 
IBMX is an inhibitor of cAMP and cGMP PDEs, inhibition of these particular enzymes 
causes an increase in the levels of cAMP/cGMP within the platelet thus, resulting in a 
decrease in platelet aggregation (refer to page 93 for an explanation of cAMP regulation 
during platelet aggregation). The purpose of this experiment is to determine that raised 
levels of cAMP by AGE are a result of AGE directly stimulating AC and not via PDEs 
inhibition. Platelets were pretreated with both AGE (0.78-25 % (v/v)) and IBMX (150 
pmol/L) and the combined effect on ADP-induced platelet aggregation was examined 
using platelet aggregometry. Figure 4.11 show that both IBMX and AGE individually 
are capable of significantly reducing platelet aggregation. The combined effect of both 
inhibitors is significantly (P<0.05) increased for the AGE concentrations: 0.78-12.5 % 
(v/v). This combined inhibitory effect was not observed for the AGE concentration 25 
% (v/v). This result suggests that IBMX has an additive effect upon inhibition of 
platelet aggregation when combined with AGE. Thus, it is a possibility that AGE 
stimulates AC to promote raised cAMP levels rather than inhibiting cAMP PDEs. This 
result also explains why low concentrations of AGE are not as effective at inhibiting 
agonist-induced platelet aggregation when compared to AGE in its most concentrated 
form within PRP (25 % v/v). 
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4.2.4. The effect of AGE on fibrinogen binding in ADP-activated platelets 
The exact mechanism by which AGE inhibits platelet aggregation has not been clearly 
defined in the literature. One potential mechanism could be that AGE interferes with the 
binding of fibrinogen to its receptor and this was investigated using four independent 
methods: 
1. disaggregation - dispersal of platelet aggregate formation via the addition of 
AGE. Monitored using light transmittance platelet aggregometry 
2. simple fibrinogen adhesion assay 
3. direct effect of AGE on fibrinogen 
4. flow cytometric analysis of fibrinogen binding in the presence/absence of AGE 
4. Z4.1.7he disaggregatory effect ofAGE on agonist-inducedplatelet aggregation 
PGEI is an excellent inhibitor of platelet aggregation and it exerts its inhibitory effect 
by increasing the levels of cAMP within the platelet. Another mechanistic action of 
PGEI is that can disperse platelet aggregates into single platelets following its addition 
to platelets that have been stimulated with an aggregating agent. In chapter 3, it was 
found that AGE when compared to PGEI had similar inhibitory aggregation profiles 
when platelets were stimulated the agonist ADP. Thus, AGE was examined to see if it 
could also disperse platelet aggregates using platelet aggregometry. 
To investigate this the following agonists: ADP, collagen and thrombin were added to 
PRP to initiate platelet aggregation. The reaction was allowed to run for 5 min in order 
to achieve maximal total aggregation 2ý 60 %. AGE at a concentration range of (0.78-25 
%, v/v) was then added to the pre-aggregated platelets and the reaction was allowed to 
run for a further 5 min. 
Figure 4.12 shows the disaggregatory effect of AGE on ADP-induced platelet 
aggregation in vitro. AGE at the following concentrations: 6.25,12.5 and 25 % (v/v) 
when added to ADP pre-aggregated platelets resulted in significant (P<0.05) 
disaggregation (dispersal of a platelet aggregate) furthermore. At the AGE 
concentration 25 % (v/v) there was complete disaggregation (100 %). Collagen and 
thrombin were also tested, as these are the main agonists used in the initiation of platelet 
aggregation in vivo. Figures 4.13 and 4.14 depict the disaggregatory effects of AGE on 
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platelet aggregation initiated with collagen and thrombin, respectively. AGE at the 
concentrations 3.12-25 % (v/v) when added to platelets that had been pre-aggregated 
with collagen resulted in significant disaggregation (P<0.05). Platelets aggregated with 
thrombin showed that AGE (1.56-25 %, v/v) significantly (P<0.05) reversed platelet 
aggregation when compared to the control sample. However, complete disaggregation 
was only noted in platelets that had been preaggregated with the agonist ADP. 
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Figure 4.12. The disaggregatory effect of AGE at various final percentage concentrations 
(%) on platelet aggregation initiated by ADP in vilro. Values are means ± SEM, n=6. Values 
are expressed as a percentage of the amount of disaggregation produced by the AGE 
concentration compared to the PBS control (62 ± 4.5) *Statistically significant (P<0.05) 
compared to the control. 
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Figure 4.13. The disaggregatory effect of AGE at various final percentage concentrations 
(%) on platelet aggregation initiated by collagen in vitro. Values are means ± SEM, 11=6. 
Values are expressed as a percentage of the amount of disaggregation produced by tile AGE 
concentration compared to the PBS control (86 ± 5.3) *Statistically significance (1)<0.05) 
was observed for the AGE concentrations (3.12-25 %, v/v) compared to the control this is 
indicated on the graph by a red line. 
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Figure 4.14. The disaggregatory effect of AGE at various final percentage concent rations 
(%) oil platelet aggregation initiated by thrombin in vilro. Values are rneans ± SIN, n=6. 
Values are expressed as a percentage of tile amount of disaggregation produced by tile AGE 
concentration compared to the PBS control (84 ± 4.3) *Statistically significant (1'<0.05), 
* *(P<0.0 I) compared to the control. 
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4.2.4. Z Simple adhesion assayfor the measurement o the effect ofAGE onfibrinogen )f 
binding during agonist-inducedplatelet aggregation 
From the experiments reported in section 4.2.4.1 it is known that AGE when added to 
ADP pre-aggregated platelets results in disaggregation (the aggregation process is 
reversed, platelet aggregates are dispersed into single platelets). The mode of action of 
AGE may be to reduce the ability of platelets to bind to fibrinogen. To investigate this 
further a simple adhesion assay was developed to monitor this process. In brief, 
microtitre plates containing fibrinogen were incubated overnight at 40C and excess 
fibrinogen was removed. Aliquots of platelet suspensions labelled with either Rose 
Bengal or chromium-51 were added to the immobilised fibrinogen and platelet 
activation was initiated with ADP (8 ýLmol/L) at 370C and the reaction was allowed to 
run for 5 min. The plates are then washed to remove any unbound platelets and the 
platelets which had bound to fibrinogen were lysed to release the Rose Bengal or 
chromium-5 1, the optical density or radioactive counts were compared to a series of 
control samples to determine the amount of platelet adhesion. 
Optical density or radioactivity counts represent the amount of platelets bound to the 
immobilised fibrinogen matrix through the release of Rose Bengal and chromium-5 1, 
respectively from the platelet cytosol. Figures 4.15 and 4.16 show that AGE does 
reduce the amount of adherent platelets to immobilised fibrinogen. A significant 
(P<0.05) reduction in fibrinogen binding was noted in the Rose Bengal treated platelets 
for the AGE concentrations: 3.12-12.5 % (v/v) when compared to the control. Platelets 
treated with chromium-51 also showed significant (P<0.05) reduction in platelet 
adhesion when pretreated with the AGE concentrations: 1.56,6.25-25 % (v/v). 
4.2.4.3. The direct effect ofAGE on thefibrinogen molecule 
In order to investigate whether AGE was having an effect at the fibrinogen receptor, the 
direct effect of AGE on the fibrinogen molecule was measured using the following 
experimental protocol: 
A 96-well microtitre, plate was coated with fibrinogen (3 g/L) and left overnight at 4'C. 
Various concentrations of AGE (0.78-25 % v/v) were added to the wells and left for 30 
min at 37'C. The wells were then washed with 3x (200 pL) with PBS. PRP was added 
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to the wells and aggregation was initiated via the addition of ADP (8 pmoUL). This was 
followed by Rose Bengal for a further 30 min. The non-adherent platelets were removed 
via aspiration and the wells were washed with PBS. Finally, lysis buffer was added to 
the wells and the optical density at 540 nm was measured spectrophotometrically. 
Fibrinogen (3 g/L) when pre-incubated with AGE (0.78-25 %, v/v) resulted in 
significant inhibition of platelet adhesion to platelets that had been activated with the 
agonist ADP (Figure 4.17). No trend was seen between any of the AGE concentrations 
used (no dose-dependency). Although an inhibitory effect is apparent from the results, 
the method is not sensitive enough to draw a valid conclusion from. Hence, more 
investigation is required in the form of flow cytometric analysis to determine if AGE is 
having a definite effect upon fibrinogen binding and the formation of platelet 
aggregates. 
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Figure 4.15. The effect of AGE at various concentrations on the ability ol'ADII-activatcd 
platelets labelled with Rose Bengal to bind to immobilised fibrinogen. PRI) was incubated 
with various AGE concentrations (0.78-25 %, v/v) for 10 min at 37"C. AGF treated platelets 
were allowed to adhere to immobilised fibrinogen (3 g/l, ) via activation with ADP (8 
i. trnol/L). Rose Bengal was added to tile platelets and its release was measured 
spectrophotometricallY at 540 rim as an indication of platelet adhesion. Values are expressed 
as means ± SEM, n=6. *Statistically significant (P<0.05) when compared to tile PBS 
control. 
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Figure 4.16. The effect of AGE at various concentrations on the ability ol'ADII-activated 
platelets labelled with chrornium-51 to bind to immobilised fibrinogen. PRP was incubated 
with various AGE concentrations (0.78-25 %, v/v) for 10 min at 37T. AGE treated platelets 
were allowed to adhere to immobilised fibrinogen (3 g/L) via activation with ADP (8 
pmol/L). Chromiurn-51 was added to the platelets and its release was measured via liquid 
scintillation as an indication of platelet adhesion. Values are expressed as nleans ± SIM, 
n=6. *Statistically significant (P<0.05) when compared to tile PBS control. 
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Figure 4.17. The direct effect of AGE on fibrinogen. Fibrinogen (3 g/[, ) was incubated 
w ith AGE (0.78-25 %, v/v) for 10 min at 37T. PRP was added to the AGE-coated 
fibrinogen and aggregation was initiated with ADP (8 ltmol/L). Rose Bengal was added to 
the adherent platelet, lysed and measured spectrophotometrically at 540 nin. Values are 
means ± SEM, n=6. All the AGE concentrations significantly (13<0.05) reduced platelet 
adhesion compared to the control. 
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These experiments were conducted on the basis that PGEI when added to pre- 
aggregated platelets resulted in disaggregation (Kikura et al. 2000). From the 
aggregation studies in chapter 3, it was found that PGEI inhibited platelet aggregation 
induced by the agonist ADP. Therefore it was decided to monitor the effects of PGE, 
using its ICSO value (31.25 pg/mL) as determined in chapter 3. This was achieved by 
using the simple adhesion assay. A range of fibrinogen concentrations (0.003-3 g/L) 
were tested in order to determine if PGEI is effective in reducing fibrinogen binding in a 
similar manner to AGE. Aggregation was initiated with the agonist ADP. 
Figure 4.18 shows that platelets pre-incubated with PGEI when added to immobilised 
fibrinogen resulted in significant (P<0.05) reduction in platelet adhesion for all the 
fibrinogen concentrations when compared to the respective controls. There was no 
difference in the actions of PGEI for each of the fibrinogen concentrations examined. 
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4.2.3.4. Flow cytometric analysis ofthe effect ofAGE onfibrinogen binding to the 
GPIM-Iffa receptor 
Flow cytometric analysis was used to monitor the effect of AGE on fibrinogen binding 
following platelet activation/ aggregation with the agonist ADP. For a detailed 
description of the method refer to Chapter 2, Section 2.5.4., page 44. 
In brief, whole human citrated blood was diluted with HEPES-Tyrode's buffer. AGE, 
CD42a-PerCP conjugate, PAC-I-FITC conjugate and HEPES was incubated for 10 min 
at room temperature. The reaction mixture was incubated for a further IS min following 
ADP addition. The platelets were then fixed with a 1.5 % formaldehyde solution and the 
samples were further diluted with HEPES prior to analysis using the flow cytometer. 
The principle behind this particular method is that the monoclonal antibody PAC-1 
detects a receptor-induced binding site on fibrinogen bound to the GPIlb/IIIa receptor 
complex on the platelet surface induced by agonist stimulation. As PAC- I is a 
fibrinogen mimetic, inhibition of PAC- I binding is indicative of a reduction in 
fibrinogen binding and aggregate formation in vitro. The antibody CD42a was used as 
an human platelet marker within the whole blood sample. No difference was noted in 
the binding capabilities of CD42a in both resting and activated platelets, AGE at a final 
concentration of 25 % (v/v) was found not to affect the binding capabilities of CD42a 
either (data not shown). 
Figure 4.19 shows that platelets pretreated with AGE, significantly inhibited the amount 
of PAC-1 binding compared to theADP activated control by approximately 50 %. This 
result indicates that AGE is definitely having an effect on fibrinogen binding in vitro. 
As mentioned previously AGE causes disaggregation of agonist-induced platelet 
aggregation (Figure 4.124.14), this was further examined using flow cytometry. It was 
found that when platelets had been pre-aggregated with ADP and AGE added to the 
aggregating platelets; AGE caused disaggregation by reducing the amount of bound 
PAC-1 by 40 % when compared to the control sample as shown in Figure 4.17. This 
study supports the findings from the disaggregation and fibrinogen adhesion assay 
experiments, that AGE inhibits platelet aggregation by affecting the binding properties 
of fibrinogen to its receptor GPIIb/IIIa. 
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4.3. IMAGING STUDIES TO MONITOR THE EFFECT OF AGE ON 
CALCIUM MOBILISATION AND FIBRINOGEN BINDING 
Fluorescence microscopy and SEM were used to capture images of the effects of AGE 
on both calcium mobilisation and fibrinogen binding during ADP-induced platelet 
aggregation. In this preliminary study it was found that AGE may inhibit platelet 
aggregation by suppressing the mobilisation of calcium during agonist stimulation. 
Using fluorescence microscopy the aim was to show that in the presence of AGE the 
intensity of the fluorescence signal emitted by Fura-2 is less than that of the control 
platelets. The images presented in figures 4.20A and 4.2013 show that there is a decrease 
(see Figure 4.2013) in the intensity of fluorescence in platelets treated with AGE and 
activated with ADP when compared to ADP-activated platelets (Figure 4.20A). The 
figures show that there is more aggregate formation on the control slide compared to 
platelets pretreated with AGE. This result further support evidence presented in this 
study that AGE may exert its inhibitory effect through suppression of calcium 
mobilisation. 
In this study AGE also appeared to affect the binding capabilities of the fibrinogen 
receptor GPIIb-IIIa. Using SEM, the aim of this particular experiment was to show that 
platelet aggregate formation is inhibited in the presence of AGE. Figures 4.2 1 A-C show 
the images obtained from the SEM, figure 4.2 1A is an image of platelets in a 
resting/inactivated state and, they are discoid in shape. Figure 4.2 1 B, represents 
platelets that have been activated with the agonist ADP. Figure 4.21 C depicts platelets 
that have been pre-treated with AGE and activated with ADP. It is not very clear from 
the images as the microscope was not capable of examining platelets in great detail, but, 
the captured images suggest that AGE is having an effect on platelet aggregation, in that 
AGE treated platelets displayed less aggregate formation when compared to untreated 
platelets (control). 
It is also apparent from the experiment that AGE allows shape change to occur (platelets 
go from a resting discoid shape to the formation of pseudopia) however, aggregation is 
not as prominent. This reinforces the previous work (fibrinogen binding study) 
suggesting that AGE is having a possible inhibitory effect on fibrinogen binding to its 
receptor and the subsequent formation of a stable platelet aggregate. 
132 
However, it should be noted this investigation was a preliminary one and further work 
needs to be conducted to ensure that the observed results are a true indication of calcium 
mobilisation suppression and a reduction in fibrinogen binding, respectively. For the 
purpose of this study the images do suggest that calcium mobilisation and fibrinogen 
binding is being reduced in the presence of AGE when compared to their respective 
controls. 
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Figure 4.20. Fluorescence rmcroscopy imaging of tile eftect ofAGE oil calcium mobilisation 
using the calcium indicator dye Fura-2/AM. The effect of AGE oil calcium inobilisation was 
monitored using fluorescence spectrophotometry. Platelets were loaded with tile calcium 
indicator dye Fura-2/AM and were activated with ADP. rhe activated platelets were allowed to 
adhere to POIY-L-lysine coated coverslips. Key: A- ADP activated platelets in tile absence of 
AGE (control); B- ADP activated platelets in the presence of AGE. White arrows indicate 
platelet aggregate formation. 
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Figure 4.21. SEM imaging of the effect of AGE on the ability of platelets to form 
aggregates when challenged with the agonist ADP. Key: A- platelets at rest/unactivated; B 
- ADP-induced platelet aggregation; C- AGE treated platelets, aggregation initiated with 
ADP. 
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4.4. PROTEOLYTIC ACTIVITY OF AGE 
It is known that incubation of PRP with AGE results in the inhibition of agonist-induced 
platelet aggregation in vitro. One possible explanation for the observed inhibition is that 
AGE may potentially act in a proteolytic manner thus, preventing platelet activation and 
aggregation from occurring by degrading the proteins (e. g. receptors) needed for the 
biochemical signalling pathways involved in the aggregatory process. Another 
possibility is that AGE may directly interact with receptors located on the surface of the 
platelet (i. e. GPIIb/IlIa fibrinogen receptor) and prevent normal function through 
proteolysis. To investigate this, the proteolytic activity of AGE was measured using two 
independent methods: azocasein spectrophotometric assay and SDS-PAGE analysis. 
The aim of this investigation is not to characterise the individual proteases that may be 
present in AGE but to determine if AGE displays proteolytic activity. 
4.4.1. Proteolytic activity of AGE using the Azocasein spectrophotometric assay 
The proteolytic activity of AGE was determined by using the azocasein assay, which 
monitors proteolytic activity by comparing the effects of potential protease(s) contained 
within AGE to the actions of chymotrypsin and its substrate casein. The assay works 
colourimetrically by measuring the release of casein from the azo group to which it is 
attached. For a detailed method of the assay see Chapter 2 (Materials and Methods, page 
47). 
AGE (3.12-100 %, v/v) was incubated for 30 min at 370 with the substrate azocasein. 
Following the incubation period, the AGE samples underwent TCA precipitation and 
the optical densities (in duplicate) were measured at 450 mn. The proteolytic activity of 
AGE was determined from a chymotrypsin standard curve. Proteolytic activity is 
evident for the AGE concentrations between 50- 100 % (v/v) and was 32 and 118 
pg/mL, respectively (Figure 4.22). Values were obtained from a chymotrypsin standard 
curve (Appendix III). There was no proteolytic activity observed for the remaining AGE 
concentrations tested (3.12-25 %, v/v). These results suggest that AGE possesses 
protease-like activity. 
Chymotrypsin is specific for the substrate casein, and although proteolytic activity is 
evident in the AGE samples, 50 and 100 % (v/v), the results are not a true indication of 
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Figure 4.21. SEM imaging of the effect of AGE on the ability of platelets to form 
aggregates when challenged with the agonist ADP. Key: A- platelets at rest/unactivated; 13 
- ADP-induced platelet aggregation; C- AGE treated platelets, aggregation initiated with 
ADP. 
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the total protease content within AGE. There are many other proteases that may be 
present and this particular assay is not specific for a range of proteases, therefore, SDS- 
PAGE analysis was utilised to observe total proteolytic activity. 
4.4.1.1. Determination ofthe protein content within A GE using the Bradford assay 
Due to the dark intense colouring of AGE, protein concentration was only determined 
for the AGE concentration 3.12 % (v/v) and was found to be 0.002 mg/mL, when 
determined from the BSA standard curve (Appendix IV). Therefore, it is apparent that 
there are proteins present however the total protein content cannot be determined from 
this particular assay. 
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4.4.2. Visualisation of the proteolytic activity of AGE using SDS-PAGE 
4.4.2.1 Sample preparation 
BSA (I mg/mL) was added to AGE (100 % v/v) and incubated at 37'C, aliquots were 
taken at the following time points: 0,0.5,1.0,5.0 and 10 min, and added to an equal 
volume of reducing sample buffer (10 mL glycerol, 0.5 mL 2-mercaptoethanol, 1.0 g 
SDS, 4.0 mL of 1.0 M Tris-HCL pH 6.8,0.1 % Bromophenol blue, made up with 
distilled water), and boiled for 5 min. The samples were prepared as above, this time 50 
pL of protease inhibitor cocktail set III was added to the AGE and BSA to see if any 
inhibition had taken place in the presence of AGE. 
4.4.2.2. SDS-PA GE analysis 
Proteolytic activity was visualised on a both a 12.5 and 15 % resolving gel (Table 4.3) 
with a5% stacking gel (Table 4.4) using a Sigma mini SDS-PAGE gel system. Protein 
bands were visualised by staining overnight at room temperature with Colodial 
coomassie blue stain and de-stained in water overnight at room temperature. 
The purpose of this experiment was to observe the effect any proteases that may be 
present in AGE and the way they interact with the protein BSA. Figure 23A shows that 
when AGE is incubated with BSA there are many bands present on the gel. Unlike the 
results obtained from the azocasein assay (refer to section 4.4.1) no proteolytic activity 
is evident from this SDS-PAGE examination. The addition of a protease inhibitor 
cocktail set to both the AGE and BSA mixture (Figure 23B) showed no apparent 
degradation products indicative that proteolysis had occurred. There was no difference 
in protein band formation observed for any of the time points tested. Therefore, these 
result indicates no that proteolysis has occurred when BSA samples were incubated 
with AGE. 
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Table 4.3. Resolving Gel 
12.5 % (mL) 15 % (mL) 
30 % Acrylamide 6.25 7.5 
I% Bis-acrylamide 1.56 1.3 
1.5 M Tris-HCL pH 8.8 3.75 3.75 
20 % SDS 0.15 0.15 
Water 3.19 2.2 
10 % APS 0.1 0.1 
TEMED 0.01 0.01 
Table 4.4. Stacking Gel 
5% (mL) 
30 % Acrylamide 2.5 
CI% Bis-acrylamide 3.9 
1.0 M Tris-HCL pH 6.8 3.75 
20 % SDS 0.15 
Water 4.0 
10 % APS 0.1 
TEMED 0.02 
0.1 % Bromophenol blue 0.6 
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Figure 4.23. The assessment of the proteolytic activity in AGE using SDS-PAGE analysis. 
A- the proteolytic activity of AGE, using the protein BSA 
B- inclusion of protease inhibitor cocktail set III 
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4.5 DISCUSSION 
For normal platelet aggregation to occur it requires the coordinated effects of many 
biochemical signalling pathways. AGE can inhibit platelet aggregation induced by a 
variety of agonists and AGE is comparable to known inhibitors of platelet aggregation 
with well established inhibitory mechanisms (Chapter 3). Hence, it is a possibility that 
AGE may exert its inhibitory effect at certain points within the signalling pathway that 
are common to all forms of agonist stimulation i. e. protein tyrosine kinase 
phosphorylation, calcium mobilisation, an increase in cAMP, fibrinogen binding etc. 
Following this it was decided to look at the following processes involved in platelet 
activation and aggregation: calcium mobilisation; AA metabolism; fibrinogen binding; 
cAMP turnover and PTK activity. All these signalling events occur downstream of 
receptor stimulation and are common to all agonists, i. e. they can be regarded as final 
common pathways that precede platelet aggregation. 
The first pathway that was looked at was calcium mobilisation and the effects of AGE 
on this process was investigated using two approaches: platelet aggregation and 
fluorescence spectrophotometry. Calcium mobilisation was chosen because earlier 
studies have looked at the inhibitory effects of garlic constituents and other natural 
compounds on platelet aggregation (Apitz-Castro et al. 1983; Moon et al. 2000; Park et 
al. 2004; Qi et al. 2000; Rendu et al. 1986; Rendu et al. 1992; Sheu et al. 2003). It was 
found in this study, that AGE significantly suppressed calcium mobilisation induced by 
the agonists ADP and A23187. However, significant variation was noted between 
individuals in their response to individual agonists and this was reflected in the results 
obtained (Figure 4.6 - 4.7). Thus, the data presented here suggests that AGE may 
inhibit platelet aggregation by suppressing the mobilisation of calcium ions within 
platelets. As mentioned previously, Dillon et al. (2003) found that AGE has metal 
chelating properties therefore AGE may act as a chelator of calcium ions during the 
aggregation process. Another possibility for the observed inhibitory effect is that AGE 
may alter intracellular signalling events that precede calcium mobilisation, i. e. increase 
in cAMP activity, fibrinogen receptor expression and binding (Rosado et al. 2001) and 
possibly PTK activity. Stafford et al. (2001) reported that aggregation initiated with the 
calcium ionophore A23187 results in aggregation due to the synergism between the 
PKC and Ca2' signalling pathways in platelets. However, as reported in chapter 3 no 
inhibition of platelet aggregation was observed with the inhibitor bisindolymalemide 
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(PKC inhibitor for all isoforms) on ADP-induced platelet aggregation. In contrast, in the 
aggregation studies it was found that AGE does inhibit platelet aggregation initiated 
with the ionophore A23187; this validates the suggestion that AGE is having an 
inhibitory effect via calcium signalling within the platelet. 
This study, although a preliminary one suggests that AGE has an inhibitory effect upon 
platelet aggregation via the suppression of calcium mobilisation. This occurrence was 
fin-ther validated through more experimentation which showed that calcium ion 
concentration was significantly inhibited in the presence of AGE (Figure 4.8). Also a 
reduction in the fluorescence intensity of the calcium ionophore Fura-2/AM in the 
presence of AGE was exhibited using fluorescence microscopy (Figure 4.20). 
The next pathway that was looked at was AA metabolism. Agonists on binding to their 
membrane receptors cause the hydrolysation of AA from phospholipids to form TXA2 
via COX and TXA2 synthase. TXA2 in turn promotes recruitment and further activation 
of platelets. A literature search conducted showed that most scientists researching 
natural compounds including garlic found that AA metabolism is an important pathway 
with regards to platelet aggregation. The underlying mechanism proposed for inhibition 
of platelet aggregation via the AA metabolic pathway is that it halts the activity of COX 
(Ali 1995; Ali et al. 2000; Apitz-Castro et al. 1983; Bordia et al. 1978; Chan et al. 
2002; An et al. 2005; Kleijnen et al. 1989; Koo et al. 2001; Macdonald and Langer 
2000; Makheja et al. 1980; Moon et al. 2000; Qi et al. 2000; Shah et al. 1999; Sheu et 
al. 2003; Son et al. 2004; Srivastava 1984; Srivastava 1986; Srivastava and Tiwari 
1980; Srivastava and Tyagi 1993; Stampfer el al. 1987; Vanderhoek et al. 1980). 
In this study AA metabolism was first monitored using the method outlined by Jin et aL 
(2002). In their study platelets were loaded with [3 H]-AA, washed and stimulated with 
an agonist. Platelet aggregation was stopped via a stopping solution, centrifuged and the 
supernatant monitored for radioactivity. It was found initially that AGE had a 
'quenching' effect upon the radiolabel 14 C-AA during scintillation counting. This 
resulted in this method being discarded for the more classical approach of TLC. 
Numerous problems were encountered when trying to measure the effects of AGE on 
AA metabolism and these included the loss of radiolabel during washing steps and 
extraction with ether. 
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It was often difficult to identify radiolabelled metabolites from AA metabolism via 
liquid scintillation counting from the process of TLC. A possible explanation for this 
occurrence is that AA is a platelet agonist; addition of AA could inadvertently activate 
platelets. Thus, addition of ADP to the platelet suspensions resulted in the amplification 
of the initial platelet response to AA (platelets may have already gone through the 
aggregation process). It was found that AGE did not have a significant effect upon AA 
metabolism during platelet activation initiated with ADP. These results were compared 
to the agonist thrombin and again no inhibitory effect was found. These results suggest 
that ADP-induced platelet aggregation can occur independently of AA metabolism. The 
aggregation studies reported in chapter 3 using the classical inhibitors: aspirin and 
indomethacin also showed that no inhibition occurred during ADP-induced platelet 
aggregation. Both of these inhibitors inhibit AA metabolism by suppressing the actions 
of COX. Thus, a TXA2 independent pathway must contribute to platelet aggregation 
induced by ADP. It is possible that AGE may have an inhibitory effect upon AA 
metabolism as other studies have shown that other garlic preparations and its 
constituents and other natural compounds do inhibit this pathway. However, 
contradictory results have been obtained in this study for ADP-induced platelet 
aggregation. Mangin et aL (2004) showed that the ADP receptor is important in platelet 
activation during collagen-induced platelet aggregation when TXA2 formation is 
prevented. Thus, platelet aggregation can still occur even when a major signalling 
pathway has been suppressed. 
It is well known that PGEI is an inhibitor of platelet aggregation and is used clinically 
in the treatment of atherosclerosis (Fisch et al. 1995; Katzenschlager et al. 1992; 
Kinlough-Rathbone et al. 1970; Kikura et al. 2000; Koga et al. 2002). It has also been 
found that when PGEI is added to aggregated platelets that the process is reversed 
(Kikura et al. 2000) and the platelets disaggregate. AGE was tested to see if like PGEJ it 
could cause the disaggregation of ADP activated platelets. The reasoning behind this 
experiment is that platelet activity is regulated in part by cyclic adenosine 
monophosphate (cAMP), and an increase in this substance reduces platelet activity by 
inhibiting various morphological and chemical changes within the cell (Kikura et al. 
2000; Kinlough-Rathbone et al. 1970). In the body PGEI working synergistically with 
the endothelial cells stimulates AC to produce more cAMP. Thus, is AGE working in a 
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similar manner to that of PGEI, in that does AGE result in an increase in cAMP levels 
which results in inhibition of platelet aggregation? 
The effect of AGE on platelet adhesiveness to immobilised fibrinogen was investigated. 
GPIlb/Illa plays a major role in the regulation of platelet aggregation during 
haemostasis. Upon activation by an agonist such as ADP a signalling process is initiated 
known as "inside-ouf' signalling, which causes a conformational change within the 
receptor and this increases the affinity of GPIla/Illb for its ligand fibrinogen. Upon 
fibrinogen binding the receptor undergoes ftirther shape changes and through another 
process termed "outside-in" signalling GPlla/IIlb results in the amplification of platelet 
aggregation (Fullard 2004; Naimushin and Mazurov 2003; Peerschke and Zucker 1981; 
Shattil el aL 1998). 
Maayani et aL, (2001) reported that disaggregation of ADP-induced platelet aggregation 
is associated with the dissociation of fibrinogen from its receptor on the platelet surface. 
It has also been found that the organosulphur compound ajoene, a constituent of garlic 
inhibits fibrinogen binding and subsequently platelet adhesion (Tapiero et al. 2004). 
The suggested mechanism for this antagonism is a sulfhydryl group-mediated effect as 
the GPIIb-IIIa receptor has a high content of -SH groups. This is due to organosulphur 
compounds being readily cleared in vivo, separating into -SH compounds as reported by 
Steiner and Lin (1998). Hence, this occurrence could possibly explain the reduction in 
platelet adhesion to fibrinogen. It was found in this study that AGE did reduce the 
amount of platelets bound to immobilised fibrinogen compared to that of the controls 
(Figures 4.14-4.16). It has been reported by Tapiero et al. (2004) that un-stimulated 
platelets express the GPIIb-IIIa complex at their surface, and that this complex is unable 
to bind fibrinogen until the platelets have been activated. Activation causes a change 
within the receptor that allows for fibrinogen to be bound and cross-linked with other 
platelets resulting in the formation of an aggregate (Shattil et al. 1998). This is why the 
platelets in this study were activated with ADP in the presence of fibrinogen. Bovine 
fibrinogen was used instead of human fibrinogen because they both contain the same 
RGD sequences, therefore human platelets when activated are able to adhere to Bovine 
fibrinogen and form aggregates with other platelets. 
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The principle behind this study was that Rose Bengal, a biological stain and chromium- 
51 are taken up by platelets that are bound to the fibrinogen matrix upon the well 
surface. Upon lysis of the platelets the Rose Bengal and chromium-51 are released and 
the absorbance is measured spectrophotometrically and radioactivity via liquid 
scintillation counting, respectively. Ile amount of absorbance/radioactivity from the 
platelets treated with AGE is compared to that of the controls. A reduction in the optical 
density and radioactive count readings indicates that there is a reduction in the amount 
of platelets that are bound to the matrix and thus AGE has prevented adhesion and 
subsequent formation of a platelet aggregate. Although the method is a simple one it 
shows that AGE does have an effect upon platelet adhesion and the formation of 
aggregates. 
The direct effect of AGE upon fibrinogen was also examined and it was found that AGE 
at all the concentrations used significantly inhibited platelet adhesion when activated 
with ADP. Therefore, AGE affects the binding properties of fibrinogen in its ability to 
form a platelet aggregate. To investigate this finther flow cytometry was used to 
monitor the effect of AGE on fibrinogen binding using the antibody PAC-1 which is 
specific for the receptor GPIlb/IlIa when it undergoes its conformational change and 
binds fibrinogen through agonist stimulation. Platelets activated with ADP have a 
higher incidence of PAC- I binding compared to those that are inactivated (Figure 4.18). 
In the presence of AGE the binding of PAC-1 to the activated form of GPlIb/Illa is 
significantly reduced when compared to those that had been activated with ADP. Thus, 
AGE is having an inhibitory effect on platelet aggregation via fibrinogen binding. 
As mentioned previously it was assumed that AGE may be acting in a similar manner to 
PGEI, as PGEI when added to pre-aggregated platelets results in disaggregation. It is 
known that the main inhibitory mechanism of PGEI is through an increase in the levels 
of cAMP within the platelet which in turn inhibits the release of calcium ions from 
intracellular stores and increases calcium ion sequestration back into the dense tubular 
system. Also, the affinity of the fibrinogen receptor can be prevented or reversed by 
compounds such as PGEI and PG12 that stimulate an increase in cAMP. Thus the effect 
of AGE on intracellular cAMP levels was examined. The results obtained show that 
AGE when added to platelets caused a significant increase (P<0.01) in the intmcellular 
levels of cAMP in both basal and activated platelets. Figure 4.9A shows that basal 
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levels are high in the AGE treated samples and as expected in the PGEI treated groups 
also. The increased levels of cAMP are still observed upon agonist stimulation (Figure 
4.913) indicating that inhibition of platelet aggregation may be in part due to an increase 
in cAMP; leading to a reduction in intracellular calcium concentration and the 
prevention of fibrinogen binding to its receptor. A simple aggregation study was carried 
out to ensure that the actions of AGE were directly upon cAMP and not cAMP- 
dependent PDEs. IBMX, a PDE inhibitor when added to AGE resulted in a significant 
increase in the inhibition of platelet aggregation compared to AGE alone 
Activators of cAMP can decrease the levels of calcium within the aggregating platelet, 
and calcium in known to be important in many intracellular signalling processes, such 
as the fibrinogen receptor undergoing its conformational change. Therefore it is possible 
that the preincubation of platelets with AGE results in inhibition brought about by an 
increase in cAMP, which in turn reduces calcium levels, ultimately leading to the 
fibrinogen receptor not being able to undergo its conformational change. It was reported 
in a study conducted by Samal and Loiko (2000), that N-ethylmaleimide caused the 
disaggregation of both ADP- and thrombin-induced aggregated platelets. In their study 
they found that the disaggregation observed, was the result of a system that removed 
calcium from activated platelets in the cytosol. Both preliminary and secondary studies 
have shown that platelet incubation with AGE leads to a suppression in calcium 
mobilisation upon the initiation of platelet aggregation via the agonist ADP. This result 
further supports the findings presented here suggesting that AGE inhibits ADP-induced 
platelet aggregation via cAMP pathway. Many other researchers looking at different 
dietary extracts such as ginger, gingko biloba etc. have also found that platelet 
aggregation in inhibited via an increase in the intraplatelet levels of cAMP (de Lange et 
al. 2003; Duttaroy et al. 2004; Innes et aL 2003; Moon et al. 2000; Osmont et al. 2003; 
Shah et al. 1999). 
Proteolytic activity experiments utilising the azocasein assay and SDS-PAGE analysis 
were conducted with AGE. The main purpose of this investigation was to examine 
another potential mechanism by which AGE may exert its inhibitory effect with regards 
to platelet aggregation. It may be possible that direct contact of the platelet with AGE 
may directly act on a specific receptor important in platelet aggregation. The potential 
proteolytic activity of AGE could be via the cleavage of receptor proteins, e. g. at the 
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fibrinogen receptor GPIIb/IIIa to prevent fibrinogen binding and subsequent platelet 
aggregate formation. The experiments show that AGE does exhibit signs of proteolysis 
through its interactions with the protein casein (azocasein assay, Figure 4.22) but not via 
incubation with BSA (SDS-PAGE analysis, Figure 4.23). 
In conclusion this study has shown through in vitro testing that AGE inhibits fibrinogen 
binding via the receptor GPlIb/IIla, suppresses the mobilisation of calcium within the 
platelet, increases the intraplatelet levels of cAMP and it also displays proteolytic 
properties through its interactions with casein. 
AGE has exhibited a wide range of potential inhibitory mechanisms with regards to 
platelet aggregation (Figure 4.24). This may be due to the complex make-up of the AGE 
preparation, in that the components contained within it act synergistically on different 
signalling pathways involved in the activation and aggregation process to bring about 
the observed inhibitory effect on ADP-induced platelet aggregation. This needs to be 
investigated further in a clinical trial. 
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4.6. SUMMARY OF RESULTS 
Platelet aggregation initiated with the agonists ADP and A23187. This was 
noted through fluorescence spectrophotometry and fluorescence microscoPy. 
AGE had no effect upon AA-uptake and metabolism during ADP-induced 
platelet aggregation. 
AGE inhibited fibrinogen binding to its receptor GPIIb/IlIa during platelet 
aggregation induced with ADP. This was validated with the use of four 
independent methods: disaggregation, a simple adhesion assay, flow cytometry 
and SEM imaging. 
e AGE significantly increased intraplatelet levels of cAMP when compared to the 
inhibitor PGEI. 
9 AGE potentially showed signs of proteolytic activity as determined by the 
azocasein assaY. 
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5. DIETARY SUPPLEMENTATION WITH AGE AND ITS EFFECT ON 
AGONIST-INDUCED PLATELET AGGREGATION: AN IN WO 
STUDY 
5.1. INTRODUCTION 
Garlic, especially the dietary supplement AGE has been shown to inhibit agonist- 
induced platelet aggregation both in vitro and in vivo by numerous scientific studies 
over the past 30 years (Table 1.2, Chapter 1, page 16-17). In vivo studies using AGE 
have found that ingestion of AGE over a set time period results in a significant marked 
decrease in the ability of human platelets to aggregate in response to various agonists 
(Rahman and Billington 2000; Steiner and Lin 1998; Steiner et al., 1996; Steiner and 
Lin 1994; Steiner and Li 2001). The present study has also shown that AGE inhibits 
platelet aggregation in vitro when platelets are stimulated with a variety of aggregating 
agents (Chapter 3, section 3.2.1, page 55). The findings from these aggregation assays 
(Chapter 3) suggested that the observed inhibition was the result of AGE acting on 
signal transduction pathways common to all forms of agonist stimulation. 
In chapter 4, the effect of AGE on the following biochemical pathways were reported: - 
" Calcium mobilisation (Chapter 4, section 4.2.1, page 98) 
" AA metabolism (Chapter 4, section 4.4.2, page 107) 
" Intracellular cAMP levels (Chapter 4, section 4.4.3, page 114) 
" Fibrinogen binding - the formation of a stable platelet aggregate (Chapter 4, 
section 4.4.4, page 118) 
The only pathways that AGE had an observed inhibitory effect upon ADP-induced 
platelet aggregation was on the following: 
o calcium moblisation - platelets pretreated with AGE had significantly 
lower levels of calcium ions compared to the controls (untreated 
platelets) when measured with a fluorimeter. 
9 Intracellular cAMP - incubation of platelets with AGE resulted in an 
increase in the levels of cAMP following agonist stimulation. 
e Fibrinogen binding - AGE reduced the fonnation of stable platelet 
aggregates. 
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All the above experiments were conducted in vitro and were the result of AGE being 
directly incubated with platelets contained in PRP (platelet-rich plasma). Hence, the 
question arises would AGE have the same effect in an in vivo situation?, as there are 
many other biological and chemical processes, which occur in the body that may effect 
the inhibitory actions of AGE upon platelet function. 
This present study is novel and differs greatly from preceeding clinical trials conducted 
on AGE (Rahman and Billington 2000; Steiner and Lin 1998; Steiner et al., 1996; 
Steiner and Lin 1994; Steiner and Li 2001) in that the major aim here is to establish at 
which point(s) in the signal transduction pathways does AGE exerts its inhibitory effect 
to reduce agonist-induced platelet aggregation. To investigate this further and to 
ascertain whether AGE does have a definite inhibitory effect upon these pathways 
(intracellular cAMP and fibrinogen binding) a clinical trial was conducted. 
5.2. OVERVIEW OF STUDY 
In this study the effect of AGE on platelet aggregation both ex vivo and in vivo was 
investigated this was done by the following: 
* Whole human blood was directly incubated with AGE. Platelets were removed 
via centrifugation, and platelet aggregation was initiated with the aggregating 
agent ADP ex vivo. 
As mentioned in previously (Chapter 3) AGE was directly incubated with platelets 
contained in platelet-rich plasma. This direct incubation resulted in the significant 
inhibition of platelet aggregation initiated by a variety of agonists. The purpose of this 
particular study is to investigate whether incubation of whole blood with AGE will 
result in inhibition of Platelet aggregation ex vivo. 
* Clinical trial - dietary supplementation with AGE over a set time period. 
For the clinical trial volunteers who matched the selection criteria were chosen from the 
university population and blood samples were taken at Day 0. The volunteers were 
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asked to ingest 5 mU day of AGE (equivalent to 1200 mg of the powder form of AGE 
and, is the recommend daily amount that has been reported not to cause any serious 
side-effects and has also been deemed safe following toxicological studies carried out 
by Wakunaga of America - www. kyolic. com) everyday for 14 days. After AGE 
consumption (Day 14), blood samples were taken, and again following a washout 
period of 14 days (Day 28). Blood samples were taken at Days 0,14 and 28 and were 
tested for the parameters listed below. During the clinical trial (28 days) subjects were 
asked to continue following their usual diet and lifestyle, including: cigarette smoking, 
alcohol intake and dietary supplementation. 
1. Platelet aggregation initiated with the agonists: ADP, AA, adrenaline and 
collagen (for methods see Chapter 2, section 2.4.1, page 3 1). In vitro studies 
(Chapter 3) showed that AGE inhibited platelet aggregation in a dose-dependent 
manner for the agonists listed above. Another reason for the choice of agonists is 
that in other studies (in vitrol in vivo) examining the effects of garlic upon 
platelet aggregation these have been widely used (Rahman and Billington 2000; 
Steiner and Lin 1998; Steiner et aL, 1996; Steiner and Lin 1994; Steiner and Li 
2001). 
2. GPIlb/IlIa receptor binding using flow cytometry (for detailed methods see 
Chapter 4, section 4.2.3.4, page 129). Fibrinogen binding was chosen because 
during in vitro (Chapter 4) testing AGE significantly reduced the formation of 
stable platelet aggregates when monitored using flow cytometry. In addition, 
sample preparation is relatively easy for this particular assay and it can be done 
in whole blood. 
3. cAMP levels (for methods see Chapter 2, section 2.4.4, page 44) The in vitro 
study showed that AGE significantly increased intraplatelet levels of cAMP. 
4. Total cholesterol (for methods refer to section, page 169) was monitored in this 
trial to see if there was any reduction in levels following AGE treatment. AGE is 
reported to exert hypolipidemic properties (Liu and Yeh, 1999; Yeh and Liu, 
2001). 
The above assays were chosen because they do not require copious amounts of platelets, 
are relatively simple, do not require long incubation periods, and are easy to conduct 
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and to investigate if AGE has any clinical relevance. During in vitro testing (Chapter 4) 
it was found that AGE significantly reduced fibrinogen binding and increased cAMP 
levels, thus it was also decided to monitor these particular assays during the clinical 
trial. 
It is important to note that platelet function can be affected by a variety of parameters 
from medication (i. e. aspirin, NSAIDs, and other anti-platelet drugs), diet, exercise, 
excessive alcohol, gender (females - menstruation), age, dietary supplements and 
smoking. Therefore, for the purpose of this study volunteers were asked to refrain from 
taking any medication that interfered with platelet function for 2 weeks prior to blood 
donation. The only variable that was under investigation was the effect of AGE upon 
platelet aggregation following AGE administration for a set time period. All volunteers 
were apparently healthy with no pre-existing medical conditions that affect platelet 
function and were within the age range 18-65 years, as this is reflective of the ages 
present within the university population. 
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53. RESULTS 
53.1. The ex vivo effect of AGE on platelet aggregation induced with ADP 
AGE inhibits platelet aggregation in vitro when PRP is incubated with AGE for 10 min 
at 37C, and stimulated with a variety of agonists (Chapter 3, section 3.2.1, page 55). In 
whole blood there are many other cells, proteins and chemical substances that could 
possibily interact with AGE and affect its inhibitory actions on platelet aggregation. 
Therefore, it is important to establish that pre-treatment of whole blood with AGE 
results in the inhibition of agonist-induced platelet aggregation using platelet 
aggregometry. 
In this experiment, AGE at various concentrations was incubated directly with whole 
blood for 15 min at 37T. To the control an equal volume of PBS was added to the 
whole blood and treated in the same manner as the AGE samples. The platelet-rich 
plasma was removed by centrifugation from the whole blood and platelet aggregation 
was initiated via the addition of the agonist ADP. Platelet aggregation was monitored 
using platelet aggregometry in a PAP41) Platelet Aggregation Profiler. 
The results (Figure 5.1) are interesting in that they indicate that ADP-induced platelet 
aggregation is dose-dependently reduced when whole blood is directly incubated with 
AGE at all the concentrations tested (12.5-50 %, v/v), compared to the PBS control 
sample. Statistical significance (P<0.05) was noted for AGE concentrations at 25 and 50 
% (v/v). The results follow a pattern in that the higher the AGE concentration the more 
inhibition is observed. 
The results presented in this study show that a much higher dose of AGE is required for 
inhibition of platelet aggregation in whole blood in comparison to the levels monitored 
during in vitro testing (25 %, v/v - maximum dose) in PRP (Chapter 3). It would not be 
practical or feasible to use this kind of dosing regime during a clinical trial, as subjects 
would have to ingest approximately 0.5 litres of AGE/ day. Therefore, for the purpose 
of the clinical trial subjects will be following the dosage recommended by the 
manufacturer of 5mUday as this dose has been shown to be effective in eliciting a 
response in other clinical studies using AGE (Rahman and Billington 2000; Steiner and 
Lin 1998; Steiner et aL, 1996; Steiner and Lin 1994; Steiner and Li 2001). 
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53.2. Clinical trial - dietary supplementation with aged garlic extract 
20 volunteers were recruited randomly from the university population at John Moores 
and were recruited for this clinical dietary supplementation trial. Before the start of the 
trial all participants answered a simple questionnaire (Appendix VII) regarding their 
physical characteristics (i. e. age, average weekly alcohol consumption, number of 
cigarettes smoked per day, prescribed medication intake etc). From the original 20 
volunteers only 17 (85 O/o) completed the clinical trial. The 3 volunteers that withdrew 
from the study complained about the taste of the AGE, claiming that it was too strong to 
ingest without feeling nauseous. Table 5.1, depicts the physical characteristics generated 
from this study. II females and 6 males undertook the study with the mean age of the 
participants being 41 ± 3.25 years. Only 3 people out of the 17 were smokers and 14 
drank on average approximately 6 units of alcohol or more per week during the trial. 3 
of the volunteers had medical conditions that required prescribed medication (the 
illnesses and the prescribed medication were revealed on completion of the trial when 
the questionnaires were returned for examination). 
Data analysis showed that the results generated in this study were not affected by those 
taking prescribed medications for pre-existing medical conditions and, 6 regularly took 
other dietary supplements on a daily basis, these included Cod Liver Oil capsules, 
omega-3 fish oil capsules and multi-vitamins. Individual data generated from this study 
is shown in Appendix VIII all the volunteers who took prescribed medications were 
included in the study to compensate for those that dropped out. The AGE given to all 
the volunteers came from the same batch. The way in which AGE was administered 
varied between the volunteers i. e. AGE was taken with orangejuice/ tomatojuice, neat, 
after evening meal, and the subjects took the AGE in a manner that was easy for them to 
tolerate. 
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Table 5.1. Physical characteristic data of participants in the clinical trial 
Physical Characteristic Number 
Total number of volunteers 17 
N* of females II 
No of males 6 
Mean AGE of volunteers 41 ± 3.2 years 
N' of smokers 3 
N* of volunteers who drank more than 6 14 
units of alcohol/ week 
No of volunteers taking prescribed 3 
medication for an illness that does not 
affect platelet function 
N' of volunteers who take 
other dietary supplements on a daily basis 
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5.3.2.1. The effect ofA GE on agonist-inducedplatelet aggregation in vivo 
Dietary supplementation with AGE significantly (P<0.05) reduced platelet aggregation 
initiated with the agonists: ADP, adrenaline and collagen (Figure 5.2). The results 
indicate that for each of the agonists: ADP (76 %±3.7), adrenaline (59 % 4- 5.6) and 
collagen (77 %: h 3.5) maximal platelet aggregation (>60 %) is observed at Day 0. 
Following AGE administration for 14 days (5 mUday), platelet aggregation is 
significantly reduced upon agonist stimulation with the following aggregating agents: 
ADP (63 %: E 4.7), adrenaline (3 0%±6.9) and collagen (5 8%±7.1). On Day 28, 
following the two week washout-out period, the levels of platelet aggregation observed 
for each of the agonists was comparable to those obtained at Day 0: ADP (79 %+3.6), 
adrenaline (60 % ±6.9) and collagen (76 %±5.1). These results suggest that AGE 
administration of 5 mUday for 14 days reduces platelet aggregation and following a 
suitable washout-period (2 weeks) the amount of aggregation monitored returned to a 
level similar to that seen at the baseline (Day 0) for the aggregating agents ADP, 
adrenaline and collagen. However, the agonist AA failed to initiate maximal 
aggregation in the group studied. There was no significant inhibition of platelet 
aggregation following AGE administration with this particular agonist. Although from 
Figure 5.2 it is apparent that following AGE consumption there is a reduction in platelet 
aggregation initiated with AA it was deemed not significant (P>0.05), as the agonist 
failed to produce maximal aggregation. 
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5.3.2.2. The effect ofAGE on the expression and binding capabilities ofthe 
fibrinogen receptor GPIMIRIa 
The effect of AGE on the expression of the receptor GPIlb/IIIa and its ability to bind to 
its ligand fibrinogen was also determined in this clinical trial. In vitro testing in our 
laboratory has shown that the direct incubation of platelet-rich plasma with AGE 
reduces the ability of this receptor to bind fibrinogen (Figure 4.19, Chapter 4, page 
13 1). Therefore, it was decided to observe if the same effects occur in vivo. The 
principle behind this particular method is that the monoclonal antibody PAC-1 detects a 
receptor-induced binding site on fibrinogen bound to the GPlIb/Illa receptor complex 
on the platelet surface induced by agonist stimulation with ADP. A reduction in PAC- I 
binding is indicative of a reduction in fibrinogen binding and thus aggregate formation. 
The antibody CD42a was used as an identifier of platelets within the whole blood 
sample. No difference was noted in the binding capabilities of CD42a in both resting 
and activated platelets (data not shown). 
The results generated from this study (Figure 5.3) show that AGE has no significant 
inhibitory effect upon fibrinogen receptor expression and binding, in both inactivated 
and activated platelets. Thus, in an in vivo situation AGE does not inhibit platelet 
aggregation via the fibrinogen receptor GPIlb/IIIa.. 
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5.3.2 3. The effect ofA GE on intraplatelet levels of cAMP in vivo 
In vitro testing has shown that the addition of AGE to platelet-rich plasma results in a 
significant increase in the intraplatelet levels of cAMP (Chapter 4, section . In this 
study, the levels of intraplatelet cAMP were monitored before AGE ingestion (Day 0), 
following AGE ingestion (Day 14) and after a washout period of 14 days (Day 28), in 
both inactivated and ADP-activated platelets. Figures 5.4 and 5.5 show the results for 
the individual volunteers (n--17) for both inactivated and ADP-activated platelets, 
respectively. 
Figure 5.5 shows that following AGE administration for 14 days only 4 volunteers 
(GPIA06 - 20 pmol/L; GP2BI8 - 11 pmol/L; GP2AI7 -8 pmol/L and GPIB224.5 
pmol/L) displayed increased levels of intraplatelet cAMP compared with the remaining 
13 participants. At Days 0 and 28 in the inactivated platelet group all 17 volunteers had 
similar levels of cAMP (0 -1.05 pmol/L and 0-3.6 pmol/L, respectively). In the 
inactivated platelet group (Figure 5.4) there was one individual who displayed 
extremely high levels of cAMP following AGE treatment (volunteer GP I A06 - 20 
pmol/L). This result may have resulted in the statistical significance (P<0.05) observed 
for the entire group (skewing the data towards statistical significance). 
In the ADP-activated platelets (Figure 5.5) a similar pattern to that observed in the 
inactivated platelets is occurring as 6 volunteers displayed increased levels of cAMP 
following AGE administration. These results suggest that certain individuals may be 
more susceptible to the actions of AGE with regards to intraplatelet levels of cAMP 
when compared to others from the same study group. The results in Table 5.1 show that 
following AGE administration the levels of cAMP are significantly increased in both 
inactivated and activated platelets for the study group as a whole. Following a washout 
period of 14 days (Day 28) the cAMP levels return to levels similar to those observed at 
Day 0. There is no significance statistical difference between the inactivated and 
activated platelet groups for any of the days tested. 
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Table 5.2. Intracellular cAMP concentration (pmol/L) for n=1 7 J: SEM. cAMP levels 
were monitored in both inactivated and ADP-activated platelets at the following time 
points: Day 0 (baseline), Day 14 (following AGE administration) and Day 28 
(washout). Volunteers consumed 5mL/day of AGE for a total of 14 days. 
Administration of AGE significantly (P<0.05) increased the levels of intracellular 
cAMP in both the inactivated and activated platelet samples (Day 14) when compared 
to the levels measured at Day 0 and Day 28, respectively. There was no significant 
difference noted in intracellular cAMP levels between the inactivated and activated 
platelets for any of the days tested. Key: U- inactivated platelets, A -ADP activated 
platelets. 
DAY 0 DAY 14 DAY 28 
At 
0.61 ± 0.14 1.18 ± 0.19 3. --59 ± 1.23 4.56 ± 1.17 
uA 
0.21 1.27 ± 0.2 
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Figure 5.4. The effect of AGE on intraplatelet levels of cAMP in vivo in un-activated 
platelets. Platelet-rich plasma was removed from citrated blood on the following days 
during the supplementation trial: Day 0 (before AGE administration), Day 14 (following 
AGE administration for 14 days, 5 mL/day), and Day 28 (14 day washout period). 
Intraplatelet levels of cAMP were determined using an EIA assay kit. Data expressed 
shows the spread of cAMP for each of the participants on the various days (n= 17). 
Individuals with high cAMP concentrations are indicated in the figure. 
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Figure 5.5. The effect of AGE on intraplatelet levels of cAMP in vivo in ADP-activated 
platelets. Platelet-rich plasma was removed from citrated blood on the following days 
during the supplementation trial: Day 0 (before AGE administration), Day 14 (following 
AGE administration for 14 days, 5 mUday), and Day 28 (14 day washout period). 
Platelets were stimulated with the agonist ADP (8pmol/L) and the reaction was allowed to 
run for 5 min before termination by placing the samples on ice. Intraplatelet levels of 
cAMP were determined using an EIA assay kit. Data expressed shows the spread of 
cAMP for each of the participants on the various days (n= 17). Individuals with high 
cAMP concentrations are indicated in the figure. 
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Figure 5.5. The effect of AGE on intraplatelet levels of cAMP in vivo in ADP-activated 
platelets. Platelet-rich plasma was removed from citrated blood on the following days 
during the supplementation trial: Day 0 (before AGE administration), Day 14 (following 
AGE administration for 14 days, 5 mUday), and Day 28 (14 day washout period). 
Platelets were stimulated with the agonist ADP (8ýtmol/L) and the reaction was allowed to 
run for 5 min before termination by placing the samples on ice. Intraplatelet levels of 
cAMP were determined using an EIA assay kit. Data expressed shows the spread of 
cAMP for each of the participants on the various days (n=17). Individuals with high 
cAMP concentrations are indicated in the figure. 
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5.3.2.4. The effect ofA GE on total cholesterol in vivo 
Over recent years cholesterol levels have become a topic of great interest within the 
media and scientific community. Cholesterol build-up within the arteries is another risk 
factor that contributes to the pathogenesis of CVD. It is reported that 7 out of 10 people 
in the UK over the age of 45 years have high cholesterol levels (>6.0 mmol/L). The 
British Heart Foundation (www. bhf. org) recommends that target cholesterol levels 
should be less than 5 mmol/L. On average, men and women in the UK have cholesterol 
levels of 5.5 and 5.6 mmol/L, respectively. Thus, agents that can reduce cholesterol 
levels are of great importance especially, if they can be used as an alternative to 
treatment strategies such as statins. It has been reported in the literature that 
consumption of garlic products can lead to a reduction in cholesterol (Liu and Yeh, 
1999; Yeh and Liu, 2001). Therefore, it was decided to observe the effects of AGE on 
total cholesterol in this study. 
The effect of AGE supplementation on total serum cholesterol was monitored in this 
study using a Randox (CHOD-PAP) kit. In brief, PPP was prepared from PRP via 
centrifugation and the plasma aliquots were stored at -80"C prior to testing. 5 PL of 
plasma was added to 250 pL of reagent in a microtitre plate and the optical density was 
measured at 500 nm after a 10 min incubation period at room temperature. All optical 
densities for each sample were done in duplicate. The standard (2 mg/mL - 5.17 
mmoI/L) provided with the kit was measured in triplicate and the optical density was 
used to determine the concentration of cholesterol (mmol/L) contained with the plasma 
aliquot. Desirable levels of blood cholesterol are < 5.17 mmoUL, values over 6.2 
mmol/L are considered undesirable. 
Figure 5.6 shows that the total serum cholesterol level for the group at Day 0 (baseline) 
was 4.32 ± 0.19 mmol/L. Following AGE administration for 14 days (Day 14) the level 
was reduced to 4.13 ± 0.19 mmol/L, and further reduced at Day 28 (washout) to 4.04 
0.22 mmol/L. Even though a reduction was observed it was not deemed significant 
(P>0.05). Hence, AGE did not reduce total serum cholesterol in this clinical trial. 
Individual results (Appendix VIII) show that the cholesterol levels ranged from 2.6 - 
5.6 mmol/L, indicating that all the subjects tested were normolipidemic. 
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5.5. DISCUSSION 
It is accepted in the literature that AGE reduces platelet aggregability to a variety of 
agonists both in vitro and in vivo. The question that arises from these studies is how 
exactly does AGE exert its inhibitory effect? This study is novel in its approach in that 
it directly examines the effect of AGE upon major signal transduction pathways 
involved in the platelet aggregation process. The majors findings generated in this study 
are summarised in Figure 5.7. 
Incubation of platelets in vitro leads to reduction in platelet aggregation when 
stimulated with a variety of aggregating agents. In this study, one of the primary aims 
was to establish that pre-incubation of whole blood with AGE results in the inhibition of 
platelet aggregation when stimulated with the agonist ADP. The results indicate that 
addition of AGE to whole blood results in the significant (P<0.05) inhibition of platelet 
aggregation in PRP induced by the agonist ADP (Figure 5.1). For AGE to inhibit 
platelet aggregation ex vivo it was observed that the concentration required to reduce 
platelet aggregation was significantly higher than those observed in vitro (Figure 3.1, 
Chapter 3, page 55). This result has interesting implications with regards to the dosage 
of AGE required for a clinical trial as participants would have to ingest in excess of 0.5 
L/day to match the levels used in this study. Therefore, the dosage recommended by the 
manufacturer and used in other clinical trials was used in this study (5 mUday). 
Another possibility for the observed result is that removal of PRP from whole blood 
could potentially lower the AGE concentration available to the aggregating platelets. It 
is also possible that AGE may interact with other components found in whole blood, 
this needs further investigation. Thus, AGE has the ability to inhibit platelet aggregation 
whether incubation occurs in PRP or whole blood. 
The second aim in this investigation was to conduct a clinical trial to observe if the 
inhibitory events recorded in vitro occur in vivo. It was found that AGE 
supplementation had significant inhibitory effects on platelet aggregation induced by 
the agonists; ADP, adrenaline and collagen (Figure 5.2). Similar studies using AGE have 
also shown that following AGE ingestion for a set time period resulted in inhibition of 
agonist-induced platelet aggregation (Rahman and Billington 2000; Steiner and Lin 
1998; Steiner et aL, 1996; Steiner and Lin 1994; Steiner and Li 2001). The major 
difference between this study and others conducted with AGE is the time period for 
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AGE administration. As Steiner and Lin (1994) conducted their study over a6 month 
period whereas, Rahman and Billington (2000) ran their study for 13 weeks. Does the 
length of the administration period play a role in the effectiveness of AGE to reduce 
platelet aggregation? 
The results from the clinical trial show that following AGE administration for 14 days 
the level of platelet aggregation is significantly reduced when aggregation is initiated 
with the agonists ADP, adrenaline and collagen (Figure 5.2). It was also observed that 
the levels of platelet aggregation after washout (Day 28) were comparable to those at 
Day 0 (baseline). Thus, it can be suggested that AGE is effective in reducing platelet 
aggregation stimulated by the agonists ADP, adrenaline and collagen in vivo. The 
disappointing result was with the agonist AA, as no significant inhibition was observed 
following AGE supplementation. The results obtained for AA-induced platelet 
aggregation showed considerable variation between the individuals tested (Appendix 
VIII). One such reason for this occurrence is that certain members of the study group 
may have taken medications such as aspirin and NSAIDs, and failed to report this 
during the study. It is well documented in the literature that aspirin reduces the efficacy 
of platelet aggregation via the inhibition of the enzyme COX. This enzyme is involved 
in AA metabolism and the subsequent production of metabolites such as TXA2, an 
important mediator in the amplification of the aggregation response, and inhibition of 
this enzyme stops platelet aggregation. As mentioned previously in this study, aspirin 
has no effect upon aggregation initiated with ADP, indicating a TXA2-independent 
pathway is involved in platelet aggregation stimulated with this agonist. The same can 
be said for the agonist adrenaline, as both receptors for these agonists are linked to G- 
proteins and alternative stimulatory signalling pathways independent of AA metabolism 
are stimulated upon agonist-receptor interaction. 
In vitro (Chapter 4, Figure 4.19, page 13 1) testing showed that pre-incubation of PRP 
with AGE resulted in a significant decrease in platelet aggregate formation via 
fibrinogen binding. Therefore, it was decided to observe the effect of AGE on this 
process in vivo. Figure 5.3 shows that AGE supplementation has no significant 
inhibitory effect upon GPIlb/IIIa binding and the subsequent formation of stable platelet 
aggregates in both the activated and inactivated platelet (Figure 5.4) groups as examined 
by whole blood flow cytometry. This result differs greatly from those obtained during in 
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vitro testing (Chapter 4, Figure 4.19, page 13 1) suggesting that AGE must exert its 
inhibitory affect at a different point(s) in the signalling pathway prior or proceeding to 
GPIIb/IIIa receptor activation in vivo. Another possible explanation for the observed 
result is that the fibrinogen receptor may have undergone a conformational change 
(receptor changed from inactive to active state) which resulted in a considerable number 
of platelets being positive for the antibody PAC- I in the activated platelet group, as 
shown in Figure 5.4. The antibody PAC-1 acts by binding to a specific site on the 
GPIIb/IIIa receptor once the receptor has undergone conformational change. It is 
possible that platelets may have changed shape following agonist stimulation and were 
prevented from aggregating by other factors involved in the aggregatory process. It is 
known from the aggregation experiments that AGE does reduce agonist-induced platelet 
aggregation in vivo (Figure 5.2, page 161). One possible explanation for this observed 
result is that AGE has to directly come into contact with the receptor in order to exert an 
inhibitory effect and that its is concentration-dependent (indirect - in vivo vs direct - in 
vitro). 
Total serum cholesterol was monitored in this study. It was found that all the subjects 
who participated in the study were normolipidemic (<6.0 mmol/L). Following AGE 
consumption (Day 14) and after the washout period (Day 28) there was a decrease in the 
total serum cholesterol (Figure 5.6) however, this reduction was not deemed significant 
(P>0.05) following statistical analysis. These results are consistent with those presented 
by Rahman and Billington (2000), in that they too found no significant changes to total 
serum cholesterol following AGE administration. Studies where AGE has been shown 
to reduce total serum cholesterol (Lau et aL 1987; Yeh et al. 1995,1997) were 
performed in patients who were hyperlipidemic. Thus, in this study it would not be 
expected to observe significant reductions in total cholesterol following AGE 
consumption as all the patients tested were apparently healthy individuals who were 
normolipidemic. Another trial would need to be conducted to include those in the 
population with elevated levels of total serum cholesterol. 
The most important result generated in this study is that AGE supplementation increases 
the intraplatelet levels of cAMP in both inactivated and ADP-activated platelets. This 
result validates the findings from the in vitro study (Chapter 4, section 4.2.3, pages 114- 
115) which also showed significant increases in cAMP subsequent to AGE treatment. 
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The levels recorded at Day 0 and Day 28 was very similar in both the inactivated and 
activated platelet groups. There was no difference between the inactivated and activated 
platelet groups. Collectively, the findings generated in this study were statistically 
significant (P<0.05) for all the volunteers tested. It is important to note that only certain 
individuals within the study were susceptible to the actions of AGE upon intraplatelet 
cAMP levels (23 %- inactivated, 35 % activated). The levels of cAMP for the 
individuals were extremely high compared to the remaining volunteers hence, the 
observed statistical significance. This result suggests that AGE is effective as long as it 
is continually being taken by the subject, and that 14 days is sufficient washout time 
period for removing the effects of thisAGE from the human circulatory system. 
The results from this study suggest that inhibition of platelet aggregation does occur 
following AGE administration and that the degree of inhibition is individual-dependent. 
Also the biochemical signalling processes affected by AGE in vivo are subject to inter- 
individual variation. 
The major problem encountered with this study is that the AGE samples were not taken 
at the same time everyday by all the participants. This was due largely in part to the 
intense flavour of the liquid extract. It is recommended by the manufacturer to take the 
liquid extract in orange juice or even tomato juice. Feedback from the volunteers 
implied that it was difficult to mask the flavour and that the only way in which it could 
be taken was in the evening with a savoury meal. One recommendation is that instead of 
taking the liquid AGE as it is, it would be better if it were placed into gel capsule like 
those used for cod liver oil, as more people would be willing to take the extract in this 
way. It is possible that many of the subjects were not very compliant throughout the 
study, although compliance was monitored through weekly doses being given to 
subjects. Also at the end of the trial volunteers were asked to return there liquid AGE 
containers. One way to measure compliance would be to monitor the amount of SAC in 
the subject's urine using HPLC as done by Dillon et al. (2002). However, for the 
purpose of this study it was impractical to measure SAC levels in urine. The sample 
collection and processing would have impeded on other experiments that needed to be 
conducted. It is also possible that more inhibition of platelet aggregation and the 
signalling pathways involved would have occurred if the study was carried out for a 
longer time period. Also a higher dose of AGE may have been more effective, as shown 
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in the in vitro platelet aggregation studies whereby, dose-dependent inhibition was 
observed. For the purpose of this study the recommended daily dose of AGE was utlised 
in order to show that ingestion over a short time period has beneficial effects with 
regards to platelet aggregation. 
Another issue that affected the planning and execution of the study was technical 
difficulties. In that there was only one experimenter conducting all the experiments. 
This greatly affected the choice of experiments that were conducted. It would have been 
interesting to observe the in vivo effects of AGE upon calcium ion mobilisation within 
the platelet. The in vitro data generated from monitoring calcium ion moblisation 
(Chapter 4) looked very promising in that, AGE appeared to reduce the levels available 
to aggregating platelets when compared with the test controls. Also there is a definate 
link between cAMP levels in the platelet and available calcium ions. An increase in 
cAMP leads to a decrease in calcium that ultimately results in a reduction in the levels 
of platelet aggregation. If this study were to be conducted again it would be advisable to 
monitor both cAMP and calcium mobilisation simultaneously. 
The sample size used in this study was sufficient enough to gather data for statistical 
purposes. However, future experiments should aim to increase this size and include 
those with pre-existing conditions such as hyperlipidemia to ensure that AGE does 
definitely reduce this in vivo. It should be noted that although more females (11) 
participated than males (6) in this study, there was no significant difference between 
their results for any of the experiments conducted (Appendix VIII). Also those who 
drank regularly were no different than those who did not. The smokers in the group 
when compared to the non-smokers had no differences either. To reiterate the primary 
variable under investigation in this study was the direct effect of AGE upon platelet 
function, and all volunteers who participated had normal platelet counts and platelet 
aggregate formation. 
The results generated in this study should be seen as a recommendation for the use of 
AGE to protect against the onset of disease states such as atherosclerosis. AGE 
definitely has anti-platelet effects and with further investigation into its properties and 
effects on the signal transduction pathways in platelets it has the potential to be a 
preventative therapy in the fight against CVD. 
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5.4. SUMMARY OF RESULTS 
* AGE inhibited platelet aggregation induced by ADP ex vivo. 
e AGE inhibited agonist-induced platelet aggregation in vivo when stimulated by 
the agonists ADP, adrenaline and collagen. 
e AGE did not suppress fibrinogen-receptor interaction to forin. a stable platelet 
aggregate in vivo. 
9 AGE increased the intraplatelet levels of cAMP in vivo in both inactivated and 
activated platelets. 
9 AGE does not have an effect upon the total serum cholesterol levels in vivo in 
normolipidemic subjects. 
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6. GENERAL DISCUSSION 
Herbal compounds such as garlic, ginger, kinetin, glucosamine, tomato extract, etc., 
through scientific testing have been found to possess cardioprotective properties (Bordia 
et al. 1978; Duttaroy et al. 2002; Fugh-Berman 2000; Hua et al. 2004; Innes et al. 
2003; Osmont et al. 2003; Rahman and Billington 2000; Sheu et al. 2003; Son el al. 
2004). These natural compounds reduce risk factors such as: a reduction in blood lipids 
and triglycerides, enhancement of circulation and reduction in blood pressure. Garlic, 
especially the dietary supplement aged garlic extract - AGE, (Kyolice) has been shown 
to exhibit all these cardioprotective properties (www. kyolic-com). One such property of 
AGE is that it reduces platelet aggregation both in vitro and in vivo (Rahman and 
Billington 2000; Steiner and Lin 1994; Steiner et al. 1996 Steiner and Lin 1998; Steiner 
and Li 2001). The exact nature of this inhibition of platelet aggregation (mechanistic 
action of AGE on platelet cell signalling) with respect to AGE is unknown. Thus, the 
primary aim of this investigation was to elucidate an inhibitory mechanism(s) of AGE 
on agonist (ADP)-induced platelet aggregation both in vitro and in vivo. The major 
findings generated in this study are presented in Figure 6.1. 
This study is novel in that; it actually monitored the biochemical signalling events that 
occurred during platelet aggregation both in vitro and in vivo. The platelet signalling 
pathways that were monitored in this study were chosen because they have been 
highlighted as potential targets from research already conducted on other garlic 
preparations in the literature, these biochemical events include: the formation of 
thromboxanes (Dimitrov and Bennick 1997; Harenburg el al. 1998; Makheja el al. 
1980; Moon et al. 2000; Srivastava 1984; Srivastava 1993); phospholipase activity and 
lipoxygenase products (Ali 1995; Apitz-Castro et al. 1983; Liu and Yeh 1999) ; calcium 
mobilisation (Park et al. 2004; Qi et al. 2000; Shah et al. 1999) and GPlIb-Illa (O'Neill 
et al. 2000; Tapiero et al. 2004) receptor activity. Another reason for using the chosen 
signalling events is that there are medicines which target these pathways to prevent 
platelet aggregation currently used in the clinic as treatment for CVD (COX activity, 
ADP receptor antagonists and GPIlb-IIIa receptor antagonism). 
Comparisons of the in vitro and in vivo data generated in the study demonstrate that 
AGE does indeed inhibit platelet aggregation induced by a variety of agonists (Chapters 
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3&5, respectively). The results generated are consistent with those presented by other 
scientific studies that have monitored the effect of AGE on platelet function both in 
vitro and in vivo (Rahman and Billington 2000; Steiner and Lin 1994; Steiner et al. 
1996; Steiner and Lin 1998; Steiner and Li 2001). In vitro testing (Chapter 4) showed 
that AGE targeted the following biochemical signalling pathways to inhibit platelet 
aggregation induced with the agonist ADP: calcium mobilisation, fibrinogen binding 
and, intraplatelet cAMP levels were increased/ decreased significantly. In vivo (Chapter 
5) testing differed greatly from the in vitro work in that; the only biochemical pathway 
to be affected by AGE was an increase to the levels of intraplatclet cAMP to inhibit 
platelet aggregation induced with ADP. This observation may be dependent upon the 
agonist (ADP) used to initiate platelet aggregation and the signalling pathways 
associated with the ADP receptor that maintain the aggregatory response. 
The signalling events that were monitored in this study occur downstream of receptor- 
agonist interaction therefore, it is important not to rule out the possibility that AGE acts 
directly at the receptor level for each agonist as the in vitro studies show that AGE 
inhibits a wide range of platelet agonists. Future studies could look at the signalling 
events associated with other agonists such as collagen, thrombin, adrenaline etc and the 
effect AGE has. Does AGE target points in the pathway common to all forms of agonist 
stimulation as shown with ADP? Also, initial studies monitoring proteolytic activity in 
AGE showed that it is possible that AGE does contain proteases following the outcome 
of the Azocasein assay. Therefore, before the idea is dismissed that AGE does not act at 
the receptor level for each agonist more experimentation is required. As AGE appears to 
be in possession of components which may exert their effects at various stages involved 
in the process of platelet aggregation. Individual components isolated from AGE 
(Chapter 3) also show that the antiplatelet potential of AGE cannot be predicted by 
organosulphur content alone and that the entire extract is required to exert any kind of 
inhibitory effect. For this reason it is impossible to compare the actions of AGE to other 
garlic preparations in that no two preparations contain the same mixture of ingredients. 
Also, the levels of certain constituents i. e. organosulphur compounds, oil-soluble 
compounds, carbohydrates, saponins etc differ in concentration when compared to 
AGE which contains compounds not found in other garlic supplements (Kasuga et al. 
2001). 
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This study shows that AGE as a dietary supplement (clinical trial data presented in 
chapter 5) does have health benefits in that it reduces platelet aggregability both in vitro 
and in vivo. Therefore, AGE would be suitable as a preventative treatment for the 
disease state CVD. However, scientific testing is required with AGE and its 
interatctions with established prescribed medications such as warfarin. Is it safe to take 
AGE alongside other medications used in the treatment of CVD? There have been 
instances with other health food supplements interacting in an adverse manner with 
prescribed medication. This needs to be addressed further by conducting both in vitro 
and in vivo testing. 
In conclusion, this study has shown that AGE is effective in inhibiting agonist-induced 
platelet aggregation both in vitro and in vivo. The principal mechanism found in this 
study for this observed inhibition both in vitro and in vivo appears to be via an increase 
to the intraplatelet levels of cAMP. 
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6.1. Future work arising from the present study: 
9 Protein tyrosine kinase activity and the effect AGE has upon these enzymes. 
e AGE and its effect upon NO (nitric oxide) production in platelets and 
endothelial cells. 
e Monitor the signalling effects associated with other agonists - does AGE still 
affect the same signalling events? Le. Does AGE increase cAMP levels in 
collagen-stimulated platelets? 
9 Clinical trial examining the effects of AGE on calcium mobilisation in platelets. 
* Repetition of clinical trial - the following questions need to be examined: 
1. Would a lower/higher dose of AGE taken over the same time period still 
produce the same response? 
2. Liquid AGE in gel capsule form - would this lead to more volunteers 
participating in clinical studies? 
3. Does AGE need to be taken everyday in order to exert an inhibitory 
response upon platelet aggregation? 
4. Is the time of day when AGE is taken important to the outcome of a 
clinical trial? 
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APPENDIX I 
Participant consent fonn 
201 
LIVERPOOL JOHN MOORES UNIVERSITY 
FORM OF CONSENT TO TAKE PART AS A SUBJECT IN A MAJOR PROCEDURE OR 
RESEARCH PROJECT 
Title of project/procedure: 
Garil 
is of Inhibil 
Voluntary donation of a 20 mL blood sample. To be taken via venepuncture of 
the median cubital vein by Gillian Allison, a PhD researcher in the School of 
Biomolecular Sciences. The platelets will be removed from whole blood and 
used to assess the inhibitory actions of AGE on platelet function. 
. ............................................................................................................................ agree to take part in (Subjects full name)* 
the above named project/procedure, the details of which have been fully explained to me and 
described in writing. 
Signed ......................................................................... 
Date 
............................................................... 
(Subject) 
I.......... Gillian Allison ................................................................................ certify that the details of 
this 
(Investigators full name)* 
projcct/procedure have been fully explained and described in writing to the subject named above and 
have been understood by him/her. 
Signed ......................................................................... (Investigator) 
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Date ............................................................... 
APPENDIX II 
Standard curve for intraplatelet cAMP determination 
203 
cAMP Standard Curve 
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APPENDIX III 
Standard curve for chyrnotrypsin standards used to determine proteolytic 
activity of AGE using the azocasein assay 
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Standard curve to determine protein concentration using the Bradford 
Assay 
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APPENDIX V 
The effect individual effects of isolated components from AGE on ADP- 
induced platelet aggregation. 
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APPENDIX VI 
Participant information sheet used for the clinical trial 
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PARTICIPANT INFORMATION SHEET 
Mechanisms of inhibition of platelet aggregation by aged garlic extract (Kyolic) 
Background information: 
Platelet aggregation plays an important role in the development of cardiovascular 
disease and atherosclerosis. Circulating platelets adhere to fatty plaques within the 
blood vessel and, become activated. Once activated chemoattractant chemicals are 
released into the blood stream which recruit more platelets to the plaque site. Platelets 
then bind together to form a platelet clot which prevents blood flow and leads to the 
clinical presentation of disease ie. heart attack and stroke. Dietary supplementation with 
aged garlic extract (AGE) has been shown to be effective in the prevention of 
cardiovascular disease, as it reduces the aggregability of platelets, lowers blood 
cholesterol levels etc. However, the exact inhibitory nature is not clearly understood. 
This will be further investigated in this trial. 
The study: 
In vitro testing has shown that AGE inhibits agonist-induced platelet aggregation by 
reducing the ability of fibrinogen to bind to its receptor GPIIb/IIIa, increasing 
intracellular levels of cAMP and reducing the availability of calcium ions needed for 
aggregation to occur. The aim of this study is to measure these processes in vivo after 
dietary supplementation with AGE. 
Participant role in study: 
Both males and females; smokers and non-smokers are required for this clinical trial. 
You will give a blood sample (15-20 mls) at the beginning of the study. You will then 
take a specified daily dose (5 m1s) of AGE for a period of two weeks. A blood sample 
will be taken again. You will stop taking the AGE for two weeks and a final blood 
sample will be taken. The aggregability of your platelets will be measured along with 
their ability to bind fibrinogen and intracellular cAMP concentrations. 
You do not have to alter your lifestyle or diet and there is minimum pain involved in 
donating blood. 
If at any time during the study, you wish to withdraw you can do so without 
prejudice. 
Contact details: 
Principle researcher: Miss Gillian Allison, 255 Max Perutz Building 
G. L. Allison@2004. ljmu. ac. uk 
Supervisors: Dr Khalid Rahman 
Dr Gordon Lowe 
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APPENDIX VII 
Participant questionnaire for clinical trial 
214 
QUESTIONNAIRE FOR CLINICAL TRIAL VOLUNTEERS 
Name: 
Sex (female/male): 
Age (years): 
Number of cigarettes smoked per day: 
Average weekly alcohol consumption: 
List type of alcohol consumed on a regular basis: 
Known medical conditions (yes/no): 
If yes please list medical conditions: 
Are you currently taking any prescribed medication (yes/no): 
If yes please list medications currently taking: 
Do you take any dietary supplements (yes/no): 
If yes please list the type of supplements you take, ie. Multivitamins, cod liver oil 
capsules etc. 
215 
APPENDIX VIII 
Individual data generated from clinical trial 
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Volunteer GP1A0I 
Gender Male 
Age 34 
No of cigarettes per day 10 
Alcohol units/weeks 14 
Medical conditions NONE 
Prescribed medication NONE 
Dietary supplements Cod Liver Oil Capsules 
%Aggregation ADP AA Adrenaline Collagen 
Baseline 88 15 50 79 
Following 
AGE 
SO 43 81 
Washout 80 7 43 78 
PAC1 binding Unactivated ADP activated CD42a expression 
Baseline 10.5 61.9 93.3 
Following AGE 72.8 
Washout 23.7 67.6 73.1 
Intracellular cAMP levels Unactivated ADP activated 
Baseline 0.61 3.6 
Following AGE 1. ) 1.8 
Washout 0 1.8 
Cholesterol analysis rnmol/I 
Baseline 4.07 
Following AGE 4.48 
Washout 4.82 
217 
Volunteer GPIA02 
Gender Male 
Age 54 
No of cigarettes per day 0 
Alcohol units/weeks 0 
Medical conditions NONE 
Prescribed medication NONE 
Dietary supplements Cod Liver Oil Capsules 
%Aggregation ADP --ý ýAA Adrenaline Collagen 
Baseline 79 39 67 91 
Following 
AGE 
0() -14 (A) 
Washout 87 65 67 17 
PACI binding Unactivated ADP activated CD42a expression 
Baseline 12.8 75.9 88.6 
Following AGE - 1( k) 1 -41.3 
-7 
Washout 
Intracellular cAMP levels 
Baseline 
Following AGE 
Washout 
Cholesterol analysis 
Baseline 
Following AGE 
Washout 
25.3 
Unactivated 
1.1 
1.1 
1.2 
70.6 46.3 
ADP activated 
1.9 
rnmol/L 
3.96 
'). 70 
3.96 
218 
Volunteer GP1A03 
Gender Female 
Age 22 
No of cigarettes per day 0 
Alcohol units/weeks 15 
Medical conditions NONE 
Prescribed medication NONE 
Dietary supplements NONE 
%Aggregation ADP AA Adrenaline Collagen 
Baseline 62 23 53 62 
Following 
AGE 
57 17 68 --1 
Washout 78 48 64 69 
PACI binding Unactivated ADP activated CD42a expression 
Baseline 17.5 74.8 93.1 
Following AGE -1 N. -1 71) 1 
Washout 30.7 56.5 56.7 
Intracellular cAMP levels Unactivated ADP activated 
Baseline 1.5 1.3 
Following AGE 1.2 1. (). ý 
Washout 3.0 3.6 
Cholesterol analysis mmol/l 
Baseline 3.78 
Following AGE 3.50 
Washout 3.86 
219 
Volunteer GPIA05 
Gender Female 
Age 44 
No of cigarettes per day 0 
Alcohol units/weeks 6 
Medical conditions NONE 
Prescribed medication NONE 
Dietary supplements B6, Zinc & Magnesium 
I /day 
%Aggregation ADP AA Adrenaline Collagen 
Baseline 74 0 80 67 
Following 
AGE 
I 
Washout 81 2 81 69 
PAC1 binding Unactivated ADP activated CD42a expression 
Baseline 13.2 75.5 91 
Following AGE 1) 1, () 1)8. o 771) 
Washout 20.9 77.6 68.2 
Intracellular cAMP levels Unactivated ADP activated 
Baseline 1.05 1 
Following AGE I. IN 
Washout 1.0 1.0 
Cholesterol analysis mmol/L 
Baseline 4.40 
Following AGE 1 ). 57 
Washout 3.76 
220 
Volunteer GPIA06 
Gender Female 
Age 23 
No of cigarettes per day 0 
Alcohol units/weeks 0 
Medical conditions NONE 
Prescribed medication NONE 
Dietary supplements NONE 
%Aggregation ADP AA Adrenaline Collagen 
Baseline 36 51 66 90 
Following 
AGE 
07 T-1 
Washout 56 59 62 91 
PACI binding Unactivated ADP activated CD42a expression 
Baseline 11 31.8 90.1 
Following AGE 75ý9 7(). 
Washout 31.3 42.0 77.8 
Intracellular cAMP levels Unactivated ADP activ ated 
Baseline 0.8 0.95 
Following AGE 20 1 
Washout 0.6 0.85 
Cholesterol analysis mmol/L 
Baseline 3.29 
Following AGE ,I () 
Washout 2.80 
221 
Volunteer GP11308 
Gender Female 
Age 26 
No of cigarettes per day 0 
Alcohol units/weeks 0 
Medical conditions NONE 
Prescribed medication NONE 
Dietary supplements NONE 
%Aggregation ADP AA Adrenaline Collagen 
Baseline 91 37 59 78 
Following 
AGE 
70 29 7() 
Washout 82 54 0 81 
PACI binding Unactivated ADP activated CD42a expression 
Baseline 28.7 78.7 85.9 
Following AGE 18.0 01.1 
Washout 20.0 64.1 66.9 
Intracellular cAMP levels Unnctivated ADP activated 
Baseline 0 1.3 
Following AGE -1 1ý7 
Washout 0.35 1.6 
Cholesterol analysis mmol/L 
Baseline 3.00 
Following AGE 2.67 
Washout 2.59 
222 
Volunteer GPIB09 
Gender Male 
Age 49 
No of cigarettes per day 0 
Alcohol units/weeks 5 
Medical conditions NONE 
Prescribed medication NONE 
Dietary supplements NONE 
%Aggregation ADP AA Adrenaline Collagen 
Baseline 80 19 38 82 
Following 
AGE 
8 
Washout 71 0 56 90 
PACI binding Unactivated ADP activated CD42a expression 
Baseline 35.9 86.7 78.3 
Following AGE 2 o. .ý .ýS, () ý). 1) 
Washout 22.3 70.7 67.8 
Intracellular cAMP levels Unactivated ADP activ ated 
Baseline 0 0 
Following AGE 1-1 
Washout 1.2 0.9 
Cholesterol analysis mmol/L 
Baseline 4.25 
Following AGE 4,1 
Washout 4.04 
223 
Volunteer GP11310 
Gender Female 
Age 48 
No of cigarettes per day 0 
Alcohol units/weeks 10 
Medical conditions Hypothyroid, depression 
Prescribed medication Thyroxine, venlafaxine 
Dietary supplements NONE 
%Aggregation ADP AA Adrenaline Collagen 
Baseline 72 62 45 86 
Following 
AGE 
64 7 
Washout 104 0 95 103 
PACI binding Unactivated ADP activated CD42a expression 
Baseline 22.3 77.2 84.1 
Following AGE 21.7 70.1) 7). 1 
Washout 19.9 39.1 86.0 
Intracellular cAMP levels Unactivated ADP activated 
Baseline 0 0.12 
Following AGE 75 
Washout 0.61 0.61 
Cholesterol analysis mmol/L 
Baseline 4.35 
Following AGE 
Washout 5.31 
224 
Volunteer GP2A12 
Gender Female 
Age 62 
No of cigarettes per day 0 
Alcohol units/weeks 10 
Medical conditions NONE 
Prescribed medication NONE 
Dietary supplements NONE 
%Aggregation ADP AA Adrenaline Collagen 
Baseline 74 10 74 89 
Following 
AGE 
60 12 12 SO 
Washout 75 7 35 70 
PAC1 binding Unactivated ADP activated CD42a expression 
Baseline 12.6 33.9 78.9 
Following AGE 20.1 68.7 76.1) 
Washout 26.3 53.9 60.8 
Intracellular cAMP levels Unactivated ADP activated 
Baseline 0 0.95 
Following AGE 1.1 -1 
Washout 1.8 1.6 
Cholesterol analysis mmol/L 
Baseline 4.30 
Following AGE -1.8 7 
Washout 4.58 
225 
Volunteer 
Gender 
Age 
No of cigarettes per day 
Alcohol units/weeks 
Medical conditions 
Prescribed medication 
Dietary supplements 
%Aggregation ADP AA 
Baseline 88 12 
Following 
AGE 
Washout 77 4 
PACI binding Unactivated 
Baseline 12.1 
Following AGE 
Washout 36.8 
Intracellular cAMP levels Unactivated 
Baseline 0 
Following AGE j. -) 
Washout 0.95 
Cholesterol analysis 
Baseline 
Following AGE 
Washout 
GP2AI3 
Female 
47 
0 
5 
Meniere's 
Betahistine 
NONE 
Adrenaline Collagen 
20 89 
Oý 
73 69 
ADP activated CD42a expression 
28.6 82.4 
7 5.5 7ý () 
68.6 72.8 
ADP activated 
1.8 
0 
0.95 
mmol/L 
5.62 
4.82 
4.14 
226 
Volunteer GP2A17 
Gender Male 
Age 46 
No of cigarettes per day 0 
Alcohol units/weeks 14 
Medical conditions Hypertension, IgA nethropathy 
Prescribed medication Nifedipine, Irbestartin, Enapril 
Dietary supplements 
%Aggregation ADP AA Adrenaline Collagen 
Baseline 96 0 87 90 
Following 
AGE 
88 -)0 78 84 
Washout 78 0 62 70 
PAC1 binding Unactivated ADP activated CD42a expression 
Baseline 17.9 67.9 89.8 
Following AGE 21.1 85.1 66.3 
Washout 35.5 72.8 70.0 
Intracellular cAMP levels Unactivated ADP activated 
Baseline 0.75 1.4 
Following AGE 9 1 k)5 
Washout 1.9 1.1 
Cholesterol analysis mmol/L 
Baseline 5.18 
Following AGE 5J)O 
Washout 5.31 
227 
Volunteer GP2A21 
Gender Female 
Age 29 
No of cigarettes per day 4 
Alcohol units/weeks 19 
Medical conditions NONE 
Prescribed medication NONE 
Dietary supplements Omega 3 -6-9,1 000mg/day 
%Aggregation ADP AA Adrenaline Collagen 
Baseline 60 1 2 72 
Following 
AGE 
4ý 4 46 
Washout 53 0 17 77 
PACI binding Unactivated ADP activated CD42a expression 
Baseline 13.4 45.9 88.7 
Following AGE 1 78.4 7S. 
Washout 18.1 73.7 88.6 
Intracellular cAMP levels Unactivated ADP activated 
Baseline 1 1.1 
Following AGE 1.1 1.6 
Washout 0.75 0.95 
Cholesterol analysis mmol/L 
Baseline 4.84 
Following AGE 4.14 
Washout 2.72 
228 
Volunteer GP21318 
Gender Female 
Age 27 
No of cigarettes per day 18 
Alcohol units/weeks 0 
Medical conditions NONE 
Prescribed medication Contraceptive pill 
Dietary supplements NONE 
%Aggregation ADP AA Adrenaline Collagen 
Baseline 57 0 52 84 
Following 
AGE 
51 1 
Washout 98 41 72 43- 
PAC1 binding Unactivated ADP activated CD42a expression 
Baseline 6.1 62.5 90.3 
Following AGE I (). -) 7(). 9 01. " 
Washout 27.2 54.0 81.8 
Intracellular cAMP levels Unactivated ADP activated 
Baseline 0 1.05 
Following AGE I I Ix 
Washout 2.5 1.6 
Cholesterol analysis mmol/L 
Baseline 5.31 
Following AGE 4.7 5 
Washout 3.99 
229 
Volunteer GP2B19 
Gender Male 
Age 60 
No of cigarettes per day 0 
Alcohol units/weeks 14 
Medical conditions Mild hypercholestemia 
Prescribed medication NONE 
Dietary supplements NONE 
%Aggregation ADP AA Adrenaline Collagen 
Baseline 88 31 70 57 
Following 
AGE 
80 14 4 
Washout 65 6 49 65 
PACI binding Unactivated ADP activated CD42a expression 
Baseline 14.2 31.9 77.9 
Following AGE , ý9., 70.8 5. 
Washout 20.4 47.4 75.8 
Intracellular cAMP levels Unactivated ADP activated 
Baseline 1.5 1.6 
Following AGE 1.7 6 
Washout 1.3 1.8 
Cholesterol analysis mmol/L 
Baseline 4.38 
Following AGE 4.04 
Washout 3.99 
230 
Volunteer GP2A20 
Gender Female 
Age 41 
No of cigarettes per day 0 
Alcohol units/weeks 2 
Medical conditions NONE 
Prescribed medication NONE 
Dietary supplements NONE 
%Aggregation ADP AA Adrenaline Collagen 
Baseline 69 17 70 83 
Following 
AGE 
Washout 82 0 82 T3- 
PACI binding Unactivated ADP activated CD42a expression 
Baseline 34.3 87.8 85.7 
Following AGE 1 66.1 68.7 
Washout 17.4 51.4 76.8 
Intracellular cAMP levels Unactivated ADP activ ated 
Baseline 0 0 
Following AGE 1.1 0.65 
Washout 0 0 
Cholesterol analysis mmol/L 
Baseline 3.83 
Following AGE 
Washout 3.96 
231 
Volunteer GPIB07 
Gender Male 
Age 28 
No of cigarettes per day 0 
Alcohol units/weeks 12 
Medical conditions NONE 
Prescribed medication NONE 
Dietary supplements NONE 
%Aggregation ADP AA Adrenaline Collagen 
Baseline 79 0 85 37 
Following 
AGE 
67 78 
Washout 103 96 108 106 
PACI binding Unactivated ADP activated CD42a expression 
Baseline 13.3 63 89.4 
Following AGE -18.8 83.4 71) , 
Washout 25.9 46.6 79.4 
Intracellular cAMP levels Unactivated ADP activated 
Baseline 1.2 1.6 
Following AGE 1.8 
Washout 0.85 1.3 
Cholesterol analysis mmol/L 
Baseline 3.24 
Following AGE 
Washout 3.32 
232 
Volunteer GP1B22 
Gender Female 
Age 57 
No of cigarettes per day 0 
Alcohol units/weeks 14 
Medical conditions NONE 
Prescribed medication NONE 
Dietary supplements Cod liver oil 
multivitamins 
%Aggregation ADP AA Adrenaline Collagen 
Baseline 92 4 78 79 
Following 
AGE 
80 64 01) 
Washout 91 0 73 69 
PAC1 binding Inactivated ADP activated CD42a expression 
Baseline 25.7 74.9 77.0 
Following AGE 20.5 59-0 8-1.1 
Washout 26.1 68.3 71.0 
Intracellular cAMP levels Inacti vated ADP activated 
Baseline 0.85 1.3 
Following AGE 4.5 5 
Washout 0 0 
Cholesterol analysis mmol/L 
Baseline 5.62 
Following AGE 5.21 
Washout 5.60 
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